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ABSTRACT 
Studies of pancreatic elastase were undertaken to examine 
substrate binding and of human leukocyte elastase to try to 
gain insight into the disease, pulmonary emphysema. Porcine 
pancreatic elastase was inhibited by various inhibitors 
p-toluene sulphonyl fluoride, phenylmethane sulphonyl fluoride, 
1-dimethylamino-naphthalene-S-sulphonyl fluoride or chloride 
and p-nitrophenyl-anthranilate. The enzyme was only fully 
inhibited by the first two inhibitors which were then treated 
under alkaline conditions to convert the serine-19S, -CH20H to 
-CH2 to form the anhydroelastase. The enzyme was shown to be totally inactive but X-ray diffraction data to 2.SA resolution 
from one preparation showed no changes at the active site. 
Further studies were carried out to modify the serine-19S to 
cysteine by thiolation of the inhibited enzyme and 
anhydroelastase but proved unsuccessful. Binding studies were 
carried out with the prepared hexapeptide substrate, 
H.Pro-Ala-Pro-Ala-Lys-Phe.OH and tetrapeptide inhibitors, 
Ac-Pro-Ala-Pro-Ala.OH (1), Ac-Pro-Ala-Pro-Alaninal (2) and 
TFA-Pro-Ala-Pro-Alaninal (3) using anhydroelastase and native 
elastase. Inhibition with inhibitors (2) and (3) showed 
TFA-peptide-aldehyde bound tighter than Ac-peptide-aldehyde 
with K for (2) - 6.1 llM and for (3) - 8.6 llM. A 
TFA-pepiide-chloromethYlketone was also examined. It showed 
anomalous binding with the TFA group bound to the active site 
region whilst the rest of the peptide bound in parallel mode 
with the main chain residues 214-216. Data on substrate (1) 
was collected but no binding around the active site region was 
observed. 
Small crystals of human leukocyte elastase were obtained by the 
technique of vapour diffusion, however sealed tube X-ray 
experiments and using the sychroton revealed no diffraction 
pattern~ Moreover, studies were done on the enzyme to remove 
the sugar content using various glycosidases of which almond 
emulsin showed some conclusive results. 
In addition, the crystal structures of two small molecules 
containing the heavy atoms ruthenium and platinium were solved 
by conventional techniques of X-ray crystallography. 
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CHAPTER ONE 
INTRODUCTION 
2 
1.1 HISTORY AND OCCURRENCE 
The serine proteases, e.g. chymotrypsin, trypsin, elastase, 
thrombin, plasmin and subtilisin, are a class of proteolytic 
enzymes characterised by the presence of uniquely reactive 
serine residue. They are of extremely widespread occurrence 
and their function is to alter or decompose other proteins 
1 into fragments by hydrolysis of peptide bonds. The two 
main groups most widely studied, are the trypsin family and 
2 the subtilisin family • 
Members of the trypsin family (e.g. trypsin, chymotrypsin 
and elastase) occur in the vertebrates, phyla of higher 
organisms and also in prokaryotes, while the subtilisin 
2 family has been identified mainly among the bacilli. Both 
families have their catalytically important functional 
groups arranged in the same geometrical pattern, but have 
entirely different overall three-dimensional structures. 
The serine proteases that are involved in blood clotting are 
plasmin and thrombin which are present in the serum of all 
vertebratesl • Another group of serine proteases which exist 
in bacteria, Streptomyces griseua protease A and B (SGPA and 
SGPB) are regarded as possible evolutionary precursors of 
the mammalian serine proteases. They are isolated from the 
cOlDlllercially available extracellular bacterial culture 
3-5 filtrate, pronase • More recently, a member closely 
related to the mammalian serine proteases 
kallikreins, has been investigated6,7. 
of animal origin, 
They have the 
ability to release a vasodepressor decapeptide called, 
kallidin or Lys-bradykinin from kininogensB• 
The serine proteales that exhibits trypsin-like specificity 
are porcine kallikrein, thrombin and plas.in. Porcine 
kallikrein splits peptide substrate. preferentially on the 
e-terminal side of internal arainyl and lysyl residue. 
Plas.in i. also like trypsin and breaks down the fibrin 
3 
matrix by splitting all the peptide bonds following arginine 
or lysine units. Thrombin, on the other hand, is much more 
selective and splits only four bonds in fibrinogen, between 
arginine and glycine whereas trypsin would reduce the same 
molecule to 150 fragments 1• SGPA, SGPB and subtilisin all 
closely resembles chymotrypsin specificity, but subtilisin 
will also accept non-aromatic a polar side-chains and even 
charged side-chains. 
The pancreas of all mammals investigated, including man, 
contains a specific elastase (Ee 3.4.21.11) which was first 
investigated in 1949 by Balo and Banga9• The work described 
in this thesis has concentrated mainly with the porcine 
pancreatic elastase (PPE) and human leukocyte elastase, 
(HLE), (discussed later in chapter five). 
PPE has been the focus of most attention, chiefly because it 
10 is easily obtained in high yield. In 1956, Lewie et al 
were first to acquire the pure enzyme from porcine pancreas. 
PPE is one of the members of the serine proteinases (Hartley 
11 1960) which originates in the pancreas as proe1astase and 
is secreted into the duodenum by the acinar tissue of the 
pancreas. The zymogen, is then activated by trypsin, during 
which a small peptide of determined sequence 12 is removed 
from the N-termina1 amino group valine-16 (the chymotryp-
sinogen-A numbering scheme will be used throughout to 
13 describe the position of amino-acid residues in PPE , thus 
facilitating comparison with chymotrypsin, trypsin and other 
homologous enzymes). This enables the molecule to adopt its 
active conformation where valine-16 forma a salt bridge with 
asparate-194. 
The activated enzyme, elastase, catalyze. the decomposition 
of proteinl into fraamentary peptide., which are reduced 
further into individual aaino-acids by trypsin and 
chymotrypsin amongst others. These aaino-acidl are then 
absorbed by the intestine and carried to the sites of 
protein Iynthesis. 
4 
10 PPE was shown to digest a wide variety of substrates but 
is distinguished from the other pancreatic endopeptidases by 
its ability to digest elastin, the elastic fibrous protein 
of connective tissue21 • It's specificity is for substrates 
22 
with uncharged non-aromatic side-chains unlike those of 
trypsin and chymotrypsin whose preferred substrates are 
basic and aromatic side-chains respectively. 
PPE is inhibited by di-isopropyl-phosphofluoridate (DFP) in 
a similar way to trypsin and chymotrypsin and a comparison 
of the pancreatic serine proteases, SGPA, SGPB, porcine 
kallikrein, plasmin and thrombin (only the B chain shows 
homology) shows that they all have similar sequences around 
the active centre, i.e. G1y-Asp-Ser*-G1y-G1y, and it 1s the 
serine that reacts with DFp23 ,24. In the case of 
subtilisin, G1y-Thr-Ser*-Met-A1a sequence is characteristic 
around the active centre serine residue in this group of 
bacterial proteins. 
PPE consists of a single polypeptide chain of 240 amino-acid 
residues, with a molecular weight of 25,90013 , which is 
homologous to trypsin and the Band C chains of 
chymotrypsin. It also contains a disu1phide-bridged 
"histidine loop" sequence similar to that in trypsin and 
25 
chymotrypsin • 
A general analY8i8 carried out on the degree of homology by 
Shotton et a1l3 between chymotrypsin and trypsin and 
elastase showed between 35 per cent and 45 per cent identity 
in amino-acid sequence, even though their specificities are 
different. They noticed that the amino-acid homologies are 
greater around the residues which are important for 
catalysis i.e., serine-195, histidine-57 and asparate-102 
than elaewhere. Abo, ana1y.18 of the distribution of 
homologous residues, in terms of per cent chemical 
similaritya between the inter~al residues and external 
5 
positions showed 71 per cent internal residues and only 19 
per cent external ones. 
aChemical similarity is defined as : Arg • Lys; Asp • Glu; 
Asn • Gln; Asp • Asn; Glu • Gln; Ser • Thr; Val • Ile; Ile • 
Leu; Tyr • Phe - Trp. 
Figure 1.0 shows the similarity in the tertiary structure 
between the various serine proteases, wi th the residues 
which are important for catalysis, i.e., serine-195, 
histidine-57 and asparate-102. Also the cysteine's in the 
molecule are shown. 
6 
(1) PPE 
(2) CHYMOTRYPSIN 
7 
(3) TRYPSIN 
(4) SGPA 
8 
(5) SGPB 
(6) PORCINE PANCREATIC KALLIKREIN 
9 
(7 ) (l - L YTI C PROTEASE 
FIGURE 1.0 
10 
1.2 PURIFICATION 
PPE is usually isolated from an activated extract of porcine 
pancreas, commercially available as trypsin 1-300 
26 (Nutritional Biochemical Corporation). Shotton has 
described the complete isolation procedure of the enzyme 
from the acetone powder. 
The steps involved are : (1) crude PPE is extracted from 
trypsin 1-300 with 0.1M sodium acetate buffer pH 4.510 ; (2) 
precipitate from the extract by 45% saturation of ammonium 
10 sulphate ; (3) the 
distilled water and the 
precipitate is dialysed against 
10 
euglobulin precipitate collected • 
(4) Batch adsorption of impurities on DEAE-Sephadex at pH 
8.827 ; is followed (5) by dialysis against 1mM acetic acid 
and freeze-drying; (6) The first batch crystallisation with 
0.1M sodium sulphate buffered at pH 5.0 with O.OlM sodium 
acetate; is followed (7) by dialysis against 1mM acetic 
acid and freeze-drying; (8) re-crystallisation is as in 
steps 6 and 7. 
PPE is always associated with some trypsin and chymotrypsin 
activity. The degree of contamination by trypsin and 
chymotrypsin for the above procedure has been shown by 
Shotton28 to be less than 0.01% and 0.04% respectively. The 
yield obtained is about 2.7g of twice-crystallised PPE per 
5008 of trypsin 1-300. This procedure has so far given the 
purest PPE reported. 
1.3 STABILITY 
In comparison with the other two pancreatic proteases, PPE 
seems more stable. The study reported by Lewis et a110 
shows when PPE is incubated for 24 hours between pH 4 to 12 
at 50 C, it does not lose its activity. However, below pH 
4.0 rapid inactivation occurs. This has been shown by 
Gertler and Hofaann29 and Wasi and Hofmann30 to be related 
11 
to the pH-dependent conformation change of the PPE molecule 
(pK 3.55). The stability of trypsin and chymotrypsin, in 
a 
comparison with PPE is greater at pH 3.0. 
Concentrations of up to 50 mg/ml of PPE were found to be 
readily soluble in water or dilute salt solutions between pH 
4.0 and 10.526 • At 20 C solutions of PPE are stable for 
prolonged periods below pH 6.0 and also reasonably stable at 
higher pH's. However, if incubated at room temperature at 
or near its optimum pH of 8.8, PPE was found to undergo 
28 
autolysis to mixture of peptides • 
Crystals of PPE in 1.2M sodium sulphate buffered at pH 5.0 
with 0.01M sodium acetate are stable indefinitely at room 
temperature and freeze-dried PPE is stable for long periods 
at _100 C28 • 
1.4 PHYSICAL PROPERTIES 
The PPE molecule consists of a single polypeptide chain of 
240 amino-acid residues containing four disulphide bridges. 
The amino-acid sequence is shown in table 1.1. From the 
13 
amino-acid composition , the molecular weight of PPE was 
calculated at 25,900 which compared very well with the 
10 figure of 25,000 estimated from ultracentrifugal analysis • 
The otber pbysical properties are summarised in table 1.2 
TABLE 1.1 
THE AMINO-ACID SEQUENCE ALIGNMENT OF PPE13 WITH THOSE OF BOVINE CHYMOTRYPSIN A {BCA)14, 
BOVINE CHYMOTRYPSIN B (BCB)15, PORCINE PANCREATIC TRYPSIN {PPTY)6, SGPA15, SGPB15 , 
PORCINE PANCREATIC KALLIKREIN (PPKK)16, CRAB COLLAGENASE (COLL)17, AND THE LIGHT 
CHAINS OF HUMAN COMPLEMENT COMPONENT Crr18, AND CiS19 
16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 
PPE V V G G T E A Q R N S W P S Q I 
BCA I V N G E E A V P G S W P W Q V 
BCB I V N G E D A V P G S W P W Q V 
PPTY I V G G Y T C A A N S V P Y Q V 
SGPA I A G G E A I 
SGPB I S G G D A I 
PPICK I I G G R E C E K N S H P W Q V 
COLL I V G G V E A V P N S W P H Q A 
crr I I G G Q K A K M G N F P W Q V 
Cls I I G G S D A D I K N F P W Q V 
32 33 34 35 ~ 
tv 
S L Q Y 
S L Q D 
S L Q D 
S L N 
T T G 
Y S S 
A I Y 
A L F I 
F T N 
F F D N 
TABLE 1.1 (Contd. 
36 36A 36B 36C 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 
PPE R S G S S W A H T C G G T L I R Q N W V 
BCA K T G F H F C G G S L I N E N W V 
BCB S T G F H F C G G S L I S E D W V 
PPTY S G S H F C G G S L I N S Q w V I-' w 
SGPA G S R C S L G F N V V A H A 
SGPB T G R C S L G F N V T Y Y F 
PPIX Y H S S F Q C G G V L V N P K W V 
COLL D D M Y F C G G S L I S P E W I 
CIr I H G R G G G A L L G D R W I 
CIs P W A G G A L I N E Y W V 
TABLE 1.1 (Contd.) 
53 54 55 56 57 58 59 60 61 62 63 64 65 65A 66 67 68 69 70 71 
PPE 
BCA 
SCB 
PPTY 
SGPA 
SGPB 
PPKK 
COLL 
CIr 
CIs 
M 
V 
V 
V 
L 
L 
L 
L 
L 
L 
T 
T 
T 
S 
T 
T 
T 
T 
T 
T 
T 
A 
A 
A 
A 
A 
A 
A 
A 
A 
I---
A 
,....--
H C 
A H C 
A H C 
A H C 
G H C 
G H C 
A H C 
A H C 
A H T 
A H V 
V D R E L 
G V T T 5 
G V T T 5 
Y K 5 R I 
T N I 5 
T D G A 
K N D N Y 
M D G A G 
L Y A S L 
V E 
T F R V V V G E H 
D V V V A G E F 
D V V V A G E F 
Q V R L G E H 
A S W S 
T T W W 
E V W L G R H 
F V D V V V G G A 
D V P L G H T N 
M Y V G S T S 
~ 
.p-
TABLE I.! (Contd.) 
72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 
PPE N L N Q N N G T E Q y V G V Q K I V V H 
BCA D Q G 5 5 5 E K I Q K L K I A K V F K N 
BCI D Q G L E T E D T Q v L K I G K V F K N 
PPTY N I D V L E G N E Q F I N A A K I I T H t-' V1 
SGPA I G T R T G T 
SGPB A N 5 A R T T V L G T T S G 5 
PPlCK N I K E D E N T A Q F F G V T A D F P H 
COLL N I R E D E A T Q v T I 5 T 0 F T V H 
CIr V E E L K K L G N H 
-CIs V Q T 5 R L A K S K K L T P E H V F I H 
TABLE L! (CoDed.) 
92 93 94 95 96 97 98 99 99A 99B 
PPE P Y W N T D D V A A 
DCA S K Y N S L T I 
BCB P K F S I L T V 
PPTY P N F N G ·N T L 
SGPA S F P 
SGPB S F P 
PPIO{ P G F N G K D Y 
COLL E N Y N S F V I 
crr P I R E S Y N F 
CIs P G W F D 
100 101 102 103 104 105 106 107 108 109 
G Y D I A L L R L A 
N N D I T L L K L S 
R N, D I T L L K L A 
D N D I M L I K L S 
N N 0 Y G I I R H S 
N N D Y G I V R Y T 
S H 0 L M L L R L Q 
S N D I A V V R L P 
E G D I A L L E L E 
- N D I A L V R L K 
~ 
(J\ 
TABLE 1.1. (Contd.) 
110 III 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 
PPE Q S V T L N S Y v Q L G V L P R A G T I 
BCA T A A S F S Q T V S A V C L P S A S D D 
BCB T P A Q F S E T V S A V C L P S A D E D 
PPTY S P A T L N S R V A T V S L P R S C A t-' 
"'-I 
SGPA N P A A A N G R V Y L Y Q D I T T A G N 
SGPB N T T I P K D G T V G G Q D I T S A A N 
ppn s P A Ie I T D A V K V L Q L P T Q E P 
COLL V P V T L T A A I A T V G L P S V G V 
CIr N S V T L G P N L L P I C L P D N D T F 
CIs D P V K K G P T V S P I C L P G T S S D 
TABLE I.!. (Contd.) 
130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 
PPE L A N N S P C Y I T G W G L T R T N 
BCA F A A G T T C V T T G W G L T R Y T N 
BCB F P A G M L C A T T G W G K T K Y N A 
PPTY A A G T E C L I S G W G N T K S S G ~ 
00 
SGPA A F V G Q A V Q R S G S T T 
SGPB A T V G M A V T R R G S T T 
PPICK E L L G S T C E A S G W G S I E P P B 
COLL G T V V T P T G W G L S D S A 
Cir Y D L G L V S G P G V M E E 
CIs Y N L G D L G L I S G W G R T E K 
TABLE I.! (Contd.) 
149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 
PPE G Q L A Q T L Q Q A Y L P T V D Y A I 
BCA A N T P D R L Q Q A S L P L L S N T N 
BCI L K T P D K L Q Q A T L P I V S N T D 
PPTY S S Y P S L L Q C L K A P V L S D S S I-' 
\0 
SGPA G L R S G S V T G L N A 
SGPI G T H S G S V T A L N A 
PPICK F E F P D E I Q c v Q L T L L Q N T F 
COLL L G I S D V L R Q v D V P I M N S D 
Cir K I A R D L R F V R L P V A N P Q A 
CIs R D R A V R L K A A R L P V A P L R K 
TABLE I.! (Contd.) 
168 169 170 170A 170B 171 172 173 174 175 176 177 178 179 180 181 182 183 184 
PPE C S S S S Y W G S T V K N S M V C A G 
DCA C K K Y W G T K I K D A M I C A G 
BCB C R K Y W G S R V T D V M I C A G 
PPTY C K S A Y P G Q I T G N M I C V G 
N 
SGPA T V N Y G S S G I V Y G M I Q T N 0 
SGPB T V N Y G G G D V V Y G M I R T N 
PPD( C A B A H P B K V T E S M L C A G 
COLL C D A V Y G I V T D G N I C I D 
Clr C E N W L R G K N R Q N M F C A G 
CIs C K E Y K V E K P T P N M I C A G 
TABLE 1.1 (Contd.) 
185 186 187 188 188A 189 190 191 192 193 194 195 196 197 198 199 200 201 
PPE G N G V R S G C Q G D S G G P L H C 
BCA A S G V S S C M G D S G G P L V C 
BCB A S G V S S C I M G D S G G P L V C 
PPTY L E G G K D S c Q G D S G G P V V C tv 
SGPA V C A G D S G G 
t-' 
S L F A 
SGPB V IC A G D S G G p L Y S 
PPICK L P G G K D T C M G D S G G P L I C 
COLL S T G G K G T C I D G D S G G P L N Y 
CIr H P S L K D A C I Q CIs G E K G M D S C K G D S G G G D S G G V F V R A F V Q 
TABLE l.! (Contd.) 
202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 217A 218 219 
r---
PPE L V N G Q y A V H G V T S F V S R L G 
BCA K K N G A W T L V G I V S W G S S T 
BCB Q K N G A W T L A G I V S W G S S T 
PPTY N G Q L Q G I V S W G Y G N 
SGPA G S T A L G L T S G G S 
N 
G N 
SGPB G T R A I G L T S G G S C N 
PPICK N G M W Q G I T S W G H T P 
COLL D G 
- L T Y G I T S F G S G 
Cir D P N R W V A T G I V S W G - I G 
CIs D P N G K F Y A A 
---L L V -L w G - p Q 
--
TABLE 1.=.!. (Contd.) 
220 221 221A 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 
PPE C N V T R K P T V F T R V S A Y I S W 
BCA C S T S T P G V Y A R V T A L V N W 
BCB C S T S T P A V Y A R V T A L M P W 
PPTY C A Q K N K P G V Y T K V C N Y V N W N 
w SGPA C R T G G T T F Y Q P V T E A L A Y 
SGPB C S S G G T T F F Q P V T E A L A Y 
PPKK C G S A N K P S I Y T K L I F Y L D W 
COLL C E A G Y P D A F T R V T Y F L D W 
CIr C S R G Y G F Y T K V L N Y V D w 
CIs C G T Y G L Y T R V K N Y V D W 
TABLE l.l (Contd.) 
238 239 240 241 242 243 244 245 
PPE I N N V I A S N 
BCA V Q Q T L A A A 
BCB V Q E T L A A N 
PPTY I Q Q T L A A N 
SGPA G A T V L N 
~ 
SGPB G V S V Y 
PPICK I B B T I T E N 
COLL I Q Q T I T P 
Clr I K K E M E E E 
CIs I M K T M Q E N 
NOTE : 
14 The numbering is that of chymotrypsinogen A , with insertions in the sequences of the other 
enzymes denoted as 36A, 36B, etc. The deletions are denoted by broken lines. Those residues 
that are chemically identical in all ten protein sequences are enclosed in solid lines. 
The residues that are doubly underlined are those that are topologically equivalent in 
a 20 the serine proteases. The single-letter code for the amino-acids is used in this table • 
PPKK, COLL, Clr and CIs were only aligned in sequences. 
TABLE 1.2 
PHYSICAL PROPERTIES OF PPE 
Parameter 
E1% 
1cm 
Isoelectric point 
S 20,w 
D 20,w 
25 
Partial specific volume 
Frictional ratio 
1.5 THREE-DIMENSIONAL STRUCTURE OF PPE 
20.226 
9.52 
2.62 
9.52 
0.72626 
1.22 
31 Before any X-ray structure deter1llination of PPE, Hartley 
in 1970 built a hypothetical model of the enzyme, into the 
three-dimensional structure of chymotrypsin, determined in 
196732 • This work was based on the assumption that the 
tertiary structures were very similar, since the covalent 
structure of PPE showed it to be homologous with trypsin and 
chymotrypsin. 
However, shortly after this 1Ilodel, the three-dimensional 
structure of PPE was determined at 3.5 A resolution from 
inhibited PPE rather than the native33- 3S • 
The X-ray diffraction data were collected on four 
isomorphous crystalline derivatives; p-toluene sulphonyl 
(tosyl) elastase, p-chloromercurisulphonyl elastase, in each 
case the active centre serine residue is blocked, and on two 
uranyl soaked crystals of these derivatives. The crystals 
crystallised were orthorhombic space group P212121 
with 
unit cell dimensions a • 51.5 J\ b • 58.0 At and c • 75.5 A. 
This corresponded to a unit cell of four molecules, with one 
molecule per asymmetric unit34 •. 
26 
They used tosyl elastase as the "parent" structure, rather 
than using the native PPE, in order to exploit high 
isomorphism in the structure determination, and provide an 
active site label. The three-dimensional structure 
resembled the hypothetical model of Hartley3l and showed 
that the single polypeptide chain of PPE was folded into two 
distinct halves to form a compact globular molecule of 
dimensions 55 x 40 x 38 A. 
The X-ray structure showed the C-terminal part as an G-helix 
and the rest of the molecule was composed of six 
anti-parallel loops of B-sheet folded into two barrel-like 
domains. The two continuous chain domains, residues 27-127 
and 128-230, were stabilised by one and three disulphide 
bridges respectively, and each had one of the catalytically 
essential residues, i.e., histidine-57 and serine-19513 ,35 
36 Ghelis et al investigated the role of the domains in the 
refolding of PPE. They were able to show that the fragment 
126-245 corresponded to one of the two domains and was able 
to refold independently. Moreover, this fragment, prepared 
by limited proteolysis was reduced in strong denaturing 
solvent to give the theoretical titre of six free thiol (SH) 
groups. They were not successful in obtaining a intact 
fragment, 16-125, to study unfolding and folding of this 
domain but managed to identify the disulphide content 
consisting of two SH groups. 
Shotton et a135 observed that the organisation of the 
N-term1nal half of the molecule resembled that of the 
C-terminal half of the molecule when traced to the middle of 
the chain. This similarity had been inferred from the 
hypothetical model of PPE. The structure of native PPE was 
determined at 3.5 A resolution by difference electron 
den81ty mapa between tosyl and native PPE. The structures 
were found to be essentially similar except the orientation 
of side-chain of histidine-57. 
27 
37 38 Shotton et al and Sawyer et al have improved the 
structure of tosy1 elastase to 2.5 A resolution. At this 
resolution all the amino-acids could be identified and were 
found to be identical with the chemically determined 
a 
sequence • Also some twenty-five water molecules bound 
internally and a large number of external water molecules 
were identified. The internal water molecules play a major 
role in stabilizing the active conformation of the enzyme. 
The interior of trypsin and chymotrypsin showed identical 
positions for many of these water molecules. By comparison, 
with the bacterial serine proteases, show only two water 
molecules structurally equivalent to internal water 
39 
molecules with pancreatic serine proteases • 
THE SPECIFICITY OF ENZYME AND THE NATURE OF ITS SUBSTRATEI 
INHIBITOR BINDING SITES 
1.6 THE SPECIFICITY OF PANCREATIC SERINE paOTEASES 
The proteolytic enzymes, trypsin, chymotrypsin and elastase 
being members of the serine protease family hydrolyse 
peptide and synthetic ester substrates by the acylenzyme 
mechanism (figure 1.1). 
E-oH + a-CO-NH-a1 • E-oH.a-CO-NH-al • 
FIGURE 1.1 
0-, 
E-O-C-a • 
k-a1 
E-o-co-a 
+ 
NH _R1 
2 
However there are major differences in the specificity of 
the substrates40 • 
In the case of chymotrypsin, cleavage occurs on the 
C-terminal side of large hydrophobic side-chains, e.g. 
phenylalanine, tryptophan and tyrosine while with trypsin, 
28 
lysine and arginine are required. PPE requires small 
hydrophobic side-chains such as those of alanine. This 
major difference is due to the residues surrounding the 
binding pocket in the active site. 
41 In chymotrypsin , the binding site is formed of a deep 
hydrophobic pocket involving glycine-2l6, glycine-226 and 
serine-189, which not only binds substrates but has the 
ability to orient them correctly for hydrolysis. In 
trypsin, the serine-189 in chymotrypsin is replaced by 
asparate and its negatively charged carboxylate forms a salt 
linkage with positively charged groups. That is, with the 
ammonium or guanidinium at the end of the side-chains of 
lysine or arginine. However, in the case of PPE both the 
flanking glycines are replaced by the bulky amino-acids 
valine-2l6 and threonine-226. This restricts the entry of 
any large side-chains of substrate/inhibitors into the 
pocket. Hence, only small side-chains are capable of 
efficient binding. The enzyme-substrate binding difference 
between chymotrypsin and PPE is shown schematically in 
41 figure 1. 2 • 
29 
Tyrosine substrate 
1 'CH-
I 
\ Q NH H~ /C'\ 
(H OH 
I I (H2 (Hz 
ChymotrYPsin substrate 
binding 'pocket 
Ser195 
FIGURE 1.2 
Alanine substrate 
1 'CH-
I 
\ ~ NH 
HN /C\ 
'CH OH 
(~3 (Hz Ser 195 
(H~ 
(H 
(H{ 
(H~ 
(H 
/ 
OH 
OH 
I (H2 
Elastase substrate 
binding pocket 
30 
1.7 EVIDENCE THAT SUBSTRATE BINDING TO PPE REQUIRES AN EXTENDED 
BINDING SITE 
The substrate binding site of PPE has been shown by Atlas 
42 43 
and Berger ' to be composed of at least seven subsites : 
five subsites towards the N-terminal end and at least two 
subsites towards the C-terminal end of the substrate •. These 
subsites are usually referred to by the nomenclature 
44 introduced by Schecter and Berger • The active site is 
divided into two categories those subsites that are 
occupied by the segment of the substrate which is towards 
the N-terminus from the scissile bond are dono ted by 51' 52 
and S~ etc., whereas those extending towards the C-terminus 
t, , 
are 51' S2 and S3· 
Substrate 
POINT OF CLEAVAGE 
s' Sl Sl 
1 2 3 
ENZYME 
Schematic representation of enzyme - substrate complex 
FIGURE 1·3 
31 
Also, studies on the binding sites have been carried out by 
several groups and have concluded that firstly, at least 
seven subsites are involved in the binding of substrate. 
Secondly, the catalytic efficiency is increased considerably 
with the extension in the chain length of the substrates and 
inhibitors45- 47 • This is emphasised in table 1.3 showing 
substrates and inhibitors with different leaving groups. 
TABLE 1.3 
INFLUENCE OF CHAIN LENGTH OF SUBSTRATE AND INHIBITORS ON 
PPE. 
Peptide 
ESTER SUBSTRATES46 ,a 
Ac-Ala-OMe 
Ac-Ala-Ala-OMe 
Ac-Ala-Ala-Ala-OMe 
Ac-Ala-Ala-Ala-Ala-OMe 
kcat/K 
m 
(M-1 Sec-1) 
1 4.9 x 10 
3 2.2 x 10 
5 3.0 x 10 
1.8 x 106 
AMIDE SUBSTRATES AND INHIBITORS46 ,a 
Ac-Ala-NH2 
Ac-Ala-Ala-NH2 
Ac-Ala-Ala-Ala-NH2 
Ac-Ala-Ala-Ala-Ala-NH2 
PEPTIDE CHLOROMETHYLKETONE 
Ac-Pro-Ala-CMlt 
Ac-Pro-Ala-Pro-CMlt 
Ac-Pro-Ala-Pro-Ala-CMlt 
a pH 9.0 and 370 C 
b pH 6.S and 250 C 
1.5 x 101 
2 5 103 • x 
(CMlt)47,b 
-2 5.0 x 10 
1 3.5 x 10 
2 2.6 x 10 
1.5 x 102 
5.0 x 101 
3.0 
32 
This evidence has also been supported by the crystallo-
graphic studies of Shotton et a148 on the inhibitors 
Ac-Ala3, Ala3 and Ac-Pro-Ala-Pro-Ala.OH. These inhibitors 
were all demonstrated to bind at the major site of PPE with 
full occupancy at subsites, i.e., S321' S4339 and S54321· 
(The abbreviation suggested by Thompson et al will be used 
for a binding mode of a peptide to the subsites for instance 
to S4' S3' S2 and S1 by the symbol S4321). Also, Hughes et 
a150 and Renaud et a151 have reported extended binding 
sites towards the 
Resonance (N.M.R.) 
C-terminal 
studies by 
end. Nuclear 
Dimicoli et 
oligopeptide inhibitor have added further evidence. 
1.8 THE SPECIFICITY OF PPE 
Magnetic 
a152 on 
The specificity of PPE was first studied by Naughton and 
22 Sanger towards the A and B chains of oxidized insulin. 
They reported that PPE cleaved peptide bonds adjacent to 
neutral aliphatic amino-acids. Later studies by Sampath-
53 Narayanan et al observed a narrower specificity toward 
peptide bonds. It was shown that the specificity was mainly 
directed toward the bonds involving alanine-8 and serine-12 
in the A chain and a1anine-14, va1ine-18 and glycine-23 in 
the B chain. 
The specificity of PPE has also been studied using synthetic 
54 55 54 
substrates ' • Bender et a1 reported their results, 
table 1.4 using p-nitrophenyl esters of benzyloxycarbonyl-
L-a1l1no-acids. From table 1.4, they found the preferred 
residue was alanine whereas proline or tyrosine esters were 
virtually unhydrolysed. These results have also been 
confirmed by others56 ,57. Hence it can be concluded that 
subsite 81 is specific for alanine. 
33 
TABLE 1.4 
THE SPECIFICITY OF SUBSITE Sl in PPE 
Substrate 
Z-Ala-oNp 
Z-Gly-ONp 
Z-Val-oNp 
Z-Leu-ONp 
Z-Ile-ONp 
Z-Pro-ONp 
Z-Tyr-ONp 
Z - Benzyloxycarbonyl 
ONp - p-Nitrophenyl 
kcat/Km 
(M-1 Sec-1) 
loS x 105 
1.5 x 104 
2.2 x 103 
2.9 x 104 
2.9 x 102 
2.0 x 101 
S.O x 101 
This subsite has also been shown to be rather stereo-
specific, when an oligopeptide amide with aD-alanine 
instead of L-alanine at Pl was not hydrolysed by PPE
46
, that 
is, Ac-Pro-Ala-Pro-D-Ala-NH K - 4SmM while Ac-Pro-Ala-Pro-
2 i 49 
Ala-NR2 Km - 3.9mM. Shotton et al have also concluded 
that to facilitate acylation, the methyl group of P1 alanine 
must be sandwiched between the side-chains of valine-216 and 
glutamine-192. This enables the Pl-Pl ' scissile bond to 
orient favourably relative to the position of serine-l95, 
facilitating acylation. 
However, subsite 51 shows a different preference in the case 
of trlfluoroacetyl (TFA) peptides. which have shown to be 
very potent PPE inhibitors. N.M.R. studies and kinetic 
52 5S-60 
measurement' deaonetrated that the TFA group forces 
the TFA peptides to bind in a special mode to the active 
center of the enzyme. 
34 
The site of binding of the TFA group to PPE in solution is 
unique and is in the vicinity of the subsite S1 of the 
61 50 
enzyme X-ray study by Hughes et al of a crystallised 
complex of PPE with CF3CO-Lys-Ala-NH-Ph-p-CF3 (Ph - Phenyl) 
showed the CF 3CO group bound at Sl and the res t of the 
peptide forming a parallel sheet with residues 214-216. 
5ubsite 52 is able to bind proline or alanine equally 
effectively as the P2 residue in substrates or inhibitors, 
bl 1 562,63 ta e. • However, subsite 52 is found to depend on 
the residue at subsite 54' since this subsite, S4' is also 
important for the binding process. Therefore, when alanine 
in P2 was replaced by proline, in the tetrapeptide 
substrates and inhibitors, kcat/K and kobsd/[I] increased 
62-64 m by a factor of 2 and 4 , table 1.5. Hence, the subsites 
52 and 54 bind a proline residue satisfactorily. Proline in 
54 is shown to bind efficiently at these subsites48 and also 
the proline side-chain forms a good hydrophobic contact with 
the side-chain of leucine-lSI and its carbonyl oxygen is 
able to form a hydrogen bond with the Jl nitrogen atom of 
histidine-40 or with the main chain nitrogen atom of 
threonine-4148 • 
35 
TABLE 1.5 
EFFECT OF ALANINE OR PROLINE RESIDUES IN POSITION P~ 
AND THE EFFECT OF SUBSTITUTION OF ALANINE IN P2 RESIDUE IN 
TETRAPEPTIDE SUBSTRATE OR INHIBITOR FOR PROLINE FOR PPE 
62 c Ac-Ala-Ala-Ala-Ala-NH2 ' 
Al NH 62,c Ac-Ala-Ala-Pro- a- 2 
62 c Ac-pro-Ala-Ala-Ala-NH2 ' 1 63,c Ac-Pro-Ala-Pro-A a-NH2 
64 d Ac-Ala-Ala-Ala-CMK ' 
64 d Ac-Ala-Pro-Ala-cKK ' 
64 e Ac-Ala-Ala-Ala-Ala-CMK ' 
64 e Ac-Ala-Ala-Pro-Ala-CMK ' 
CpR 9.0 and 370 C 
dpH 6.5 and 300 C 
epH 5.0 and 300 C 
K 
m 
(mM) 
2.9 
2.1 
3.9 
3.9 
Ki kobsd/[I] kcat/K m 
-1 -1 -1 -1 (mM)(M sec ) (M sec ) 
9.8 
38.0 
1.5 
1.2 
1.2 x 10 3 
2.2 x 10 3 
Subsi te 53 has been shown to bind only alanine. When 
proline is the P3 residue no binding occurs. However their 
analogues with alanine show reactivity. 
51 Renaud et al have investigated the specificity of subaite 
r , 
51 and 52 using trifluoroacetyl dipeptide anilidea. They 
carried out mapping of theae subsites for PP!, since Hughes 
et alSO had already studied, its complex with C'3Co-LY1-
Ala-NH-Ph-p-C'3 at a resolution of 2.5 A. 
Subsite SI is found to prefer larse p{ residues compared to 
the other subsitea, (table 1.6). They oblerved that 
, 
substitution of alanine by lysine in '1 lead. to • 6-fold 
36 
decrease of the Michaelis constant. This is also in 
agreement with their previous result shown by enzymatic and 
61 N.M.R. studies • 
TABLE 1.6 
, , 
SPECIFICITY OF SUBSITES SJl AND S~ 
Peptide 
P P' pi 
1 1 2 
CF3CO-Ala-Ala-NH-Ph-p-CF3 
CF 3CO-Lys-Ala-NR-Ph-p-CF3 
CF3CO-Lys-Ala-NR-Ph-p-CH(CH3)2 
CF3CO-Lys-Phe-NR-Ph-p-CH(CH3)2 
9 0 10-8 • x 
2.5 x 10-8 
5.0 x 10-8 
4.4 x 10-7 
Renaud et a151 explained the high affinity of the 
Lys-containing peptide on the basis of the examination of 
50 the atomic coordinates obtained by Hughes et a1 with 
CF 3CO-Lys-Ala-NH-Ph-p-CF 3. PPE complex. It was due to a 
favourable van der waals interaction of the 0 -CH2 group of 
lysine with the Y-CH3 group of va1ine-99 which may not exist 
or be weaker in alanine containing peptides. 
, 
Subsite S2' shows a marked specificity for alanine based on 
results of Hughes et alSO and Renaud et a15l • From table 
1.6, it was found that substitution of alanine by phenyl-
alanine for the inhibitor caused a lo-fold increase in Ki • 
X-ray results of C'3CO-LYS-Ala-NB-Ph-p-C'3 showed that Cs of 
the alanine was very far from the centre of 
phenylalanine-21S (9.4 A) and was directed away fro1ll the 
ring suggesting that a strong ring interaction between 
phenylalanine-21S and the phenylalanine residue of the 
peptide CF3CO-tys-Phe-NH-Ph-p-CH(CH3)2 was 1Ilost unlikely. , 
Further1llOre Co of lysine in Sl appeared to interact with the 
, 
side-chain of valine-99 rather than the side-chains of S2. 
37 
Renee the overall conclusion for the preference of subsite 
is :- 51 has preference for two different residues, that is, 
alanine in the case of acetyl peptides or for TFA group in 
the case of TFA peptides; 52 and 54 for proline; 53 for 
, , 
alanine; 51 for lysine and 52 for alanine. 
1.9 X-RAY DIFFRACTION STUDIES ON THE BINDING OF SUBSTRATE! 
INHIBITORS 
PPE might be expected to exhibit similar substrate binding 
sites to those of the other members of the family. However, 
low resolution studies (3.SA) by Shotton et a148 have shown 
that the binding sites for substrates are apparently 
65 66 different to those of chymotrypsin and trypsin ' • 
Thus, there is an apparent confusion as to the exact mode of 
substrate binding in PPE between Shotton and other workers. 
SO Further confusion has arisen from Hughes et a1 involving 
binding of a trif1uoroacety1 dipeptide inhibitor with PPE. 
The mode of binding will be referred to the subsites 
assigned to trypsin, chymotrypsin and SGPA39 • X-ray studies 
on bacterial serine proteases have shown that in the 
immediate vicinity of the active site, there is strong 
homology with the pancreatic enZym8s67. The binding sites 
in SGPA which form anti-parallel S-sheet contacts between 
the peptide group and the main chain residues 214-216 have 
been referred to PI' P2 and P3 i.e., to the N-terminal side 
of the scissile bond (figure 1.4). Si1l1lar S -8heet binding 
arrangements are found in complexes of chymotrypsin and 
trypsin. X-ray diffraction studies on various peptides have 
shown the C-terminal side of the scissile bond in SGPA was 
, , 
found clo8e to the active 8ite i.e., Pl ,P2 etc. 
48 Shotton et al indicated the binding mode of di, tri and 
tetrapeptides 8ubstrate were towards the subaite PI in SGPA 
38 
ACTIVE-SITE OF PPE WITH RESIDUES 214-216 
IN ORANGE 
FIGURE 1.4 
39 
where as has been said, the substrate binding in the other 
enzymes appeared to be associated with the enzyme residue 
214, 215 and 216. Also, the substrate residues for PPE were 
oriented very differently in the direction of the main chain 
of threonine-41 and glutamine-192. 
However, a similar mode of binding to SGPA was observed by 
50 Hughes et al (CF3CO-Lys-Ala-NH-Ph-p-CF3) but resulted in 
further confusion. Firstly, the result obtained contrast 
48 
sharply with those reported by Shotton et a1 • Secondly, 
it was found that the TFA group was found at S1 compared to 
similar group, N-acetyl bound at S4' Thirdly, Hughes et 
a150 observed a similar mode of binding in the same vicinity 
as SGPA but the peptide chain portion was associated in a 
parallel pleated-sheet fashion with the protein chain (he 
describes these subsites as S~, S~ etc). 
Further eVidence for the TFA binding has been obtained from 
19 F N.M.R. spectra of TFA-oligopeptide and TFA-oligopeptide 
anilide inhibitor molecules (Dimicoli et al 1980}61. Also 
by enzymatic and N.M.R. studies (Dimicoli et al 1976}52. 
The binding sites observed by Sawyer67 (unpublished reported 
by Johnson et al) on X-ray diffraction studies at 3.5 A 
resolution of two inhibitors were as that observed by Hughes 
et a150• The binding mode of these inhibitors was 
anti-parallel along the protein chain in the vicinity of 
residues 214-216 with the C-terminal group between 
phenylalanine-215 and glutamine-192 and the N-terminal 
groups in the region between tryptophan-172 and 
threonine-179 (binding of the inhibitor at subsites S1' S2 
and S3)' This is in the same manner with SGPA, chymotrypsin 
etc. 
Thus, there is still uncertainty as to the exact physical 
mode of binding of substrate/inhibitors to PPE. In order to 
map out conclusively the substrate binding site (both to the 
40 
N-terminal and C-terminal side of the scissile bond i.e., 
Pl-P~ sites} evidence from a variety of techniques is 
required. 
1.10 TECHNICAL APPROACHES TO THE INVESTIGATION OF BINDING SITES 
In order to describe the catalytic mechanism of PPE in 
detail, it is necessary to correlate evidence from a variety 
of techniques. Thus, kinetic data from solution studies 
with a variety of substrates and inhibitors need to be 
correlated with structural data showing detailed binding of 
these molecules to the enzyme. The main structural 
technique available is X-ray crystallography, but being a 
time average technique does not allow one to examine the 
catalytic event at regular intervals throughout the 
turnover. 
Several possible strategies are available which approximate 
the ideal experiment. One such is to cool the crystal down 
to low temperatures where the turnover is essentially 
stopped completely and by careful control of temperature, to 
allow the reaction to proceed by discrete steps until the 
69-71 product is formed. Various workers are thought to be 
investigating the structure of PPE at high resolution under 
a variety of conditions of temperature and pH but no results 
have been published. 
An alternative approach can be used where substrate 
analogues for the enzyme allow room temperature mapping of 
the binding site and this approach has already yielded 
excellent results with many enzymes. These inhibitors can 
either be naturally occurring or synthetically produced. 
The naturally occurring inhibitors are classified into two 
categories i.e., inhibitors from animal tissues, turkey 
ovomucoid and chicken ovoinhibitor72 and the serum 
73 74 inhibitors, a-l-ant1tryps1n and armacroglobulin • Also 
small size natural inhibitors, such as elastinal75 ,76, have 
been investigated. 
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Turkey ovomucoid and chicken ovoinhibitor (molecular weight 
of 28,00077 and 46,50078 ) inhibit PPE with a 1:1 stoichio-
metry. They both inhibit the estero1ytic, proteolytic and 
elastolytic activities of PPE72 • The complexes formed are 
stable and the inhibitor totally inhibits the activity of 
PPE. 
72 Gertler et a1 have shown that chicken ovoinhibitor has 
three independent sites for trypsin, chymotrypsin and PPE, 
while turkey ovomucoid has only two binding sites, one for 
trypsin and the other for PPE and chymotrypsin. 
The other category, the serum inhibitors like a -1-
73 
antitrypsin and azmacrog1obul1n are both glycoproteins 
with molecular weight of 52,000 and 725,00079 • The major 
difference between them is that whilst the a -1-
antitrypsin.PPE complex is inactive against elastin80 and 
synthetic substrates/inhibitors81 , the armacroglobu1in.PPE 
complex82 still shows 80-100% of its activity with small 
synthetic substrates/inhibitors although it is totally 
inactive against elastin. It can be assumed that a -1-
antitrypsin binds at the active site while armacroglobu1in 
81 binds somewhere else. The esterolytic and elasto-
lytic80,82 activities of PPE are inhibited by a -1-
antitrypsin compared to armacroglobulin which inhibits only 
the esterolytic activity8I. Meyer et a183 have studied the 
properties of <l -1-antitrypsin and <lZ-macroglobul1n and 
have shown that PPE binds preferentially to <lZ-macro-
globulin. Also the dissociation constant between a -1-
antitrypsin.PPE complex is much less than that of ~cro­
globulin.PPE complex. 
Elastinal, N[(S)-1-carboxy-isopentyl]-carbamoyl-(2-imino-
hexahydro-4(S)-pyrim1dyl]-(S)-glycyl-(S)-glutaminyl-(S)-alan 
75 76 ina1 ' was found to be, a specific inhibitor of PPE. It 
exists in various species of actinomycete and i8 found in 
the culture filtrate of Streptomyces griseoruber. 
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Elastinal shows biological activity only towards PPE and not 
with the other serine proteases. Its inhibition is 
competitive with the substrate. Ki is 0.24 1.I M with 
Ac-Ala-Ala-Ala-NR-Ph-N02 and 0.2 1.I M with Ac-Ala-Ala-Ala-OMe. 
Synthetically produced substrate analogues have already been 
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applied with great success by James et a1 , Stroud et a1 
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and at lower resolution by Henderson et al and Davies et 
a186 • This approach was pursued in this work, since there 
was controversy as to the exact mode of binding of 
substrate/inhibitor in PPE as mentioned in section 1.9. 
Another possible way to deterDline the binding sites for 
substrates (both to N-termina1 or C-termina1 of the 
substrate's scissile bond), is to modify the enzyme active 
site thus allowing binding of a c01llplete peptide. The 
active site serine-195 is first che1llically inhibited 
followed by an eli1llination reaction to convert -CR20R into 
-CH2• This totally inactivates PPE. Low resolution studies 
(3.5 A.) on the modified enzYDle87 , anhydroelastase, have 
shown S01lle changes in the active site. SiDlilar to those 
with anhydrotrypsin and anhydrochymotrypsin, che1llically and 
also by X-ray studies88- 91 • 
The refined structure of anhydroelastase and that of PPE 
1Ilodified by diffusion of substrate/inhibitors into the 
crystals would distinguish the binding sites on both sides 
of the scissile bond, thus establishing the required 
orientation for peptide eleavage. Using the well 
92 
established teehniques of protein erystallography it 
should be able to resolve the eontroversy between various 
workers about the binding sites of PPE. 
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1.11 STUDIES TO BE CARRIED OUT TO ESTABLISH THE BINDING MODE IN 
PPE USING SYNTHETIC SUBSTRATE/INHIBITORS 
Various studies to block the active site serine-l95 will be 
carried out firstly, followed by the elimination to convert 
-CH20H into -CR2• This totally inactivates the enzyme and 
hence the whole substrate should be able to be bound intact 
to the active site. 
87-91 Previous studies with the serine pancreatic proteases 
where the enzyme was inhibited using radioactive labelled 
14 inhibitor i.e., C labelled tosyl fluoride or phenylmethane 
sulphonyl fluoride (PMSF) (the carbon atom labelled is 
attached to the sulphonyl group) have been used in the 
preparation of anhydroenzyme. 
The preparation of anhydroenzyme is a two stage process as 
shown in figure 1.5. The first stage can be performed using 
non-radioactive label inhibitor, because the per cent 
inhibition will give an indication of the inhibition 
measured using a substrate. However, the second stage is 
crucial since the base elimination of the inhibitor is 
difficult to detect. Moreover, since the anhydroenzyme 
formed is inactive there is no certainty of the inhibitor 
has been removed. 
44 
ELASTASE. 
ANHYORQELASTASE 
A schematic representation of reaction steps 
FIGURE 1·5 
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However, with the present work, non-radioactive tosyl 
fluoride and PMSF inhibitor were used for several reasons. 
Firstly the procedure was more straight forward as the 
optimum condition for the preparation of anhydroelastase had 
87 
already been found by Murphy • Secondly, the major problem 
was 14C labelled inhibitor was not available on the market 
and therefore required special preparation by the supplier, 
which meant the inhibitor was prohibitively expensive. 
Lastly, there were local restrictions on non-qualified 
persons using labelled compounds. 
Thus, during the preliminary studies potential fluorescent 
probes, I-dimethylamino-naphthalene-5-sulphonyl halide 
(Dansyl fluoride or chloride) and p-Nitrophenyl anthranilate 
(NPA) were also examined, since they had been found to 
93 94 inhibit a-chymotrypsin ' • These could be detected by 
fluorescent emission at 505 and 422 mll when bound to the 
enzyme. On base elimination no emission spectra should be 
obtained. 
The other modification attempted was to convert serine-195 
to cysteine, either by substitution of the inhibited PPE or 
Michael type addition to the double bond in anhydroelastase 
with thiolacetate (this latter giving another means of 
detecting the presence of dehydroalanine). The reaction 
steps are summarised in figure 1.6. 
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C~O-S02-<_)-(H3 
~~~ OH- ) 
INHIBITED ENZYME A NHVPRQELASJASE 
CH3COSH Subst itution CH3COSH Addition 
THIOl- ENZY ME IHIOL- ENZYME 
A schematic representation of reaction steps involved 
in prepara tion of Thiol- Enzyme 
FIGURE 1.6 
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This is of interest, since thiol proteases are analogous to 
the serine proteases. The thiol proteases are another 
widely distributed group of plant enzymes, (papin, 
actinidin, ficin and bromelain) which contain an active site 
cysteine. This plays a role analogous to that of serine-l95 
in the serine proteases. The conversion from OH to SH in 
PPE may provide completely different insight into the 
reactivity of PPE. 
Once the anhydroelastase is prepared and crystallised, the 
crystals will be soaked with the hexapeptide substrate 
(according to section 1.8) i.e., R.Pro-A1a-Pro-A1a-Lys 
-Phe.OR. The substrate will be examined to reveal the 
binding sites to the carboxyl side of the scissile bond 
, , 
i.e., Pl , P2 etc. Also a number of tetrapeptide inhibitors 
Ac-Pro-Ala-Pro-Ala.OH, Ac-Pro-Ala-Pro-Alaninal (peptide 
aldehyde) and TFA-Pro-A1a-Pro-A1anina1 will be investigated. 
The product inhibitor Ac-Pro-Ala-Pro-Ala.OH will be examined 
for the anomalous binding since previous work (Sawyer 
unpublished) has failed to reproduce the reported results of 
48 Shotton et a1. The purpose of peptide aldehydes is 
firstly to distinguish the different mode of binding between 
acetyl and TFA group. Since, it has been suggested that the 
TFA group binds to PPE in a unique binding mode50 ,52. 
Secondly, they bind to PPE more tightly than the substrates 
(table 1.7). This is probably due to the formation of a 
95 transition state analogue, a hemiacetal ,which is like the 
tetrahedral intermediate in figure 1.7. 
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TABLE 1.7 
KINETIC CONSTANTS FOR PPE CATALYSED HYDROLYSIS OF 
PEPTIDE AMIDES AND PPE BINDING TO ALDEHYDES 
Peptide 
64 f Ac-Ala-Pro-Ala-NH2 ' 95 g Ac-Ala-Pro-Alaninal ' 
64 f Ac-Pro-Ala-Pro-Ala-NH ' 
2 95 h Ac-Pro-Ala-Pro-Alaninal ' 
fpH 9.0 and 370 C 
gpH 7.0 
h pH 4.0 
Ki 
(mM) 
0.062 
0.002 
K 
m 
(mM) 
4.2 
3.9 
59 The inhibitor TFA-Ala3-CMK prepared by Bieth et al will be 
examined for anomalous binding at 2.5 A resolution. (Data 
collected by Dr Sawyer). Beith et a159 have investigated 
this inhibitor using 19, and IH N.M.R. spectroscopy. They 
have shown the TFA-peptide binds directly to the active 
centre of PPE which is irreversibly inhibited. 
O.H 
R-(-O-Ser-Enz 
.1 
H 
g l;~ C I 
/ \ 
_ /CH 2 
\ ~r (H O-H--N -H--·O 195 
2 V I 
Asp 1 02 His 57 /C" 
HzN -b R 
Hemiacetal compared to enzyme catalysis intermediate 
FIGURE 1·7 
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CHAPTER TWO 
PREPARATION or PPE AND ANHYDROELASTASE 
S6 
Anhydroelastase is prepared by converting the active site 
serine-195 of PPE into dehydroalanine by an elimination 
reaction. This is performed by inhibiting PPE with various 
inhibitors; tosyl fluoride, PHSF, NPA, and Dansyl fluoride 
or chloride, followed by a base elimination reaction 
involving treatment of the inhibited PPE with alkali. Also, 
modification of serine-195 to cysteine either by substi-
tution of the inhibited PPE or addition to the double bond 
in anhydroe1astase was attempted. 
2.1 MATERIALS AND METHODS 
PPE (EC 3.4.21.11) was purified from trypsin 1-300 (United 
States Biochemical Corporation, Cleveland, Ohio, U.S~A.) by 
the method of Shotton1• Thrice crystallised chymotrypsin 
(EC 3.4.21.1 activity 8895 A.T.E.E. units/mg) was purchased 
from Koch Light Ltd and trypsin (EC 3.4.21.4 activity 15,000 
B.A.E.E. units/mg) from Sigma Chemical Ltd. 
N-t-Buty1oxycarbonyl-L-alaninate-p-nitrophenyl ester (NBA), 
N-a-Benzoyl-L-arginine ethyl ester (B.A.E.E.), N-Acetyl-
L-tyrosine ethyl ester (A.T.E.E.), NPA, PHSF and Dansyl 
fluoride or chloride were all obtained from Sigma Chemicals 
Ltd. Tosy1 fluoride was purchased from Aldrich Chemicals 
and potassium thiolacetate was obtained from F1uoro 
Chemicals Ltd. 5,5 ' -dithio-bis-(2-nitrobenzoic acid) 
(Ellman's reagent) was purchased from Koch Light Ltd. 
DEAE-Sephadex A-50 was purchased from Pharmacia Fine 
Chemicals. Buffers and reagents were prepared according to 
2 the tables published in Data of Biochemical Research. A 
radio-meter, pH M 7010 with glass electrode was used for all 
pH measurements. 
2.2 PROTEIN CONCENTRATION AND ENztME ASSAY 
Concentrations were determined by measuring absorbances at 
280 nm using a Beckman Acta MIV SpectrophotoMter. The 
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E I1i-em· • 20.2, following standard absorbances were used : PPE, 
1% 
molecular weight 25,900; chymotrypsin, E lc~ 20.0, molecular 
weight 25,100; trypsin, E~!m- 15.9, molecular weight 23,900. 
PPE was assayed using NBA at 347.5 nm by' the method of 
Visser and Blout3• The standard assay conditions for PPE 
were as follows: An exact volume of 30 ~l of 10-~ stock 
solution of NBA in spectroquality methanol was added to 
2.95 ml of O.OSM sodium phosphate buffer, pH 6.5 in quartz 
reference and sample cuvettes (I-em pathlengths). The 
absorbances were balanced and after 3 minutes of incubation, 
20 ~l of PPE solution (1 mg/ml) was added. The increase in 
absorbance was followed for 2 to 3 minutes. 
The assay conditions for trypsin were as fOllows4: To the 
quartz reference and sample cuvettes (l-cm pathlengths) 
2.80 ml of 10-4M stock solution of B.A.E.E. in 0.05M 
2-amino-2-hydroxy-methyl-propane-1,3-diol (Tris) buffer, pH 
8.0 containing 0.2 mg CaC12/ml was added to the reference 
and sample cuvettes and the absorbance balanced at 253 nm. 
After incubation for 3 minutes, 0.2 ml of 10-4 M hydro-
chloric acid (HC1) was added to the reference cuvette and to 
the sample cuvette, 0.2 m1 of stock solution of trypsin 
(0.003 mg/ml) in 10-4 M HC1 was then added and the increase 
in absorbance followed for 2 to 3 minutes. 
To assay for trypsin contamination in PPI. similar assay 
conditions were used except 0.2 m1 of stock solution of PPE 
(1 mg/m1) was added to the sample cuvette. 
4 Similar assay conditions were used for chymotrypsin. This 
time the substrate. A.T.!.!.. dissolved in O.OSM sodium 
phosphate buffer pH 7.0 was used. In this case the decrease 
in absorbance was followed for 2 to 3 minutes at 237 nm. 
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2.3 PREPARATION AND MODIFICATION OF PPE 
2.3.1 PURIFICATION OF PPE 
All stages are conducted at +40 C. AnalaR reagents were used 
throughout. 
Two different batches (100g and 200g) of trypsin 1-300 were 
used in separate purifications of PPE. The yields obtained 
were considerably lower (115mg for twice-crystallised and 
120mg for thrice-crystallised) than those obtained by 
1 Shotton , who quotes 2.7g of thrice-crystallised material 
from a 5008 batch. It was found at the crystallisation 
o 
stage that cooling to 4 C was necessary for crystallisa-
tion. (In the case of the first batch the DEAE-Sephadex 
filtrate (freeze-dried) had to be put through stage 21 again 
since the enzyme would not crystallise with 0.1M sodiu1D 
sulphate). The percentage contamination by trypsin and 
chymotrypsin was shown to be less than 0.02% for these 
enzymes. 
2.3.2 PREPARATION OF TOSYL ELASTASE AND PHENYLMETHANE SULPHONYL 
ELASTASE (PHSE) 
5 These were prepared by the method of Murphy. Preliminary 
studies (once crystallised PPE was used, purchased from 
Worthington Biochemical Corporation, the activity was 20 
times les8 than the fresh batch) revealed that the PHSF was 
found to be more reactive and PPE ~ 98% inhibited within 4 
hours. Tosyl fluoride was less reactive and ~ 98% 
inhibition was achieved only after 24 hours. The measure of 
percentage inhibition was by assaying PPE with NBA. 
METHOD 
Once crystallised PPE (SO.4mg, 1.96 l..I mol) was dissolved in 
19.5 ml of ice cold 0.05K sodium phosphate buffer, pH 7.2, 
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containing 0.5 ml of dioxane. The sulphonyl fluoride 
inhibitor (O.9mg, 5.17 1.1 mol) was dissolved in 0.5 ml 
dioxane and added over 1 minute. The solution was left 
stirring in the cold room for 24 hours. During this time 
the solution turned faintly cloudly. It was dialysed 
extensively against 1mM acetic acid and finally against 10mM 
sodium acetate buffer, pH 5.5. The solution was spun for 
half-an-hour at 21,00 rpm (Superspeed 50) and- freeze-dried. 
The enzyme was ~ 98% inhibited. 
2.3.3 PREPARATION OF ANTHRANILOYL ELASTASE6• 
Anthraniloyl elastase was prepared by addition of 0.75 ml of 
4.8mM NPA (4.86 llmol) in acetonitrile to 10 ml of PPE 
(51. 8ml, 2.0 llmol) in 0.1M sodium phosphate buffer, pH 6.8 
o 
at 6 C. The NPA was added in five aliquots at one and a 
half-an-hour intervals. A yellow cream precipitate occurred 
which was dialysed extensively against distilled water. spun 
for half-an-hour at 21,000 rpm (Superspeed 50) to remove the 
precipitate and freeze-dried. The enzyme was ~ 98% active. 
2.3.4 PREPARATION OF DANSYL ELASTASE 
7 The Horton et al method was carried out for the dansylation 
of PPE at pH 8.4 using 0.03M sodium phosphate buffer. This 
method was also used at various pH's (S.S, 6.0, 6.5, 7.2 and 
7.5) using O.OSM sodium phosphate buffer. A solution of PPE 
(32.lmg, 1.2411mol) in 8 ml of O.OSM sodium phosphate buffer 
was cooled in ice and treated with 2.0 ml of Dansyl halide 
(S.l llmol) in dioxane. When the reactions were carried out 
in alkaline conditions dansyl halide was dissolved in 
acetone to stop the protein denaturation. The solution was 
left stirring for 24 hours in the cold room, spun for 
half-an-hour at 21,000 rpm (Superspeed 50) before dialyising 
exhaustively for 2 days against lmM acetic acid and 
freeze-dried. PPE was ~ 20% inhibited at pH 8.4, while no 
inhibition occurred at pH's 5.5, 6.0,6.5,7.2 and 7.5. 
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Dansylation was also carried out on anhydroelastase 
(prepared in 2.3.5). 
2.3.5 PREPARATION OF ANHYDROELASTASE FROM TOSYL ELASTASE OR PMSE 
The procedure used to modify the inhibited PPE to 
anhydroelastase was that of MurphyS and Ako et a18 • 
The inhibited PPE (15.2mg) was dissolved in 1mM acetic acid 
(15.2 ml) and cooled in ice. Potassium hydroxide solution 
(0.1M) was added dropwise over 1 minute until the pH of the 
solution was 12.4. This gave a final concentration of 
hydroxide of 0.025M. After 4 hours the pH of the solution 
was adjusted to 5.0 with HCl (0.5M). 10 ml of 0.01M sodium 
acetate buffer, pH 5.0 was added and the solution dia1ysed 
exhaustively against 1mH acetic acid, spun for ha1f-an-hour 
at 21,000 rpm (Superspeed 50) and freeze-dried. As a 
control the native PPE waa also treated by the above method 
with 0.1M potassium hydroxide and found to be ~ 97% active, 
while the inhibited PPE remained ~ 98% inactive. 
2.3.6 PREPARATION OF THIOL-ELASTASE BY THE ACTION OF THIOL-ACETATE 
2.3.6.1 FROM TOSYL ELASTASE OR PMSE 
The reaction was carried out at two different pH's (6.5 and 
7.5) and temperature (00 C and 200 C). The inhibited PPE 
(16ml, ~ 98% inhibited) waa dissolved in 8 m1 of 1mM acetic 
acid and treated with potalsium thio1acetate (9 ml, 
143 mgtlll) in 0.6M acetate buffer at the appropriate pH 
and temperature. The aolution was left stirring for 2 hours 
and the solution hydrolysed with dilute aamonium hydroxide 
to pH 12 and the pH brought to 13 with sodium hydroxide. 
After four and a half hours, it was dialYled extensively 
against ImH acetic acid and freeze-dried. The enzyme 
wal ~ 98% inhibited. 
61 
2.3.6.2 FROM ANHYDROELASTASE 
The procedure was as for 2.3.6.1 but with anhydroelastase 
instead of inhibited PPE. 
2.4 DISCUSSION 
The percentage inhibition for an inhibited PPE was 
determined by assaying PPE with NBA. Tosyl elastase and 
PMSE were ~ 98% inhibited and PMSF was found to be a better 
inhibitor than tosyl fluoride since inhibition was completed 
within 5 hours compared to 24 hours for the latter. 
The use of fluorescent chromophore. (NPA). to inhibit PPE 
was not successful as it had been found by Haugland et a16 
with chymotrypsin, where the active site serine-195 was 
acylated with this reagent. They found the enzyme was 
inhibited ~ 95% within 24 hours. 
One of the major problems in the case of PPE, was that 
activity could not be measured during the reaction. This 
was because both the inhibitor and the substrate. (NBA). 
produced p-nitrophenol when cleaved by PPE and a180 by the 
buffer. This resulted in a considerable increase in the 
absorbance. However, the activity of the inhibited PPE 
after dialysis was found to be the same as the native 
enzyme. This result confirmed that the anthraniloyl group 
was not attached to the active site. 
Further evidence for the reactions having occurred could be 
obtained by measuring the fluorescence spectrum after 
excitation at 290 m~. Haugland et a16 observed a change in 
the tryptophan emission spectrum (all the tryptophans in the 
enzyme molecule) on excitation at 290 m~ The indication of 
the anthraniloyl group being bound to the active site was 
observed by the tryptophan emisaion at 333 m~ being 
decreased, in the cas. of (l -chymotrypsin. This enhanced 
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the fluorescence maximum at 422 mll due to the release of 
p-nitropheno1 by the inhibitor. This evidence was 
inconclusive and the peak at 333 mu remained the same over 
several hours for PPE. , 
The other fluorescent chromophore, Dansyl halide, used by 
7 9 Horton et a1 and Gold to inhibit a -chymotrypsin by 
dansy1ating 
Dansylation 
serine-195 was 
was carried out 
• 
investigated with PPE. 
on PPE and also on the 
anhydroelastase (pH 8.4). The activity of PPE under 
different pH conditions, including PPE treated under the 
same conditions but without the inhibitor, was measured 
throughout the reaction. A considerable increase in the 
activity of PPE was read at first which gradually dropped 
over 24 hours. After incubation for a further 48 hours, the 
activity dropped by 40% for PPE between pH 5.5-7.5 and by 
20% at pH 8.4. It was impossible to detect with 
anhydroelastase, if dansylation had taken place since the 
enzyme was inactive at the beginning. 
Fluorescence spectra were run for all the dansyl elastase 
preparations at different pH's. Horton et a17 indicated 
that the absorption maximum was around 325-360 m~ and the 
fluorescence maximum around 525 m~. The dansyl elastase 
prepared at pH 8.4 was found to be excited at 340 mu and the 
fluorescence maximum at 505 mu. The wavelength at 340 ml.1 
was taken as a reference for the rest of dansyl elastase 
preparations. but no fluorescence maximum around 525 m~ was 
observed. 
It was concluded that dansylation did not take place in 
acidic or neutral conditions because no change in the 
activity and no fluorescence spectrum were obtained. 
Dansylation did take place in alkaline conditions (pH 8.4) 
and this was also observed by Horton et a17 • Since there 
was' no change in the activity at this pH it was concluded 
the .erine-l95 was not dan.Ylated a. Horton et a17 and Gold9 
had found in the ca.e of a- chyaotryp.in. 
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There was no indication of a fluorescence maximum for 
dansylated anhydroelastase probably because the enzyme had 
the -CH20H converted into -CH2 and hence the OR was not 
available for dansylation. Also there was no indication of 
dansylation taking place anywhere else in the molecule. 
This suggested that the amino-acids prone to dansylation 
were affected under basic conditions in the preparation of 
anhydroelastase. 
TABLE 2.1 
SUMMARY OF PERCENTAGE INHIBITION OF PPE BY VARIOUS 
INHIBITORS 
Inhibited PPE 
Native PPE 
Tosyl elastase 
PMSE 
Anthraniloyl elastase 
Dansyl elastase (only at pH 8.4) 
Inhibition 
0% 
~ 98% 
~ 98% 
~ 2% 
~ 20% 
The use of the fluorescent chromophores gives some 
indication of the mode of binding since these inhibitors 
were found to inhibit a-chymotrypsin very quickly. The 
binding site of PPE (P l ) is different and can only 
accommodate a small group such as methyl because of the 
occulslon by valine-216 and threonine-226. whilst 
in a-chymotrypsin these amino-acids are replaced by 
glycines-216 and -226. 
Attempts were carried out to convert the active center 
serine to cysteine by thiolation of the inhibited PPE and of 
the anhydroelastase. The activity of the enzyme was 
measured against the substrate. MBA. and no change in the 
activity was observed in either case. 
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Experimental evidence to detect the presence of the SH group 
10 in the active site was carried out using Ellman's reagent • 
This reagent reacts with the SH group at pH 8.0 and release 
one p-nitrophenol anion per mole thio1. From this, one can 
measure the thio1 concentration. All of the thio1 
derivatives prepared were reacted with Ellman's reagent to 
detect the presence of the SH group. No change in 
absorbance was noticed. Hence it can be concluded that 
neither substitution nor addition at serine-195 had taken 
5 place. This was also observed by Murphy , when preparing 
from tosy1 elastase, Varying the conditions from his, that 
is, from pH 5.3 to pH 6.5 and 7.5 and also performing the 
o 0 
reaction at 0 C and room temperature rather than at 2 C 
did not result in any change in the reaction. 
From these results, two possible explanations are possible 
about the formation of anhydroelastaae. Firstly, it is 
possible, that the alkaline treatment on the inhibited PPE 
did not eliminate the tosyl or the PMS groups from the 
serine-195. Secondly, if the anhydroelastase were formed 
then conditions used for the addition of the -SR group were 
not sufficient to cause addition at the double bond. 
Hence, to distinguish these two possibilities, a 2.4 A 
resolution data set was collected. After processing and 
comparing the electron density around the active site region 
with the native PPE no change was observed, (figure 
2.0-2.1). Therefore the tosyl and the PMS groups were 
removed. 
However, the anhydroelastase prepared was inactive and 
moreover it crystallised indicating no gross conformational 
changes or denaturation. One possible explanation for no 
difference in the active site could be, the dehydroalanine 
is formed under basic conditions, but changing the pH 5.0 
causes addition to the double bond. If addition takes place 
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in terms of Anti-Markownikoff rule then it results in the 
formation of serine. That is, 
OH 
~H20H 
-8N-C-CO-
I 
H 
It was decided to investigate further 
anhydroelastase crystals (prepared from a 
PPE) in the hexapeptide substrate 
by soaking the 
fresh batch of 
H.Pro-A1a-Pro-
A1a-Lys-Phe.OH (discussed later in chapter eight). 
Collecting the data to 2.5 A 'resolution and processing would 
reveal the mode of binding and in theory the whole peptide 
should be intact. 
After the work reported was carried out, Tasi et a111 have 
reported studies on the inhibition of PPE and 
anhydroelastase by Boronic acids. They used a similar 
14 
method for the preparation of anhydroe1aatase using [ C) 
PMSF, and proved chemically the formation of dehyroa1anine 
at the active site by the addition of radioactive tritium 
sodium borohydride (NaB3H4). They noticed considerably 3 higher radioactivity in the NaB H4 - reduced anhydroe1astase 
than in the control. Further study using NaB3H4 could be 
used to justify the formation of dehydroalanine. 
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6F a NAT ANHYDROELASTASE-NATlVE 
FIGURE 2.0 
FIGURE 2.1 
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CHAPTER THREE 
PEPTIDE SYNTHESIS 
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Interest in the chemical synthesis of peptides stems 
principally from (1) use of such synthesis for the 
unambiguous assignment of structures to naturally occurring 
peptides and (2) use of such synthesis in the production of 
chemical analogues of the naturally occurring peptides. 
Peptides of the latter class are of great interest in terms 
of aiding the understanding of the relationships between 
chemical structure and biological function and for their 
potential medicinal value. 
3.1 PROBLEMS OF PEPTIDE SYNTHESIS 
Peptides and proteins consist of chains of amino-acids 
linked to one another by amide bonds. Peptide synthesis is 
the joining together of chira1 amino-acids to form chains of 
pre-determined length and sequence. Formally peptide 
synthesis consists simply of elimination of water from two 
amino-acids or peptides, figure 3.0. 
FIGURE 3.0 
but due to the dipolar nature of the amino-acids, this 
reaction is thermodynamically unfavourable and requires 
unacceptably high temperatures. It would also lead to a 
mixture of peptides, cyc1isation and po1ycondensation 
reactions (figure 3.1). 
x+Y 
-H 0 2 
) x-x + Y-Y + X-Y + Y-X 
FIGURE 3.1 
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and each of the dipeptides formed could then react further 
to give an even greater mixture of peptides. 
Natural biosynthesis overcomes these problems, at the 
ribosomal level where in DNA is translated into a specific 
peptide but in the laboratory a rational peptide synthesis 
is required 
(i) destruction of the dipolar nature of reacting 
amino-acids. 
(ii) differentiation of the amino and the carboxyl 
components. Since amino-acids are di- or 
p~lyfunctional, and the coupling of the carboxyl group 
of one to the amino group of the other is achieved 
only by protecting some of the functional groups. 
(ii) activation of the carboxyl component so that coupling 
to form the peptide bond can occur with high 
efficiency under mild conditions. 
Steps (i) and (ii) are usually met by use of reversible 
protecting groups which have been developed for both the 
amino and carboxyl groups, as well as for the groups 
occurring in the side-chains. 
A suitable protecting group must 
(i) be easily introduced into the molecule. 
(ii) protect the functional groups under the conditions of 
amide formation. 
(i11) be easily removable under the conditions that leave 
the newly formed amide link intact. 
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A major requirement of peptide synthesis is that all 
reactions should lead to a single product. However, this is 
complicated by unprotected functional groups and the danger 
of racemisation during synthesis, since all the amino-acids 
with the exception of glycine contain at least one 
asymmetric carbon atom. 
1 The general scheme involved in peptide synthesis is shown 
in figure 3.2 and the individual steps will be discussed in 
the subsequent sections. 
The general scheme involved in peptide synthesis' 
H3N -CHR~COO- H3it-CHfi-coo-
1 ®-HN-CHR~COO- Protection 1 H~-CHR~COO® 
(CARBOXYL COMPONENT) (AMINO COMPONENT) 
r - -YCTIVATION 
@-NH-CH R- COO X 
~--..--_-Iftt'-. ~ - - - - - 7 
/ 
®-HN-CHR~O-NH-CH R!.COO@ 
~BLOCKING 
L~NH-CHR~CONH-CHRt(OOH 
/ 
/ 
~ 
/ 
/ 
/ 
/ 
/ H2N-(HR-CONH-(HR~(OO® 
FIGURE 3· 2 
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3.2 PROTECTING GROUPS 
There is a whole host of protecting agents for amino and 
carboxyl groups available and those of importance will be 
discussed in the following section. Their choice depends on 
their ease of introduction, the adequacy of the protection 
provided, their stability during peptide synthesis, the 
protection of adjacent chiral centre from racemisation and 
finally, their ease of removal at the completion of the 
synthesis • 
3.2.1 AMINO PROTECTING GROUPS 
An amino group is usually acylated. In general the 
protecting groups function by suppressing the basicity and 
the nucleophicity of the nitrogen atom. 
2 Emil Fischer used amino-acid chloride-hydrochloride for 
simultaneous carboxyl activation and amino protection. 
However, this resulted in impure products in solution, due 
to the equil1brium which occurs (figure 3.3). An amino 
group is released free and which is susceptible to further 
acylation. 
FIGURE 3.3 
One of the first successful groups, tosyl chloride, that 
could be exclusively removed from the amino group was 
suggested by du Vigneaud et a13• a-tosyl amino-acids are 
prepared by the reaction of an amino-acid with tosyl chloride 
in alkali. Reduction with sodium of a solution of the tOByl 
3 peptide in liquid alllllonia yields the free amine and this 
group gained enough popularity for general application in 
peptide synthesis. However, the tosyl group has its 
disadvantages. The severe conditions used in the removal of 
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the N-tosyl group in the intermediates also removes other 
blocking groups. Hence, these groups require to be 
reintroduced afterwards. There are also problems in the 
isolation of pure peptides, since a large amount of 
inorganic salt must be removed, and the a-tosyl amino-acids 
4 
cannot be coupled using the mixed anhydride method • 
3.2.1.1 BENZYLOXYCARBONYL GROUP (Z) 
5 In 1932, Bergmann and Zervas introduced the Z group, which 
made modern peptide synthesis possible. This group 1s the 
first choice for the protection of amino nitrogen. 
N-Benzyloxycarbonyl derivatives are stable compounds readily 
obtained in high yields (figure 3.4). 
FIGURE 3.4 
5 Several deprotection methods exist:- hydrogenolysis, 
reduction with liquid ammonia6 , HC1 sOlutions7, HCl8 or 
Hydrobromic (HBr)9 or Hydroiodic (HI) acid10 in acetic acid 
and p-toluenesulphonic aCidll • The Z-group protects 
amino-acids not only against unwanted acylation but also 
against racemisation. Of the above methods, solvolysis in 
HBr and hydrogenolysis are the most commonly used. 
However, the method does have a few limitations. Firstly, 
the Z-group is sensitive to alkali and if Z-peptide esters 
contain glycine as a second amino-acid from the amino 
12 terminal, the formation of hydantoin derivatives results 
(figure 3.5). 
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FIGURE 3.5 
OH H 
I 
---.of) R-C - CO 
I I 1 
HN N-CHf COOR 
\ / 
C-O 
Excess alkali opens the hydantoin, with the formation of a 
12 
urea derivative (figure 3.6). 
/NH-CH2-COOH 
O-C 
" NH-CHR-COOH 
FIGURE 3.6 
Secondly, N-carboxyanhydrides (Leuchs anhydrides)13 are 
readily formed on heating acid chloride derivatives of 
Z-amino-acids which are stable in the cold, however. 
Next, catalytic hydrogenation fails in the presence of 
sulphur containing amino-acids because of catalyst poisoning 
but this can be overcome by the use of dry liquid ammonia as 
14 
solvent • Lastly, if HBr in acetic acid is used for the 
removal of the Z-group in methionine derivatives then the 
methyl group is displaced by the benzyl group to form 
s-benzylhomocysteine8,15. Addition of methyl ethyl sulphide 
can prevent this side reaction16 • 
The success of this blocking group. has led to the 
preparation of a number of modified versions of the Z-group. 
These include the halogen and nitro substituted forms which 
are more resistant to acid and are more suitable for the use 
alongside the t-butyloxycarbonyl group. 
7S 
3.2.1.1 TERT-BUTYLOXYCARBONYL GROUP (BOC) 
(a) 
(b) 
(c) 
17 In 1957, Carpino reported the BOC-group as a general amino 
protecting group and shortly afterwards it was applied to 
15 18 peptide synthesis ' • Introduction of the BOC-group is 
not as simple as that of the Z-group, since t-butyl-
chloroformate (tBu-O-CO-Cl) is much too unstable except at 
o 19 temperatures below -10 C • Therefore, alternative methods 
for the synthesis of BOC-amino-acids have been 
15 18 ZO Zl suggested ' , , (figure 3.7a, b, c and d). 
1 (CH ) -C-O-CO-NH-CHR-COOR 3 3 
HZN-CHR-COONa 
B~_>-N02 
(CH3)3-C-o-CO-NH-NHZ + HN02~(CH3)3-C-o-C0-N3 + H2N-CHR-COOR1 t-so C 
(CH3)3-C-o-C0-NH-CHR-COOR
1 
(d) (CH3)3-C-0-C,0 
o 
/ (CH3)3-C-o-CO 
Dioxane 
+ H2N-CHR-COOR ~ (CH3)3-C-O-CO-NH-CHR-COOR1 
NaHC03 
FIGURE 3.7 
The synthesis of the BOC-protected amino-acids by the azide 
method (figure 3.7c) proceeds efficiently if the acyl-azide 
is coupled with the amino component in organic solvents 
o below 5 C, otherwise there is the likely chance of 
22 
explosion • The method 1s complicated, but is still one of 
the most commonly used coupling techniques. 
The BOC-group is stable to hydrogenation and also extremely 
resistant to hydrolys1a by base but ia cleaved easl1y by 
mild acids. Thus, the two groups Z and BOC can be used 
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together in the same molecule which allows selective 
protection/deprotection of the amino groups within a 
molecule. This provides the peptide chemist with more 
versatility in complex peptide synthesis. Further both 
groups can be removed simultaneously with HBr in acetic 
acid. Acid cleavage of the BOC from the derivative is shown 
in figure 3.8. 
+ (CH ) -C-O-CO-NH-CHR-COOH + H 
33 1 
FIGURE 3.8 
3.2.1.3 TRIFLUOROACETYL GROUP (TFA) 
Another means proposed by Weygand et a123 for the 
N-protection of amino-acids was the TFA group. This group 
is easily cleaved by treatment with alkali. TFA-amino-acids 
are obtained by the action of trif1uoroacetic anhydride on 
amino-acids. However, there 1s danger of racemisation 
occurring if excess trif1uoroacetic acid anhydride is used 
as a solvent. Alternatively, if acylation is performed in 
ethyl thiotrif1uoroacetate in aqueous media at pH 8-9, 
24 
optically pure derivatives can be obtained. Another 
possibility for the synthesis of trif1uoroacety1ated 
amino-acids is the aminolysis of trif1uoroacetic acid 
esters, for example phenyl and methyl esters. Sodium, 
barium or a1llllonium hydrox1de24 or p1perdine solutions are 
most commonly used for the deprotection. The groups 
mentioned above for N-protection are those most generally 
used by the peptide chemist although others have been 
reported. 
77 
3.2.2 CARBOXYL PROTECTING GROUPS 
Peptide coupling can be carried out, without protection of 
the carboxyl group of the amino component only if activation 
and coupling are not used together. Otherwise, the amino 
component participates as a second carboxyl, and a mixture 
of products results. The simplest form of carboxyl 
protection is by salt formation with a strong base, but the 
most widely used is the methyl or ethyl esterification of 
the amino-acids. 
3.2.2.1 METHYL AND ETHYL ESTERS 
The most convenient method used for esterification is mixing 
o 
methanol or ethanol with thionyl chloride at -10 C and 
2S 
adding the amino-acid • Other catalysts which can be used 
are sulphuric acid, p-toluenesulphonic acid and phosphorus 
pentachloride. The deprotection of alkyl esters after the 
completion of peptide synthesis, is usually done by mild 
alkaline hydrolysis in organic solvents, (methanol, dioxane 
or acetone) at or below room temperature. There is a 
danger, if excess alkali is added, of cleavage of sensitive 
amide bonds, cyclisation, racemisation and also formation of 
hydantoin or urea derivatives, (figures 3.5 and 3.6). These 
esters are also convenient intermediates for the preparation 
of protected peptide hydrazides. 
Amino-acid hydrazides are intermediates of peptide synthesis 
in the azide coupling method and can also serve as a 
carboxyl protected form of the acids. The free carboxyl 
group can be regenerated by oxidation of a d11mide, with 
N-brotlosuccinimide (NBS) or 12, which is then attacked by 
hydroxyl ions or by an amine to form a peptide (figure 3.9). 
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NBS or 
Z-HN-CHR-CO-NH-HN
2 
----~) Z-HN-CHR-CO-N-NH 
a1-NH/ ~20 
1 Z-HN-CRR-CO-NH-R 
FIGURE 3.9 
Z-HN-CHR-COOH 
13 Besides the methyl and ethyl esters, Bergmann et a1 
introduced benzyl esters. 
3.2.2.2 BENZYL ESTERS (-OBz) 
This group can be selectively cleaved by catalytic 
hydrogeno1ysis in a similar manner to the Z-group. Besides 
the methyl and ethyl esters, the -OBz group was regarded for 
a long time as the only carboxyl protecting group. The 
esterification procedure is simpler and also results in 
25 improved yields • However, it is not possible to cleave 
-OBz esters selectively by catalytic hydrogenation in the 
presence of the z-group27. Therefore substituted -oBz 
groups were developed which show increased resistance 
towards reagents such as HBr in acetic acid and 
tr1f1uoroacetic acid; for example p-Nltrobenzy1, 
p-Halobenzyl etc. (figure 3.10). 
H~H2-\ > X 
FIGURE 3.10 
The benzyl group can be removed from the C-terminal of a 
peptide by catalytic hydrogenolysis, HBr in acetic acid28 or 
sodium in liquid ammonia29 • 
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3.2.2.3 TERT-BUTYL ESTERS (otBu) 
One of the most important advances in protecting the 
t 30 
carboxyl group was the use of t-butyl esters (0 Bu) • The 
advantage was that it could be hydrolysed very readily in 
acidic reagents, while other esters required more vigorous 
conditions. The ease of deprotection is due to formation of 
the "stable" intermediate cation (figure 3.11). 
R-CO-O-C-(CH ) 3 3 
FIGURE 3.11 
+ R-COOH 
Other advantages are, the free OtBU of the amino-acids are 
stable unlike methyl-, ethyl-, or -oBz esters can be stored 
and distilled. The OtBu are also resistant to nucleophilic 
attack, including attack by amino groups. They are prepared 
by acid catalysed addition of isobutene to free amino-acids 
31 in dioxane or with N-protected amino-acids in methylene 
chloride30 (figure 3.12). 
Z-HN-cn-COOB 
(i) 
Dioxane 
(i) 
) 
) 
H N-CHR-CO-O-C(CH ) 233 
Z-HN-CHR-CO-O-C(CH ) 3 3 
Methylene chloride 
FIGURE 3.12 
t The cleavage of the 0 lu esters can be carried out with RBr 
in acetic acid, p-tolueneaulphonic acid in benzene or with 
trifluoroacetic acid. 
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3.2.3 SIDE-CHAIN PROTECTION 
Consideration must also be given to side-chain protection, 
if amino-acids with active functional groups on their 
side-chains are to be used. In the work undertaken here, 
only the side-chain of lysine needed to be protected. 
In the case of lysine, all of the protecting groups 
discussed in section 3.2.1 for the protection of terminal 
amino groups, can also be used for the protection of this 
side-chain. Combinations of groups are particularly useful 
for peptide synthesis. For example, the Z-group for the 
terminal amino and the BOC group for the side-chain amino 
allows the selective deprotection of the terminal amino 
group whilst the N-protection is left intact. 
Selective reaction of the E -amino group during the 
protection can be achieved by using the copper complex of 
the amino-acid and subsequently removing the copper with 
EDTA (figure 3.13). This method is of general applicability 
for blocking a -amino and a-carboxyl groups during the 
introduction of protecting groups to side-chains. 
FIGURE 3.13 
Other protecting groups have been revlewed32 and the use of 
protecting groups in poly functional amino-acids has been 
discussed by Rudlnger33 • 
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3.3 RACEMI SAT ION 
High optical purity of the peptide is essential in the 
synthesis, but there is no guarantee that the peptide 
synthesis would proceed without racemisation occurring at 
almost every stage of the preparation. Hence, to prevent or 
suppress racemisation, careful selection of protecting 
groups and coupling methods is essential. Two mechanisms 
have been suggested, which facilitate the loss of optical 
purity in reactions concerned with the carboxyl group of 
acylamino-acids or peptides the withdrawal of proton from 
the asymmetric a -carbon atom and the formation of an 
intermediate 5-oxazolone (azlactone) which are known to 
undergo internal nucleophilic attack and racemise. 
The mechanism for the formation of 5-oxazolone (figure 3.14) 
occurs when any acyl derivative of an N-acyl- a -amino-acid 
is sufficiently electronegative to undergo internal 
nucleophilic attack. It is reasonable to suppose that the 
enhancement in the electrophilic character of the carbonyl 
carbon, C-5 will facilitate the elimination of XH. There is 
a strong tendency for the loss of the proton at C-4 in the 
presence of a base, thus leading to the formation of the 
resonance stabilised oxazolinone intermediate anions as 
4 
shown • 
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H X H ~X V 1 I I Rl I I Rl R - C - C • 0 - C - C - 0 - C - C - 0 I~ 5 ~+ <) I I HNj, N 0 ~ / \~l ~ /0_ ~ t R C c 
i I R 
Rt - t - at 
-c-c-o a - c - c - 0 - c - c - 0 I I I I II I 
N 0 <:--4 N 0 ~ N 0 ~ 1 \ / '-I C C C 
I I , 
a a a 
Oxazlinone intermediate 
FIGURE 3.14 
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Amino protecting groups which are monoacylating such as Z-, 
BOC-, and other urethane-type protecting groups were not 
thought to form oxazolinone anions. However, although 
35 
recent work shows its formation, racemisation does not 
take place unless coupling is performed in the presence of a 
tertiary amine base. Since it has already been suggested 
34 that oxazol1none formation is base catalysed , the major 
difference between an amide and urethane is the lower 
acidity of the N-H in the latter. This is because the 
urethane oxygen can partially donate its electrons to the 
adjacent carbonyl group (figure 3.15). 
H 0 
I II 
R - C - C - X ~ 
1+ -HN 0 
\/ 
r 
~H2~ ) 
H 0 
I II 
R-C-C-X ~R 
I 
HN 0 
\ II' 
C 
I 
bH2{ ) 
FIGURE 3.15 
o 
II 
- C - X 
Extensive experimental evidence for an alternative mechanism 
has been proposed, which suggests the withdrawal of a proton 
from the asymmetric a -carbon atom. For example, amino-
acids or Z-amino-acids having electronegative substituents 
in the B-position such as cysteine, serine, threonine, 
phenylalanine and tyrosine are capable of undergoing 
base-catalysed racemisation36 ' 37 , and also BOC-benzyl 
histidine racemised when activated by dicyclohexyl-
carbodiimide (DCCI)38, due to the bascity of the imidazole 
ring. The B -substituent facilitates the proton abstraction 
from the a-carbon atom, hence erasing the centre of 
asymmetry39(figure 3.16). 
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CH2 \I ~H2-X (3 -elimination 
--- -NH-CH-CO- --- ~( ____ .-;...) --- -NH-C-CO- --- + H-X 
Recombination with 
racemisation. 
x - OH, SH etc. 
FIGURE 3.16 
With protecting groups other than those of the urethane type 
no defence against racemisation is available. 
Thus general features which lead to racemisation are 
(i) reaction conditions where polar 
temperatures, and the presence of 
prevalent, and 
solvents, 
salts40 ,41 
high 
are 
(ii) the nature of the amino-acid at the C-terminal of the 
carboxyl component, since it has been observed that 
42 
racemisat10n almost exclusively occurs there • 
To reduce the problem of racemisation, various tactics can 
be used : 
(i) use the azide method for coupling as discussed in the 
next section. 
(11) use glycine or proline as the carboxyl component at 
the C-terminus. 
(iii) use a stepwise strategy for peptide synthesis. 
(iv) use of DCCl with additives for coupling. 
Various workers have shown that addition of 
N-hydroxysuccinim1de (NHS) also markedly diminishes 
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43 44 
racemisation ' • Other new additives where are more 
efficient than NaS have been proposed, 1-hydroxybenzo-
triazole45 and EthYl-2-hYdroximinO-2-cyanoacetate46 (figure 
3.17). 
OH 
I 
((I :;N N' 
FIGURE 3.17 
3.4 FORMATION OF THE PEPTIDE BOND 
A large number of methods are available but generally only 
those involving the formation and aminolysis of activated 
carboxyl acid derivatives have found application in peptide 
synthesis, where emphasis is on high yield, low racemisation 
and easy purification of the product. 
3.4.1 THE AZIDE METHOD 
47 48 In this method which is highly regarded ' , the reaction 
proceeds via several steps. The azide is formed by 
converting the acylamino-acid esters into the corresponding 
hydrazides, which in turn, are then treated with nitrous 
acid. The azide formed is then treated under 
Schotten-Baumann conditions with the amino-acid to form the 
acyldipeptide (figure 3.18). 
) 
(i) 
Z-HN-CHR-CONR-Cn1-COONa + HN3 ~(---
(i) 
FIGURE 3.18 
Z-HN-CHll-C0-N3 
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The formation of acylazide, however, may lead to side 
reactions because following proton abstraction from the 
nitrogens, the azide assumes the structure in figure 3.19. 
The azide is unstable and undergoes a Curtius rearrangement 
to produce the corresponding isocyanate. The rate of 
formation of isocyanate depends on the reaction conditions 
such as solvent and temperature and is a major route in the 
formation of by-products. Hence, this reduces the peptide 
49-51 yield and the peptide desired is impure (figure 3.20). 
Also there is a possibility of the azides acylating 
unreacted hydrazide to form symmetrical diacylhydrazines. 
Z-HN-CHR-CO-NH-NH + HNO 122 
+ - - + 
[Z-HN-CBR -CO-N-N-N ~ Z-HN-CBR -CO-N-N == N] 
-+ 
-N 2 
FIGURE 3.19 
Z-HN-CHR-CO-N-NiIN ~ Z-HN-CHR-CO-N ~ Z-HN-CHR-N-C-o 
r V1NR2 
CO + Z-HN-CBR-NH Z-RN-CHR-NH-CO-NHR 2 2 
FIGURE 3.20 
1 
The azide is usually generated in situ52 in acidic solution 
by the addition of sodium nitrite or an organic acid and 
o 
reacted immediately at -5 C, because of its instability. 
This method can be applicable for coupling of peptides and 
for nonaqueous systems. Although, probleas exist, it still 
remains popular. 8i ving produc ta of high hydraz ide 
intermediates and is entirely free fro. raeemisation. 
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There are a number of methods available for the 
53 54 preparation' but care must be taken to avoid possible 
side reactions, especially primary amide formation (figure 
3.21). 
Z-HN-CHR-NH-NH 2 ----~> Z-HN-CHR-NH-NH -N=O 
-H 0 2 ~20 ~ 
Z-HN-CHR-CO-NH 2 
FIGURE 3.21 
Z-HN-CHR-CO-N 3 
Optimum conditions for the reactions are low temperature, 
homogenous solution, high acidity and presence of organic 
nitrite (e.g. t-butyl nitrite or nitrosyl chloride). 
3.4.2 MIXED ANHYDRIDE METHOD 
One of the most widely used methods, is the mixed anhydride 
5S 
method ,which is compatible with many of the protecting 
groups available and is used when a fast coupling method is 
required (figure 3.22). 
H N-al 2 
FIGURE 3.22 
1 Z-HN-CHR-CO-NH-R 
To gain satisfactory yields with this method, it is 
necessary to use electron-releasiua aroups in the activating 
acid, to coapete with the protected a1linoacyl part of the 
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molecule in the acylation of an amine. Suitable groups are 
long chain aliphatic acids, especially with branched chains. 
56 For example, mixed anhydrides containing isovaleroyl or 
trimethylacetyl residues result in high yields and little 
side product formation (figure 3.23). 
Z-HN-CHR-CO 
\ 
o 
/ (CH ) -CH-CH -CO 322 
FIGURE 3.23 
Z-HN-CHR-CO 
\ 
o 
I 
(CH3)3-C-CO 
The mixed anhydrides are prepared by the addition of 1 mole 
of the acid chloride to a cooled solution of 1 mole of 
protected amino-acid in the presence of 1 mole of tertiary 
base (triethylamine or N-ethylmorpholine (NEM». Toluene, 
chloroform, dioxane and tetrahydrofuran (THF) are the most 
frequently used solvents. The formation of mixed anhydrides 
requires anhydrous conditions and is usually rapid. It can 
be used directly in the acylation reaction, which can take 
place under aqueous conditions. A breakthrough in the 
development of the mixed anhydride method came with the use 
of monoesters of carbonic acid for coupling57- 59 (figure 
3.24). 
FIGURE 3.24 
In this case, the eleetron-releasin8 part of the molecule is 
the alkoxy group, such as ethylchloroformate57 ,58 or 
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59 isobutylchloroformate • This method has the advantage that 
no undesired by-products are formed, since the aminolytic 
cleavage of the anhydride yields the peptide and the 
corresponding alcohol and CO2 as shown in figure 3.25. 
FIGURE 3.25 
3.4.3 DICYCLOHEXYLCARBODlIMlDE (DCCl) 
Coupling reagents are also required for the formation of 
peptide bond and the most used reagent is DCCl. It was 
54 60 first used for amide formation by Sheehan and Hess ' • It 
is highly reactive and gives high yields in a relatively 
short time. The great advantage of DCC! is that there is 
very little tendency for racemhation to occur and it is 
usually used for the preparation of N-protected amino-acid 
61 62 
active esters ' • The mechanism was first suggested by 
63-65 66 Khorana and has since been reinvestigated by De-Tar • 
It involves the addition of N-protected amino-acid to the 
reagent to form a reactive O-acylisourea intermediate 
(figure 3.26). 
Z-HN-CBR-COOB + 
~6Hn 
N 
II C6HII-N-C-N-C6H11~ Z-HN-CHR-CO-o-~ 
N 
I 
C6Hn 
FIGURE 3.26 
The resulting intermediate formed can undergo several 
reactions : 
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(i) the formation of the peptide bond by the direct attack 
of the amino component on the reactive intermediate. 
(ii) if there is a presence of further acid, then a second 
addition of a proton takes place on the intermediate 
resulting in a formation of a sY1Dllletricai anhydride 
and disubstituted urea. The sY1Dllletrical anhydride 
then acylates the amines, and 
(11i) lastly 0 ... N acyl migration, with the formation of 
N-acylurea, which is not an active compound. 
The formation of N-acylurea means separation of an undesired 
by-product is necessary. However, N-acylurea can be 
suppressed if reactions are carried out in dichloromethane 
(DCM) or acetonitrile60 • The N,Nl-dicyclohexylurea formed 
is insoluble in most of the solvents, but not in the 
solvents used for coupling. Therefore the peptide formed 
has a minor amount of urea incorporated. To overcome the 
problems of separating the impurities, water soluble 
dlimldes can be substituted: For example 
1 N-cyclohexyl-N -(p-diethylaminocyclohexyl)-carbodiimide. 
To reduce racemisation, especially during the 
acyl peptides with neC! and to avoid 
N-acylurea, NHS can be added to the reaction 
activation of 
formation of 
43 67 
mixture ' • 
The O-acylurea is 
which then reacts 
coupling is not 
converted rapidly 
smoothly with the 
totally free of 
into the active eater 
amine. However, NBS 
racemisation and an 
alternative was proposed, namely l-hydroxybenzotriazole. 
The procedure45 involving this additive hal proved useful in 
68 69 
stepwise synthesis aa well as fragment condensation • 
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3.4.4 ACTIVE ESTERS 
In 1950, Wieland et a170 described the synthesis of peptides 
via the active esters, phenyl thioesters which were regarded 
71 
as asymmetrical anhydrides. Bodanszky observed later that 
this type of activation was not restricted to the SH group, 
72 but aryl and alkyl esters could be used. Active esters 
are less reactive and are more selective and also more 
resistant to hydrolysis than are the mixed anhydrides. The 
difference between the active esters and mixed anhydrides is 
that only a single product is formed during acylation. 
73 An important development by Nefken et al in the chemistry 
of active esters was the use of substituted hydroxylamines 
as the "alcohol" components. The use of N-hydroxy-
73 74 phthalimide ester and NHS ester become widely accepted ' • 
These active intermediates resembled the mixed anhydrides 
than· most substituted aryl esters but are sufficiently 
justified to classify them as active esters. They owe their 
reactivity towards nucleophiles both to electron-withdrawing 
effects and to intramolecular hydrogen-bonding as shown in 
figure 3.27. 
FIGURE 3.27 
The rate of acylation with active esters i~ usually 
satisfactory but in the case of hindered amino-acids or 
sparingly aoluble peptides, catalytie enhaneement i8 needed. 
The catalytic effects of tertiary base and carboxylic acid 
75 
are known. Various reagents are available for the 
catalysia of the aminolysis reaction such aa imidazole 76, 
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71 l,2,4-triazole and 2-hydroxypyridine and more recently 
78 l-hydroxybenzotriazole. This was found to be a good 
catalyst, especially in polar solvents and for solid phase 
synthesis. 
3.5 STRATEGY OF SYNTHESIS 
In considering the problems of protection, coupling method 
and racemisation, it is also essential to take into account 
the method of assembling of amino-acids into a peptide. 
Three strategies are available : 
(i) Stepwise elongation starting from the N-terminal 
amino-acid. 
(ii) Stepwise elongation starting from the C-terminal 
amino-acid. 
(iii) Fragment condensation (Joining together smaller 
peptides). 
(i) STEPWISE ELONGATION FROM THE N-TERMINUS 
The N-terminal, N-protected amino-acid of the peptide chain 
to be synthesised is activated at its carboxyl group and 
coupled to the second amino-acid. The partially protected 
dipeptide so produced is activated and coupled to a third 
amino-acid to yield an amino protected tripeptide. 
Elongation in this manner. can progress until the de.ired 
peptide is synthesised. The deprotection of the amino group 
and any side-chain protecting groups, completes the 
formation of peptide (figure 3.28). 
1 Z-HN-CHR -CO-X + 
! 
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1 2 Z-HN-CHR -CO-NH-CHR -COOH 
Activated 1 
1 2 3 Z-HN-CHR -CO-NH-CHR -CO-X + H N-CHR -COOH 2 
1 2 1 3 Z-HN-CHR -CO-NH-CHR -CO-NH-CHR -COOH 
FIGURE 3.28 
The scheme assumes that the carboxyl group of the amino 
component is protected only by the addition of a base, which 
converts the zwitterion form of the amino-acid to a salt. 
This leaves the amino group free to act as nucleophile in 
the acylation. The number of steps involving protection and 
deprotection is reduced to a minimum and makes this an 
economical and attractive approach to peptide synthesis. 
This type of strategy is regarded as similar to that taken 
by nature 
procedure 
synthesis, 
in the synthesis of proteins. However, this 
has no wide spread application in chemical 
since racemisation can occur at the C-terminal 
residue of the intermediates during activation and coupling. 
The first N-protected amino-acid will not be prone to 
racemiaation but all the subsequent peptidea formed are, 
unless glycine or proline are at the C-terminus. Hence, it 
is very unlikely that this type of stepwise strategy i8 of 
any practical use. 
(ii) STEPWISE ELONGATION FROM THE C-TERMINUS 
One of the most· generally applied strategi.. in which a 
racemate-free peptide is prepared is to start with the 
C-terminal residue of the peptide. In this case the 
carboxyl group is usually protected because of the 
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zwitterions in the intermediates. One advantage of this 
procedure is when Z- and BOC-protecting groups are employed, 
the tendency for racemisation to occur is reduced. 
Moreover, if active esters are used for the coupling steps, 
it is reasonable to expect the products to have appreciably 
different solubilities from the starting material and hence 
simplify the isolation and purification of the desired 
peptide. The procedure is shown in figure 3.29. 
n-l Z-HN-CHR -CO-X + 
1 
Z-HN-CHRn-l-CO-NH-CHRn-COOR 
+ 
Deprotection 
n-l n H N-CHR -CO-NH-CHR -COOR 2 
n~ n4 n Z-HN-CHR -CO-NH-CHR -CO-NH-CHR -COOR 
FIGURE 3.29 
(iii) FRAGMENT CONDENSATION 
In this method fragments of the desired peptide are coupled 
together, but several points have to be taken into 
consideration to achieve any success. There is a high risk 
of raeemisation occurring, since it involves the activation 
of the carboxyl group of the protected peptide rather than a 
protected amino-acid. To overcome thil problem, it would be 
better to have glycine or proline al the C-terminus residues 
for reasons mentioned earlier. The major consideration is 
to avoid aliphatic or aromatic amino-acids having 
electronegative substitutents in the a -position as the 
C-terminal amino-acid of the carboxyl component in fragment 
condensation. If however, they are chosen, the problem of 
racemisation could be reduced by the introduction of NHS in 
the coupling stage as discussed earlier. 
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3.6 SCHEME OF PRESENT SYNTHESIS 
The amino-acids required to prepare the hexapeptide and 
tetrapeptides (mentioned in chapter one), for the study of 
the binding sites of PPE were alanine, proline, lysine and 
phenylalanine. The N-terminus was protected wi.th the 
Z-group and the C-terminus as the active ester in the 
hexapeptide and one of the tetrapeptides. The other tw 
tetr apeptides had their C-terminus conver ted to the 
corresponding alcohol, so that in the final stage of the 
peptide synthesis it was easier to conver t into the 
aldehyde. The strategy applied to the synthesis of the 
peptides involved the stepwise addition to the C-terminus 
except for the hexapeptide, where the last coupling step 
involved fragment condensation of the tetrapeptide to a 
dipeptide. The Z-group was used to remove the danger of 
racemisation via oxazolinone intermediates (figure 3.14). 
The coupling method employed throughout the peptide 
synthesis of the hexapeptide and tetrapeptides is 
illustrated in figure 3.30-3.32. 
3.7 EXPERIMENTAL 
In all the following synthetic peptide wrk, all the 
amino-acids used were of the L-form and obtained from 
various commercial supplier s. 
MATERIALS 
L-alanine. 
L-proline. 
L-lysine. 
L-phenylalanine. 
N-Benzyloxycarbonyl-L-alanine. 
Solvents used were obtained fr01ll the various cOllllDercial 
supplier s stored over A4 molecular aieve, if applicable. 
Melting points were determined with a Tottli-type apparatus. 
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All evaporations were carried out on a Buehl rotatory 
evaporator fitted with a cold finger fo't' solid cabondioxide, 
o 
at temperature of less than 37 C. Hydrogenations we-re 
carried out in a round bottom flask fitted with a 
carbondioxide trap fitted with sodalime. The system used 
was closed to the atmosphere. All hydrogenations, were 
flushed with "white spot" N2 fo't' 5 minutes, before the 
catalyst, 5% palladium on charcoal (Pd/C) WlS added. Thin 
layer chromatography (T. L. C.) was used to determine when the 
hydrogen uptake was complete. All the lXoducts and the 
intermediates were homogenous on T.L.C. and had the expected 
1H N.M.R. spectra. This spectra were recorded on 
Perkin-Elmer R34 N.M.R. spectrometer at 220MHz with 
tetramethylsilane as internal reference. 
CHROMATOGRAPHY SOLVENTS 
10% Methanol in Chloroform. 
5% Methanol in Chloroform. 
Butanol Acetic acid Water : Ethylacetate 
Butanol Acetic acid Water (4:1:1). 
Chloroform Methanol Acetic acid Water 
Chloroform Methanol Acetic acid Water 
Chlo't'oform Methanol Acetic acid Water 
DETECTION OF AMINO-ACIDS AND PEPTIDES 
(1:1:1:1). 
(120: 15: 3: 2). 
(60:18:2:3) 
(30:15:3:2). 
Detection and identification of the products by T. L.C. i. 
impor tanto Spray. are available for detection of car tain 
groups in the amino-acids and peptides. 
(i) NINHYDRIN 
A 0.02% solution of ninhydrin in Mthanol or butan-l-ol 1s 
used fot' detection of a nee amino group in a peptide o't' 
amino-acid. The spray reagent i. developed by heating the 
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treated plate and ninhydrin posi tlve gt'oups at:' e c ecognised 
by the appearance of purple or yellow (for proline) coloured 
spot. 
(ii) CHLORINE/STARCH/POTASSIUM IODIDE 
Immersing the treated plate in a chlorine tank. for 2-3 
seconds and the excess chlorine b10m off before being 
sprayed with a solution containing 1% starch and 1% 
potassium iodide in _ter. The appearance of a purple or 
blue spot indicate the presence of a peptide or amino-acid. 
(iii) IODINE 
Detection for peptides and amino-acids can also be done by 
immersing the plate in a tank containing solid iodine for 10 
minutes. 
(iv) u.v. LIGHT 
The method is used in conjunction with others for detection 
of aromatic ring (e.g. Z, Phe) under the examination of U.V. 
light, using self-indicating plates. 
(v) ALDEHYDE DETECTION 
Using a spray made of 2,3,S-triphenyltetrazonium chloride in 
methanol and 10% sodium hydroxide in methanol. Indication 
of a aldehyde in the peptide is shown by the formation of a 
red spot. 
3.8 INDEX TO EXPERIMENTAL 
(1) N-Benzyloxycarbony1-L-prol1ne. 
(2) N-Benzy1oxycarbonyl-L-prolyl-N-hydroxyauccinim1de 
eater. 
(3) L-alanine-methyl .ater hydrochloride. 
98 
(4) N-Benzyloxycar bonyl-L-alanyl-N-hydroxysucclnlmide 
ester. 
(5) N-Benzyloxycarbonyl-L-prolyl-L-alanlne-methyl ester. 
(6) N-Benzyloxycarbonyl-L-alanyl-L-prolyl-L-alanlne-methyl 
ester • 
(7) N-Benzyloxycarbonyl-L-prolyl-L-alanyl-L-prolyl-L-
alanlne-methyl ester. 
(8) N-Benzyloxycarbonyl-L-prolyl-L-alanyl-L-prolyl-L-
alanine. 
(9) N-Benzyloxycarbonyl-L-phenylalanine. 
(10) N-Benzyloxycarbonyl-L-phenylalanine-tert-butyl ester. 
(11) N- t-ter t-butylcar bonyl-L-lysine. 
(12) N-a.-Benzyloxycarbonyl-N- e:-ter t-butylcar bonyl-L-lysine. 
(13) N-a.-Benzyloxycarbonyl-N-e:-tert-butylcarbonyl-L-lysyl-
N-hydroxysuccinimide ester. 
(14) N-a-Benzyloxycarbonyl-N-e-tert-butylcarbonyl-L-lysyl-
L-phenylalanine-tert-butyl ester. 
(15) N-Benzyloxycarbonyl-L-prolyl-L-alanyl-L-prolyl-L-
alanyl-N-e:-tert-butylcarbonyl-L-lysyl-L-phenylalanine-
tert-butyl ester. 
(16) L-pr olyl-L-alanyl-L-pr o lyl-L-alanyl-L-ly syl-L-
phenylalanine. 
(17) N-Acetyl-L-prolyl-L-alanyl-L-prolyl-L-alanine. 
(18) N-Benzyloxycarbonyl-L-alanine-methyl ester. 
(19) N-Benzyloxycarbonyl-L-alaninol. 
(20) N-Benzyloxycarbonyl-L-alanyl-L-proline. 
(21) N-Benzyloxycarbonyl-L-alanyl-L-prolyl-N-hydroxy-
succinimide ester. 
(22) N-Benzyloxycarbonyl-L-alanyl-L-prolyl-L-alaninol. 
(23) N-Acetyl-L-proline. 
(24) N-Acetyl-L-prolyl-L-alanyl-L-prolyl-L-alaninol. 
(25) N-Acetyl-L-prolyl-L-alanyl-L-prolyl-L-alaninal. 
(26) N-Trifluoroacetyl-L-proline. 
(27) N-Trifluoroacetyl-L-prolyl-L-alanyl-L-prolyl-L-
alaninol. 
(28) N-Trifluoroacetyl-L-prolyl-L-alanyl-L-prolyl-L-
alaninal. 
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(1) L-pro1ine (51.5g, 0.5 mol) was dissolved in 2M sodium 
hydroxide solution (250 m1) and cooled to 00 e in an 
ice/salt bath. The solution was stirred vigorously and 
benzy1ch10roformate (85 m1, 0.6 mol) and 2M sodium hydroxide 
o 
solution (250 m1) added simultaneously over 30 minutes at 0 
o e. The mixture was stored overnight at 4 e before 
extracting with diethy1 ether (2 x 100 m1) and the aqueous 
layer acidified with concentrated hydrochloric acid to pH 
2.0. The aqueous layer was ext~acted with ethy1acetate (2 x 
100 m1), washed with water (100 m1), dried over (MgS04), 
filtered, and evaporated to an oil. Addition of petroleum 
ether 60-800 C gives a white solid (67.97g, 52%), m.p. 
76-770 e (Lit79 78-800 C). 
(2) To a solution of N-Benzy10xycarbony1-L-pro1ine (62.5g, 0.25 
mol) in DME (625 m1), NBS (28.75g, 0.25 m1) was added. The 
mixture was stirred and cooled to 00 e in an ice/salt bath 
before neer (61.75g, 0.3 mol) was added. The mixture was 
filtered and DME removed by evaporation. The resulting oil 
was titurated with ether to give a solid after standing at 
00 e for 3 hours. (67.56g, 78%), m.p. 88.5-89.50 e (Lit. 80 
900 C). 
(3) L-a1anine (62.4g, 0.7 mol) was suspended in methanol (200 m1 
o 
and cooled to 0 e in an ice/salt bath. Thiony1ch10ride 
(44.4 ml) was added at 00 e, dropwise over 30 minutes and 
the mixture then heated to 400 C for 2 hour s. The solvent 
was evaporated and TIll (800 m1) added. The mixture was 
o 
cooled to 0 e to give a White solid. (84.958, 73.2%), m.p. 
109-1100 C (Lit. 81 110.5-1110 C). 
(4) N-Benzy10xycarbonyl-L-a1anine (56.75g, 0.2 mol) 1II8S dis-
solved in DME (625 m1), NBS (28.75g, 0.25 mol) added and the 
mixture cooled to 00 C in an ice/salt bath. neer (61.75g, 
0.3 mol) was then added and the mixture stirred at 00 C for 
2 hours before allowing it to stand overnight at 00 C. The 
mixture 1II8S filtered and the solution evaporated to an oil, 
100 
o titurated with ether and left standing at a C for 3 hours 
to give a white solid (65.67g, 83%), m.p. 121.5-1230 C 
(Lit. 80 123-1250 C). 
(5) L-alanine-methyl ester hydrochloride (6.98g, 0.05 mol) was 
dissolved in DMF (80 ml) at 00 C in an ice/salt bath and NEM 
(6.25 ml) added. The mixture _s stirred for 1 minute 
before N-Benzy10xycarbonyl-L-pr0 ly1-N-hydroxysuccinimide 
ester (17.3g, 0.05 mol) _s added, atirred for a further 
hour at 00 C and left to stand overnight at room 
temperature. The solvent was evaporated the oily residue 
-dissolved in _ter and the product extracted into 
ethy1acetate (2 x 200 m1). It _s _shed with 5% citric 
acid, _ter, 5% sodium bicarbonate, saturated bt'ine, dried 
over (MgS04), filtered and evaporated to give an oil, which 
was dissolved in minimum of ethylacetate and addition of 
o petroleum ether 40-60 C gave the product. (13. 32g, 79%), 
75-760 C (Lit. 82 79-800 C). 
(6) N-BenzyloXYcarbonyl-L-proly1-L-a1anine-methy1 ester (11.7g, 
0.035 mol) _a dissolved in DMF (95 m1), glacial acetic acid 
(5 m1) _s added and the mixture hydrogenated over Pd/C for 
5 hour s. After hydrogen uptake _s complete the solution 
_s filtered through Hyf10 and evaporated under reduced 
pressure. The oily residue _s wshed with toluene (3 x 50 
ml) and the oily residue redissolved in DMF, 
N-Benzy10xycarbonyl-L-a1any1~-hydroxyauccinimide eater, 
(ll.2g, 0.035 mol) _s added and stirred for 1 hour at 00 C 
in an ice/salt bath before allOwing to stand overnight at 
room temperature. The solvent _s evaporated, and the oily 
residue dissolved in wter and the product extracted into 
ethy1acetate (2 x 200 ml). It _s _shed with 5% citric 
acid, wter, 5% sodium bicarbonate, saturated brine, dried 
over (MgS04), filtered and evaporated to give 
N-Benzyloxycarbonyl-L-alanyl-L-prolyl-L-alanine-methyl ester 
as an oil. (11.5g, 811). 
Anal for: C20H27N306: C, 59.25; 
C, 59.01; 
H, 6.71; 
H, 6.55; 
N, 10.37; found 
N, 10.27% 
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(7) N-Benzy10xycarbony1-L-a1any1-L-pro1y1-L-a1anine-methy1 ester 
(11.5g, 0.028 mol) was dissolved in DMF and hydrogenated 
over Pd/C for 5 hour s. When the uptake of hydrogen lES 
complete the solution was filtered through Hyf10 and 
N-Benzy10xycarbony1-L-pro1y1-N-hydroxysuccinimide ester 
(8.23g, 0.024 mol) added, stirred at 00 C in an ice/salt 
bath for 1 hour and left to stand overnight at room 
temperature. The solvent was evaporated, the oily residue 
dissolved in water and extracted into ethy1acetate, dried 
over (MgS04), filtered and evaporated to oil. The oil was 
chromatographed on silica gel (1% methanol/chloroform) and 
fractions containing the product were evaporated to a White 
foam (4.2g, 30.5%). 
c, 59.75; H, 6.82; N, 11.15; found 
C, 57.92; H, 6.51; N, 10.86%. 
(8) N-Benzy10xycarbony1-L-pro1y1-L-a1anyl-L-proly1-L-a1anine-
methyl ester (1.5g, 2.98 mao 1) _s dissolved in 50% 
methanol/water and sodium hydroxide (O.lg, 3.5 mmo1) was 
added. The reaction stirred for 4 hour s at room 
temperature, the methanol evaporated and the pH of the 
solution adjusted to 7.0 before extracting with 
ethy1acetate. The aqueous layer _s adjusted to pH 2.8 and 
then extracted with chloroform, the or ganic layer dried over 
(MgS04) and evaporated to a white foam. N.M.R. confirmed 
that no methyl ester peak .s present. 
Anal for: C24H32N407 C, 59.00; H, 6.60; N, 11.47; found 
C, 57.46; H, 6.29; N, 11.10%. 
(9) The procedure was as for N-Benzyloxycarbonyl-L-prol1ne (l). 
Yield: (144.27g, 96.5%), m.p. 83-840 C (Lit. 83 88-890 C). 
(l0) N-Benzyloxycarbonyl-L-phenylalanlne (71.21, 0.24 mol) was 
dissolved in DCM (500 ml) and cooled in a cardice/acetone 
o bath at -10 C. Concentrated sulphuric acid (S till) and 
iaobutene (300 al) distilled at -700 C wre added and the 
mixture left stirring for 4 days at rooa telllperature. The 
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mixture was cooled and sodium bicarbonate solution (10%) 
added until the mixture was basic to litmus. An emulsion 
formed, which was dissolved in OCM and washed with water, 
brine, dried over (MgS04), filtered and evaporated to a 
solid. The crude solid crystallised from DCM-petroleum 
ether to give a white crystalline product (66.7g, 79%), m.p. 
78-79.50 C (Lit. 28 80.5-81.50 C). 
(11) L-lysine hydrochloride (54.8g, 0.3 mol) was dissolved in 
boiling water (400 ml) and copper (II) carbonate (58g, 0.26 
mol) added in por tions, then the solution was boiled for 10 
minutes, filtered and cooled. Sodium bicarbonate (25.2g, 
0.3 mol), Oi-tert-butyl-dicarbonate (65.4g, 0.3 mol) and 
dioxane (200 ml) were added and the mixture stirred for 24 
hours. The mixture was filtered and the solid washed with 
water, ethanol, diethyl ether and dried at 600 C in Vacuo. 
The solid was suspended in boiling water (600 ml) containing 
ROTA (di-sodium salt, 75g, 0.20 mol), cooled and filtered, 
washed with water, ether and the product dried in Vacuo. 
(42.0g, 57%), m.p. 237-2550 C (Lit. 21 237-2550 C). 
(12) N-E-tert-butylcarbonyl-L-Iysine (36g, 0.15 mol) was dis-
solved in 2M sodium hydroxide (73 ml) at 00 C. Benzyl-
chloroformate (25 ml, 0.17 mol) and 2M sodium hydroxide (73 
ml) were added simultaneously over half-an-hour while 
o 
stirring at 0 C in an ice/salt bath. The mixture was 
stirred for a further hour before being allowed to stand for 
2 hours at room temperature. The mixture _s extracted with 
diethyl ether (2 x 200 ml) and the aqueous layer acidified 
(litmus) with 6M hydrochloric acid (100 m1). The product 
_s extracted into ethylacetate, .shed with _ter, brine, 
dried over (MgS04) and evaporated to an oil (35.8g, 
64.6% )84. 
(13) To N-a-Benzyloxycarbonyl-N-E-tert-buty1carbonyl-L-lysine 
(35.8g, 0.09 mol) dissolved in DMB (200 ml), NRS (10.S5g, 
0.09 mol) _s added and the solution cooled to 00 C. To the 
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stirred solution DCC! (24.2g, 0.12 mol) was added and 
stirred for 1 hour at 00 C in an ice/salt bath before being 
left overnight at 00 C in the cold room. The mixture was 
filtered, the DME removed by evaporation and the addition of 
diethy1 ether gave a solid product. (36.6g, 81%), m.p. 
94.5-95.50 C (Lit. 85 94.5-95.50 C). 
(14) N-Benzy10xycarbony1-L-pheny1a1anine-tert-buty1ester (9g, 
0.025 mol) was dissolved in DMF (150 m1) and hydrogenated 
over Pd/C for 4 hours. After the intake of hydrogen was 
complete, the solution was filtered through HyFlo, 
N-a-Benzy1oxycarbonyl-N-E-tert-butylcarbony1-L-1ysyl-N-
hydroxysuccinimide ester (11.9g, 0.025 mol) added and 
stirred at 00 C in an ice/salt bath for 1 hour. The 
solution was left to stand overnight at room temperature. 
On evaporation of DMF, an oily residue resulted which was 
dissolved in water and extracted with ethy1acetate (2 x 200 
m1). The organic layer was washed with 5% citric acid, 
water, 5% sodium carbonate, brine, dried over (MgSO 4) and 
evaporated to give an oil. The oil was dissolved in 
petroleum ether and the addition of hexane to this solution 
gave a gel overnight. The solvents were evaporated and the 
product dried in Vacuo. (13.9g, 95%), m.p. 57-600 C. 
Anal. for: C32H45N307: C, 65.85; H, 7.77; N, 7.20 found: 
C, 65.56; H, 7.75; Nt 7.22%. 
(15) N-Benzy10xycarbony1-N-E-tert-buty1carbony1-L-1ysyl-L-phenyl-
alanine-tert-butyl ester (1.86g, 3.19 mmol) was dissolved in 
THP (SO ml) and hydrogenated over Pd/C for 4 hours. When 
the uptake of hydrogen was complete the solution was 
filtered through Hyflo, and the solvent evaporated under 
reduced pressure. The oily residue was redissolved in THP 
and N-Benzyloxycarbonyl-L-prolyl-L-alanyl-L-prolyl-L-alanine 
(1.3g, 2.66 mmol) added with stirring in an ice/salt bath at 
00 C before being left to stand overnight at room 
temperature. The mixture was filtered, the THP evaporated 
and the oily residue dissolved in water and extracted with 
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ethylacetate (2 x 200 ml). The or ganic layer was washed 
with 5% citric acid, water, 5% sodium bicarbonate, brine, 
dried over (MgS04 ) and evaporated to an oil. The oil was 
dissolved in ethylacetate and hexane added. After standing 
for 1 hour at 00 C in the fridge the product was obtained. 
The crude product was chromatographed on silica gel (5% 
hexane-ethylacetate) and the fractions containing the 
product were evaporated to a foam. 
Anal. for: C48H69N7011: C, 62.66; H, 7.56; N, 10.66; found: 
C, 62.89; H, 7.55; N, 10.64%. 
(16) N-Benzyloxycarbonyl-L-prolyl-L-alanyl-L-prolyl-L-lysyl-L-
phenylalanine-tert-butyl ester (0.5g, 0.54 mmol) was 
dissolved in a solution of 45% HBr in glacial acetic acid 
(25 ml) in a flask fitted with moisture trap. The mixture 
was stirred at room temperature for 2 hour s. Anhydrous 
ether was added to the solution, to precipitate the product 
and remove excess RBr and acetic acid. The ether layer was 
decanted and the procedure repeated until all yellow 
colouration had been removed. The solid was filtered and 
o dried in vacuo overnight, then dried for 3 hour s at 100 C 
at 0.5 vacuum. 
Anal. for: C31 H49N707Br 2: 
C, 45.19; H, 6.03; N, 11.90; found: 
C, 44.98; H, 6.01; N, 12.03% + 2.4 mol HBr 
Therefore analysis show 0.4 mol of HBr extra. 
(17) N-Benzyloxycarbonyl-L-prolyl-L-alanyl-L-prolyl-L-alanine 
(0.5g, 1 mmol) prepared in (8) ~s dissolved in acetic acid 
and hydrogenated overnight over Pd/C. After the intake of 
hydrogen ~s complete, the solution .. s filtered through 
Hyflo and evaporated to an oil. The oily residue was washed 
with toluene (4 x 100 m1) and then redissolved in minimum 
acetic acid, acetic anhydride (0.2 ml) and dry pyridine 
(1.25 ml) were added. The reaction mixture was stirred for 
3 hours at room temperature and on evaporation, an oily 
residue resulted. This was dissolved in water and 
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freeze-dried. The crude product was put through a Sephadex 
G-10 column using 1% acetic acid. The fraction containing 
the product was identified by T.L.C. using an iodine system 
(70 mg, 17%). 
Anal. for: C1SH2SN406: C, 54.53; H, 7.12; N, 14.13; found: 
C, 54.S9; H, 6.97; N, 13.98%. 
(lS) L-a1anine-methy1 ester hydrochloride (20g, 0.14 mol) was 
dissolved in water (50 m1) and ethylacetate (300 m1). 
Potassium bicarbonate (50g) dissolved in minimum water was 
added to the stirred solution, fo11ollled by a dropwise 
addition of benzy1ch1oroformate (3S m1) over half-an-hour. 
After stirring for 2 hours, pyridine (14 m1) ws added and 
the organic layer separated and wshed with 1M hydrochloric 
acid, water, 5% sodium bicarbonate, brine, dried over 
(Mg504 ) and on evaporation gave an oil. The oily residue 
was dissolved in hexane and left to stand overnight at 40 C 
to give oily crystals (20.49g, 97%). 
(19) N-Benzy1oxycarbony1-L-alanine-methyl ester (9.4Sg, 0.04 mol) 
was dissolved in dry TlIP' (50 ml), lithium borohydride 
(1.76g, 2eq) was added and the mixture stirred under 
nitrogen. After 1 hour ethy1acetate (200 m1) and water (100 
ml) were added and the mixture acidified with hydrochloric 
acid. The organic layer _s separated and washed with 
water, 5% sodium bicarbonate, brine, dried over (Mg804) and 
evaporated to an oil which crystallised on addition of 
hexane (6.7g, SO%), m.p. 56-580 C. 
Anal. for: C11H1SN103: C, 63.14; a, 7.23; Nt 6.70; found: 
C, 63.12; a, 7.21; N, 6.73%. 
(20) A solution of L-pro1ine (1048, 0.903 mol) in water (1350 m1) 
and triethylamine (267 m1, 1.8M) wre added to 
N-Benzyloxycarbonyl-L-alanyl-N-hydroxysuccinim1de ester 
(298g, 0.903 mol, prepared in (4» in OM! (1800 al). The 
mixture was stirred for 6 hour 8 and the DME rellOved by 
evaporation. The aqueous layer after extraction with 
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ethylacetate (2 x 300 ml) was acidified to pH 1-2 wlth 2M 
acid. The oil was dissolved in ethylacetate (2 
washed with water (2 x 400 ml), dried over 
hYdr oc hlor ic 
x 900 ml), 
(Na2S04) and evaporated to an oil. The product crystallised 
o 
on addition of diethylether (221.4g, 77%), m.p. 124-125 C 
(Lit. 86 120-1220 C). 
Anal. for: C16H20N205: C, 60.0; H, 6.30; N, 8.70; found: 
C, 59.90; H, 6.40; N, 8.86%. 
(21) The procedure was as for (2) using N-Benzyloxycarbonyl-L-
alanyl-L-prollne. 
(22) N-Benzyloxycarbonyl-L-alaninol (6.27g, 0.03 mol) was 
dissolved in DMF (50 ml) and hydrogenated over Pd/c for 4 
hour s and after the uptake of hydrogen was complete, the 
solution was filtered thr:ough Hyflo. N-Benzyl-
oxycarbonyl-L-alanyl-L-prolyl-N-hydroxysuccinim1de ester 
prepared in (21) (12. 52g, 0.03 mol) was added and stirred 
for 1 hour at 00 C in an icel salt bath befor e leaving to 
stand overnight at room temperature. Evaporation of the 
solvent resulted in an oily residue which dissolved in brine 
and extracted with chloroform (3 x 150 ml), dried over 
(MgS04) and evaporated to a foam. This was dissolved in DCM 
and the product crystallised to give a white crystalline 
solid (5.37g, 47.4%), m.p. 157.5-15So C. 
Anal. for: C19H27N305: C, 60.46; H, 7.21; N, 11.13; found: 
C, 59.99; H, 6.98; N, 11.02% 
+ 0.5 mol H20. 
(23) A solution of L-proline treated in lO-fold amount of boiling 
acetic acid with exactly 1 mole of acetic anhydride. After 
evaporation of the solvent the product crystallised from 
acetone. m.p. 114-1160 C (Lit. S7 11So C). 
(24) N-Benzyloxycarbonyl-L-alanyl-L-prolyl-L-alaninol (2.43g. 
6.46 maol). was dissolved in DMP (100 ml) and hydrogenated 
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over Pd/C for 4 hour s. After the intake of hydrogen was 
complete, the solution was filtered thcough Kyf10 and 
N-Acety1-L-pro1y1-N-hydroxysuccinimide ester (prepared as 
(2) from (22», (1.01g, 6.43 mmo1) in situ was filtered into 
the solution. The reaction was stirred for 1 hour and left 
to stand overnight at room temperature. The solvent was 
evaporated and the oily residue was dissolved in water and 
extracted with chloroform (3 x 100 m1). The aqueous layer 
was separated and evaporated to an oil. The crude product 
was chcomatographed on silica gel (5-55% methano1-
ethy1acetate) and the f~actlon8 containing the product were 
evaporated to a foam (1.63g, 66%). 
Anal. for: C1SH30N405: C, 56.53; H, 7.91; N, 14.65; found: 
C, 51.40; H, 7.70; N, 12.99% + Ash. 
(25) N-Acety1-L-pr 0 1y1-L-a1any1-L-pr 0 1y1-L-a1anino 1 (0.5g, 1.31 
mmo1) was dissolved in DCM and pyridinium ch10rochcomate 
(0.74g, 3.43 mmo1) was added and stirred at room temperature 
for 4 hours. The crude product was chromatographed on 
silica gel by making the column in ethy1acetate and eluting 
with 10% methanol-chloroform. The fraction containing the 
product were evaporated and redissolved in chloroform and 
was reco1umned in the same system to remove all the 
oxidising agent. The product after re-evaporation _s 
dissolved in _ter and freeze-dried (0.128, 24%). 
Anal. for: C1SH2SN405: C, 56.83; H, 7.42; N, 14.73; found: 
C, 53.42; H, 7.47; N, 13.60 + 
1.35 mol of H20. 
(26) L-pro1ine (43.68, 0.04 mol) _s suspended in methyl 
trif1uoroacetate (24.26g, 0.21 mol) and N,N,N' ,N' ,-tetra-
methy1guanidinium (6.448, 7 111) _s added. The reaction 
mixture refluxed for 20 minutes and exceS8 methyl 
trlfluoroacetate removed by evaporation. The mixture _s 
dissolved in water and made acidic (litllUs) w1.th 
concentrated sulphuric acid and extracted w1.th ethy1acetate 
and evaporated to an 011. (7.97g, 96%, (Lit. S8 46-480 C). 
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(27) The procedure was as for (24), N-Trifluot'oacetyl-L-prolyl-N-
hydroxysuccinimide ester substituted for N-Acetyl-L-prolyl-N 
-hydroxysuccinlmide ester. 
Yield (0.94g, 33%). 
Anal. for: C18H27N405F3: C, 49.54; H, 6.24; N, 12.84; found: 
C, 47.87; H, 6.14; N, 12.24% + Ash. 
(28) The procedure was as for (25). 
Yield (0.26g, 56%). 
Anal. for: C18R2SN4oSF3: C, 49.47; R, 5.80; N, 12.90; found: 
C, 47.72; H, 6.20; N, 12.25% + 
1 mol of H2O. 
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The complete reaction scheme for the hexapeptide (16) is 
summarised in Figure 3.30. 
AMINO-ACIDS 
Ala 
Lys 
Alol 
L-Phe.OH NaOH~ ZCl 
HCl.H-Lys.OH 
'OC 
Z-Lys.OB 
NBS 
DCC! 
Z-Lr.~SU 
~H3 
-HN-CH-CO-
(yH2 )4NB2 
-HN-CH-CO-
Pro 
Phe -HN-yH-CO-
o 
Z-Phe.OH Isobutene~ H2SO4 
Z-Phe-<f Bu 1 H2 /Pd 
N2 
t Phe-O -Bu 
(CH2 ) 4 -NH-BOC 
(BOC40 ~ I (H2N)-CH-COOH)2Cu cuc03 1 EDTA 
(CH2) 4 -NH-BOC 
, 
E: NaOH 
ZCl 
H2N-CH-COOH 
+ t Phe-O Bu ) 'OC t Z-Lys-Phe-O Bu 
.. 
BOC 
I t Z-Lys-Phe-o Bu 
L-Ala.OR 
L-Pro.OR NaOR) ZCl 
R. Pro-Ala-oMe 
+ 
Z-Ala-ONSu 
1 
Z-Ala-Pro-Ala-OMe 
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+ 
Z-Pro.OR 
Ci H2,/Pd 
N2 
~ NRS nec! 
Hz/pd ) 
N2 
Z-Pro-Ala-Pro-Ala.OR (SOl Ale NaOH 
+ 
(X*) 
NBS 
DCCI 
,oe t 
Z-Pro-Ala-Pro-Ala-Lya-Phe-o Bu 
BOC 
H-Lys-Phe-Ot Bu (X*) 
HCL.H-Ala-OMe 
+ 
NHS) Z-Pro-oNSu DCcr 
NEM 
Z-Pro-Ala-oMe 
Z-Ala.OB 
R.Ala-Pro-Ala-OMe 
1 Z-Pro-oNSu 
Z-Pro-Ala-Pro-Ala-oMe 
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,OC t 
Z-Pro-Ala-Pro-Ala-Lys-Phe-O Bu 1 45% H~ CH3COOH 
R.Pro-Ala-Pro-Ala-Lys-Phe.OH 
FIGURE 3.30 
The complete reaction scheme for the tetrapeptide (17) is 
summarised in Figure 3.31. 
Z-Pro-Ala-Pro-Ala.OH H2/Pd H.Pro-Ala-Pro-Ala-OH CH3COOH 
Under N2 Pyridine 
(CH3CO)20 
CH3CO-Pro-Ala-Pro-Ala.OH 
+ impuri ties 
SEPHADEX G-10 
~CO-PrO-Ala-Pro-Ala.OH 
FIGURE 3.31 
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The complete reaction scheme for the tetrapeptides (25 and 
28) are summarised in Figure 3.32. 
RCl.R-Ala-OMe K2RCOa ~ ZClf1,yr i dine Z-Ala-OMe 
LiBH4 
N2 
CH3 CH3 I H2/Pd t H2 N-CR-C~ OR ( 
N2 
Z -lIN -CR-CH2 OR 
L-Ala.OB ZCl Z-Ala.OR NBS ~ Z-Ala-ONSu NaOB ) DeCI 
+ 
L-Pro.OH 
1<C2HS»)N 
Z. Ala-Pr o. ONSu NBS ( DCCI 
Z-Ala-Pro.OH 
+ 
CR) 
I 
Ht'-car2OB 
Z.Ala-Pro.Alol H2,/Pd ) Ala-Pro. Alol 
N2 
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Ala-Pro-Alol 
L-Pro.OR L-Pro.OR 
(CR3CO)20 
CR3COOR 
Ac-Pro.OR TFA-Pro.OR 
iNHS DCCI 1 NRS DCCI 
Ac-Pro-oNSU--4) f-( --TFA-Pro-oNSu 
1 1 
Ac-Pro-Ala-Pro-Alol 1 Pyr+C1Cr°3 - . TPA-Pro-Ala-Pro-Alol 1 Pyr + C1Cr°3 -
Ac-Pro-Ala-Pro-Alal (25) TFA-Pro-Ala-Pro-Alal (28) 
000 CRod CH 0 II II I 3" ~ I 3 ; 
CH3-C C~H-CH-C- -NU-CU-C 
'R 
(25) 
000 CRO QO ~U 0 
" II I 311 II I 3 # 
CP3-C C-NH-CH-C~ C-NH-CR-C 
'H (28) 
FIGURE 3.32 
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CHAPTER FOUR 
KINETIC STUDIES 
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4.1 INTRODUCTION 
The hydrolysis of ester or amide substrates catalysed by 
serine proteases involves an acyl-enzyme intermediate in 
which the substtate acylates the hydroxyl group of 
serine-19S1• The attack of serine-19S on the carbonyl group 
of the substrate involves the formation of a high ener gy 
tetrahedral intermediateZ• 
R 
I , (=0 ;::::,==~ 
X 
R , 
(=0 
X 
~ 
E- CH-O-C=O 
I 2 
1m 
Hl. ~ _ 
~(--~~) E-CH-Q-C-O 
, 2 I + I 
Im-- ---H--~ 
ACYL - ENZYME 
Reaction pathway for serme protease catalysis 
FI GURE 4'0 
The enzyme represented by E has tw important functional 
groups the hydroxyl of serine-l95 (-caZOR) and the imidazole 
of histidine-57 (1m) for catalysis. 
From. X-ray data. Blow et a13 proposed that the catalytic 
centre of serine proteases (chymotrypsin) involved in 
"charge-relay system". This involved the three residues, 
the buried asparate-102 hydrogen bonded to histidine-57 
which in turn hydrogen bonded to serine-l95. 
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H 
~ - /~ Asp- (-0- - - - --H-N N- -- - -+t-O-Ser 195 
102 I I H( ( 
I 
His 
57 
Charge relay system in elastase without the substrate. 
In this case transfer of electrons from the buried carboxyl 
~oup to the oxygen of serine-195 occurs 80 that the 
hydroxyl becomes a powerful nucleophile and is able to 
attack the carbon atom of the substrate (figure 4.1). 
Substrate Tetrahedral 
in te r m e d i ate 
I -0 ~ 
Ser 195 0 = e...R \ / 
-(H2- q R-N-H /(\ 
H, -(H 2-Q 
, R-N-H , 
N-(H--~) ~ 
I /N-eH 
H( 
His 57 \-e He 
H I ~H---( 
I CH 2 I I ~. ' A THz 
o~S- 6 
Asp 102 'c 0,. 
I C 
I 
FIGURE 4·1 
Acyl- Enzyme 
intermediate 
0, R' ~(/ 
-CHrO/ 
R-N-H 
I ) ~ 
I )-CH 
He 
\ 
N-C 
H ' I CH2 
, I 
I 0-
~~ 
I 
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During this acylation step, which proceeds through a 
tetrahedral intermediate, a proton is transferred from the 
imidazole ring to the nitrogen atom of the substrate. In 
turn the carbonyl carbon atom binds covalently to the oxygen 
atom of the serine. 
2 However, in 1980 James et al proposed that ther e was no 
"charge-relay system" as such, which contributed to the 
catalytic rate enhancement of hydrolysis by the serine 
proteases. Their deductions were based upon SGPA which has 
a similar structure in the active centre to the pancreatic 
2 
serine proteases. James et al proposed that the 
intermediate came from the potentially strong electrostatic 
interaction provided by the tw dipole moments of the 
oxyanion binding si teo This enhances the polarization of 
the carbonyl group of the substrate. The carbonyl oxygen 
approach towar ds the oxyanion binding site is coupled with 
an enhancement of polarization of the peptide bond with the 
carbonyl carbon atom developing a partial positive charge. 
It is this positively charged carbon atom of the substrate 
which induces the depar ture of the hydroxyl proton of 
serine-U5. The pathway that the proton tak.es is as 
mentioned previously, that is, the aspar ate-hi stidine 
couplet (figure 4.1). This is then followed by the collapse 
of the tetrahedral intermediate to the acyl-enzyme (figure 
4.1). 
The next stage in the catalysis is the deacylation step 
2 
sho1lll in figure 4.2. 
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R HIC R t I 
-E- CH-O-C=O ( ) E -CH2-9-(-0 I 2 I I + I 
1m lm----H--Y 
ACYL- ENZYME J 
R R 
I ~ I E-(H20H + (-0 
" 
E-CH 2OH (=0 I I I I 
1m Y 1m Y 
FIGURE 4·2 
2 James et a1 proposed that the acyl-enzyme formed has a 
pyramidal carbonyl carbon atom and the carbonyl oxygen atol'll 
remains in the strongly polarizing electrostatic environment 
of the oxyanion binding site. As in the acylation step. 
formation of an enzyme-substrate tetrahedral intermediate 
occurs by partial positive charge on the carbonyl carbon 
atom allowing the second substrate (water molecule) to 
dissociate a proton. This creates a strong nucleophilic 
hydroxide ion and finally the break dom of the intermediate 
4 to the substrate and enzyme. Figure 4.3 • 
Acyl- Enzyme 
intermediate 
1 o~ /R ~C 
/ -C~-O H 0/ 
A 
I 
I 
N-CH 
;/ 
HC 
His 57 \ 
N-( H I 
I CH2 I I 
I 0-O~, 
C 
Asp 102 I 
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Tetrahedral 
intermed iate 
FIGURE 4.3 
Acid Component 
the substrate 
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4.2 THE EFFECTS OF ENZYME INHIBITORS ON SERINE PROTEASES 
Enzyme inhibitors can be classified into tll«) general 
categories: irreversible and reversible. 
The irreversible inhibitors are so called because on binding 
to the pt'otein they form covalent bonds, thus obstructing 
entry of the substrate either by steric hindrance at a site 
near the active site or within the active site itself. 
Excess substrate added to such a system will not remove the 
inhibitor which has now become irrever sibly bound to the 
protein e.g. active site-directed inhibitors and succide 
inhibitors are usually of this type. 
Reversible inhibitors, on the 
non-covalently to the pt'otein 
substrate in this case wi 11 
other hand, 
and addi tion 
remove the 
will bind 
of excess 
inhibitor. 
Generally, reversible inhibitors can be sub-divided into 
three groups as follows : 
a) COMPETITIVE 
These compete with the substrate for binding to the active 
site but, once bound, cannot be transformed by the enzyme 
and vice-versa. Competitive inhibition can be reversed or 
relieved simply by increasing the susbtrate concentration. 
These inhibitor s generally resemble the substrate in 
three-dimensional structure and "trick." the enzyme into 
binding it. Michaelis-Menten theory can be used to analyse 
quantitatively the inhibition. The competitive inhibitor, 
I, binds exclusively to E and not enzyme-substrate complex 
[ES], to form enzyme-inhibitor complex [EI]. In this case 
V 1s unchanged whilst K. is changed. 
ux m 
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b) UNCOMPETITIVE 
These are very rat"e and the inhibitor only binds to the 
[ES]. The inhibitot" therefore binds to a secondary site. 
Both V and K are changed. 
max m 
c) NON-COMPETITIVE : 
Substtate and inhibitor bind simultaneously to the enzyme 
t"ather than competing fot" the active site. 
dect"eased but K does not change. 
m 
V is 
max 
In PPE, a number of synthetic irreversible inhibitot"s can 
form a stable bond with a catalytically impor tant 
amino-residue, 1. e. those which block set"ine-195 and those 
that alkylate histidine-57. 
The former ~oups include DFp5 , PMSF, tosyl fluot"ide, 
6 p-chloromercuri-benzene-sulphonyl-fluoride, and p-fluot"o-
1 phenyl sulphonyl-fluoride. The latter groups includes 
peptide chloromethyl-ketones8 ,9. 
Reversible inhibitors (peptide aldehydes, TFA-peptides) of 
PPE have been synthesised which are also thought to generate 
10 tettahedral intermediate analogues to PPE catalysis • In 
this case, the hemiacetal (figure 1.6) which is formed is 
relatively stable and breakdown of this complex will give an 
aldehyde. The aldehydes are unique among carbonyl compounds 
in preferring to exist as tetrahedral addition complexes. 
The inhibition constant (Ki ) for the various competitive 
inhibitors can be calculated from Dixon plotsll using the 
substrate (NBA). This allon the use of very low 
concentrations of enzyme and the maintenance of a high 
inhibitor : enzyme ratios. 
4.3 
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TO MEASURE llv AND K USING THE MICAHELIS-MENTEN 
------------~max m 
EQUATIONS IN ~ORM OF A LINEWEAVER-BURK PLOT 
The inhibition constants, Ki' for the inhibitors Ac-Pro-A1a-
Pro-A1aninal (25) and TFA-Pro-A1a-Pro-A1anina1 (28) (refer 
to Chapter Three for the inhibitor numbering) were evaluated 
from Dixon P10tsll at t~ substrate concentrations using the 
intercept with llv 
12 max 
Lineweaver -Burk plot 
which was determined by 
4.4 EXPERIMENTAL PROCEDURE 
Buffer 
Substrate 
Enzyme 
Temperature 
50mM sodium phosphate, pH 6.5 
: NBA 
PPE (200 l.l g/m1) 
300 C 
The standard conditions _re those of Visser and Blout13• A 
volume of 10mM stock solution of NBA (10, 15, 25, 50 and 100 
1.11) in spectroquality methanol was added to quartz reference 
and sample cuvettes (l-cm path1ength), containing 2.95 m1 of 
buffer. The cuvettes ~e incubated for 5 minutes at 300 C 
befor e 10 l.ll of the stock enzyme solution _s added to the 
sample cuvette. The rate of release of p-nitropheno1 waa 
measured for 3 minutes at 347.5 nm in a unicalll SP 1800 
ultraviolet spectrophotometer. The experiment _s repeated 
until three consiatent results for each substrate 
concentration were obtained. 
4.5 EXPERIMENTAL PROCEDURE FOR INHIBITION CONSTANT, KJ.' 
DETERMINATION 
For the inhibitors (25) and (28). This time the 
measurements were carried out at two different subatrate 
concentrations i.e. lomM and SaM. 
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4.5.1 A similar procedure to the above was used, but this time an 
exact volume of substrate (10mM, 100 1.11) was added to 2.95 
m1 of buffer and the inhibitor volume was varied. The 
inhibitor volume used, from the stock solution (10mK) were 
3, 10, 20, 30 and 50 l.ll. 
4.5.2 As above, except this time 5mM substrate concentration was 
used. 
4.6 RESULTS 
FOR 4.4 
[S] Rate (V) l/[S] l/V 
mM ~OD/min mM -1 Min 
0.0337 0.0037 29.67 270.27 
0.0504 0.0053 19.84 188.68 
0.0837 0.0080 11.95 125.00 
0.1661 0.0160 6.02 62.50 
0.3268 0.0273 3.06 36.63 
4.5.1 and 4.5.2 FOR INHIBITOR (25 2 
SUBSTRATE lomM and SmM 
Substrate 10mM Substrate SlIM 
[1 ] Rate (V)x 10-3 l/V Rate(V)x 10 -3 l/V 
PM ~OD/min Min A.OD/Illin Min 
0.9775 14.870 67.25 7.000 142.86 
3.2501 7.887 126.79 4.333 230.79 
6.4805 5.667 176.46 3.333 300.00 
9.6890 4.333 230.79 2.667 374.95 
16.0450 3.333 300.00 2.000 500.00 
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4.5.1 and 4.5.2 FOR INHIBITOR (28) 
SUBSTRATE 10mM and 5mM 
Substtate 10mM Substrate 5mM 
[ I] Rate (V)x 10 -3 l/V Rate(V)x 10 -3 l/V 
llM Ii OD/min Min !i OD/min Min 
0.9650 2.467 40.54 1.600 62.50 
3.2094 1.867 53.56 1.167 85.69 
6.3981 1.717 58.24 1.133 88.26 
9.5660 1.400 71.43 0.950 105.26 
15.8408 1.100 90.90 0.500 200.00 
4.6 RESULTS FROM THE GRAPH 
GRAPH 1 K (mM) V (Min-i) 
111 max 
PPE 1.023 + 0.146 0.111 + 0.013 
Graph Inhibitor Ki 
(}J M) 
2 (25) 6.1 (5.8)* 
3 (28) 8.6 (8.3)* 
* corrected for i1l1puri ties 
4.7 DISCUSSION 
The value K obtained (1.023 mM)14. for the PPE varies 
m 13 
significantly from the results of Visser and Blout (K
m
• 
0.3 11M). This discrepancy is probably the reBult of a 
difference in temperature (not specified by Visser and 
Blout13) and for different batch of PPE used (Visser and 
Blout used PPE from Worthington Biochemcal Corporation. 
whereas that used bere .s fro. Sigma Chemcals Ltd and was 
approximately three year sold) •. 
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for the The inhibition constant, Ki , was measured 
aldehydes are not significantly different. 
10 
results with those of Thompson et al for 
Comparing the 
Ac-Pro-Ala-Pro-
A1anina1 (25), the Ki value is significantly different, i.e. 
Ac-Pro-A1a-Pro-A1anina1 Ki • 0.8UM, 37
0 C, pH 7.0, 
Ac-Pro-A1a-Pro-Alaninal Ki - 2.0 II M, 370 C, pH 4.0. 
However, it was noted by Thompson 
aldehydes was not ~eatly affected 
4.00-7.00. The difference in the 
10 
et a1 that the Ki for 
by pH over the range of 
inhibition constant for 
(25) is probably the result of reaction conditions. The 
10 lower temperature than Thompson et al could affect the 
binding of the inhibitor. Also they used a different 
substrate (acety1trialanine methyl ester)15 which has a 
difference K (0.44 mM) and kcat/K (170,000 M-1 sec-1 ) 
m m -1 1 
compared to a K (0.3 mM) and kcat/K (19,000 M sec - ) 
m m 
which in turn would affect the Ki value. 
The purity of the aldehyde will also affect the Ki since any 
impurities in the aldehyde would raise or lower the Ki 
value. The aldehyde prepared was approximately 94% pure, 
10 
while Thompson et a1 have not carried out any analysis to 
check the purity of the~r aldehyde. 
The inhibition constant for TFA-a1dehyde (28) has not been 
reported elsewhere, but in comparison with other reversible 
TFA-peptides (table 4.0) it agrees quite well. 
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TABLE 4.0 
COMPARISON OF THE INHIBITION CONSTANT Ki , OF VARIOUS 
TFA-PEPTIDES WITH TFA-PEPTIDE ALDEHYDE 
Peptide 
7 CF 3CO-Ala-Ala-Ala.OH 
CF3CO-tYS-Ala-Ala-Ala.OH
16 
CF 3CO-Pro-Ala-Pro-Alaninal 
GRAPH 1: A DOUBLE-RECIPROCAL PLOT ts-} Vs -+ 
1 
V 
300 
240 
180 
120 
6 
7.9 
10.0 
8.3 
4 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 
..L mM-1 (5J 
GRAPH 2: FOR INHI BllOR (2S) 
4 
Kj 
so 
400 
_1_ 
V 
300 
200 
2 
GRAPH 3: FOR INHIBITOR (28) 
1 
200 
140 
120 
V 100 
80 
12 4 2 
Kj 
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x 
S:5mM 
4 6 8 10 '12 14 16 
----
4 6 a 10 . 12 14 16 
134 
REFERENCES 
1. Fer sht, A. 
Enzyme Structure and Mechanism. (1977). 
2. James, M.N.G., Sielecki, A.R., Brayer, G.D., 
Delbaere, L.T.J. and Bauer, C.A. 
J.Molec.Biol., 144, 43 (1980). 
3. Blow, D.M., Birktoft, J.J., and Hartley, B.S. 
Nature, 221, 337 (1969). 
4. Stryer, L. 
Biochemistry, 2nd Edition, Freeman. (1975). 
5. Naughton, M.A., and Sanger, S. 
Biochem.J., 78, 156 (1961). 
6. Watson, H.C., Shotton, D.M., Cox, J.C., and Muirhead, H. 
Nature, 225, 806 (1970). 
7. Dimico1i, J.L., Bieth, J., and Lhoste, J.M. 
Biochemistry, 15, 2230 (1976). 
8. Powers, J.C., and Tuhy, P.M. 
Ibid., ~, 4767 (1973). 
9. Thompson, R.C., and Blout, E.R. 
Ibid., 12,47 (1973). 
10. Thompson, R.C. 
Ibid., ~, 44 (1973). 
ll. Dixon, M. 
Biochem.J.,1!, 170 (1953). 
12. Line_aver, H., and Burk, D. 
J.Amer.Chem.Soc., ~, 658 (1934). 
13. Visser, L., and Blout, E.R. 
Biochim. eta Biophya. Acta., 268, 257 (1972). 
14. Wilkinson, G.N. 
Biochem.J., 80, 324 (1961). 
15. Gertler, A., and Hoffmann, T. 
Can.J.Biochem., 48, 384 (1970). 
16. Dimicoli, J.L., Renaud, A., Bieth, J. 
Eur.J.Biochem., 107,423 (1980). 
135 
CHAPTER FIVE 
HUMAN LEUKOCYTE ELASTASE 
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5.1 INTRODUCTION 
HLE ~s first recognised as a serine protease by Janoff and 
co-wrker sl. This elastase is involved in pulmonary 
emphysema which causes progressive loss of lung elasticity 
due to the destruction of lung e1astin2• This in turn 
causes respiration problems and eventually leads to death. 
The main group of sufferers from this disease, is people who 
are deficient in the serum protease inhibitor a -anti-
3-8 1 
trypsin which inhibits a variety of proteases including 
elastase and which is produced in 
9-12 leukocytes • a. -antitrypsin, 
the granules of human 
protects the lung from 
1 
digestion by any of the proteases in normal pet' son, but 
lung persons with insufficient inhibitor proteo1yse their 
elastin and so develop emphysema. Other factor s l' epor ted in 
the literature which aggravate this problem at'e smoking and 
air pollution. 
Indi vi duals who smoke cigarettes partially inacti-
vate a. -antitrypsin resulting in lung damage by elastase 
due to ~he pt'esence of oxidant present in the smoke13 ,14. 
The cause for 
methionine-358 
this is, 
residue at 
the modification of the 
the active centre 
of a. -antitrypsin resulting in a dramatic dect'ease in the 
1 
inhibitor activity to war ds elastase. This in turn 
inactivates the protective function15• 
Recently studies were carried out with the possibility of 
modulating the biological properties of a. -antitrypsin by 
substituting the 
16 17 
to valine ' • 
1 
methionine-358 residue at the active centre 
a -antitrypsin (Met358 )Val) proved to be 
1 
resistant to oxidation as while as an efficient inhibitor. 
a -antitt'ypsin (Met3~ Val) could be a 
1 
Moreover , 
particularly effective therapeutic agent in the tt'eatment 
of a. -antitrypsin deficiency or in protecting the lung in 
situa;ion of increased oxygen burden17 
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HLE consists of four isoenzymes, which are all 
glycoproteins, with a carbohydt'ate content mainly composed 
18 
of neutr a1 sugar They have been shown to cleave 
19 20 
as elastin , azo-casein , structural proteins such 
21 
collagen and proteog1ycan. HLE has been purified from 
22-26 leukocytes ,obtained by leukaphoresis from patients 
wi th chronic leukemia or from normal donor s1. The 
"buffy-coat residues" containing the leukocytes can also be 
obtained from outdated blood. Other useful sources of this 
27 form of HLE are purulent sputum and also the human 
sp1een28 • The e1astases obtained from these sources ar e 
immunologically identical to that of leukocytes. 
The HLE used in this wrk, a gift from Dl' Rober ts, 25 was 
found to be homogeneous by 5DS electrophoresis and had a 
molecular weight of 22,000 by gel-filtration. This was in 
. 28 
agreement with other wrkers (20,000 Starkey and Barrett , 
24 22,000 Taylor and Crawford ). However, it was inconsistent 
wi th other data obtained by SDS electrophor esis (30,000 
18 Baugh and Travis ). The reasons for these discrepancies in 
the molecular weight repor ted for HLE, (for which one 
expects a molecular weight of approximately 25,000 for the 
210 amino-acids plus 20% for the carbohydrate content giving 
a molecular weight of approximately 30,00023 ,29) is probably 
due to gel-filtration. There is also a disagreement in the 
percentage of neutral sugar in the isoenzyme, E4• A 22.8% 
sugar content has been reported by Baugh and TraVis18 , and 
24 Taylor and Crawford of which 21.2% was due to hexose. 
27 Twumasi and Liener have obtained half this value and also 
the figure obtained by Roberta et a125 is considerably 
lower. The isoenzyme, E4 has an isoelectric point in the 
range of 8.77 - 9.1430• 
5.2 COMPARISON WITH PPE 
The amino-acid compositions of E4 , obtained by various 
writer s have been c01lpared 14th. that of PPE. Table 5.1 
shows the amino-acid residues per molecule and also as a 
percentage of the total amino-acids. 
TABLE 5.1 
AMINO-ACID COMPOSITION OF PPE AND HLE REPORTED IN LITERATURE 
AMINO-ACID PPE(31) REF(27) REF{l8) PPE(31 ) REF(lB) REF(27) REF (23) 
RESIDUE/MOL % MOL AMINO-ACID 
Aspartic acid 24 22 24 10.0 10.5 10.5 9.6 
Threonine 19 6 7 7.9 3.1 2.9 2.B 
Serine 22 12 13 9.2 5.7 5.7 5.2 
Glutallic acid 19 16 18 7.9 7.9 7.6 7.0 
Proline 7 9 10 2.9 4.4 4.3 7.4 
Glycine 25 25 28 10.4 12.2 11.9 11.2 
Alanine 17 22 24 7.1 10.5 10.5 11.1 
Half-Cystine 8 4 6 3.3 2.6 1.9 
...... 
w 
Valine 27 23 25 H.3 10.9 11.0 11.4 00 
Methionine 2 2 2 0.8 0.9 0.9 0.7 
Isoleucine 10 9 H 4.2 4.8 4.3 4.2 
Leucine 18 21 20 7.5 8.7 10.0 9.7 
Tyrosine 11 3 3 4.6 1.3 1.4 1.1 
Phenylalanine 3 932 933 1.3 3.9 4.3 3.9 
Tryptophan a 7 2 2 2.9 0.9 0.9 
Histidine 6 5 4 2.5 1.7 2.4 2.8 
Lysine 3 1 1 1.3 0.4 0.5 0.5 
Arginine 12 19 22 5.0 9.6 9.0 11. 7 
240 210 229 100 100 100 100 
-
a Determined spectorphotometrically. 
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The amino-acid compositions for HLE when compared with PPE, 
show quite a difference in the total amino-acids pet' 
molecule, but agree most closely when expressed as the 
number of residues/mol of protein. Compared to PPE there 
are major differences in the individual amino-acids i.e., 
threonine, serine, half-cystine, tyrosine, phenylalanine, 
tryptophan and arginine. The majority of these amino-acids 
are bulky groups and may affect the specificity around the 
active centre. 
Another major 
which plays 
difference 1s the disulphide bond content 
an important role in stabilising the 
three-dimensional structure. HLE shows tlO or three 
disulphide bridges as indicated from the amino-acid 
composition compared to four in 
molecule is compact and globular. 
same number of disulphide bridges 
PPE, wher e t he who le 
However, HLE shows the 
as SGPA and SGPB34 ,35. 
These bacterial 
si te region as 
Hence, with 
enzymes have the same features in 
34 PPE , but one or tlO impor tant 
the differences in amino-acid 
the active 
deletions. 
and the 
carbohydrate 
ac t1 vi ty for 
affected. 
content, the specificity and the catalytic 
substrate and inhibitors are likely to be 
Various studies comparing the specificity of HLE with PPE 
have been made using peptide chloromethyl ketone 
inhibitors19 ,36,37, synthetic 8ubstrates38 ,39 and the 
40 insulin B chain • Peptide chloromethyl ketones have proved 
to be very effective inhibitors of PPE41 ,42. Hence, several 
tri and tetra peptide chloro_thyl ketones have been 
prepared by research groups36,37,41 and tested on HLE. 
On the basis of the result obtained by Tuhy et a136 that 
Ac-A1a-A1a-Pro-Ala-CMK .. s the most effective inhibitor for 
PPE and HU. Powers et a137 synthesised various inhibitors 
with the sequence Ac-Ala-Ala-Pro-X-CMK (X - lIe, Val and 
Tlr) and they compared the inbibi tion of both elastases. 
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The inhibition rates obtained for PPE and HLE are listed in 
table 5.2 and 5.3, for HLE rates (at pH 6.5) were also 
considered relative to kobsd/[I) for Ac-Ala-Ala-Pro-Ala 
_CMK36 • The P5 residue in the sequence was also changed 
from acetyl to a succ1nyl (Sue) and methyl 8uccinyl 
(MeO-Suc). 
TABLE 5.2 
INHIBITION OF PPE WITH PEPTIDE CHLOROMETHYL KETONES 
Inhibitor [ I] kobsd/[I] kobsd/ [I] 
P5 P4 P3 P2 Pl (taM) (M-
1 sec-1) (rel) 
Ac-Ala-Ala-Pro-Ala-CMK 0.05 40* 1.0 
Ac-Ala-Ala-Pro-Val-CMK 0.05 35* 0.9 
Suc-Ala-Ala-Pro-Val-CMK 0.05 73*,** 1.8 
MeO-Suc-Ala-Ala-Pro-Val-CMK 0.05 55*,** 1.4 
Ac-Ala-Ala-Pro-Ile-CMK 0.05 48* 1.2 
Ac-Ala-Ala-Pr o-Thr-cMK 5.00 0.08* 0.002 
PPE concentration 5lJ M, O.Q.5M acetate buffer, pH 5.0, 5% 
(v/v) methanol, 300 C 
* Average of three runs 
** No methanol was used in the buffer 
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TABLE 5.3 
INHIBITION OF HLE WITH PEPTIDE CHLOROMETHYL KETONES 
Inhibitor 
P5 P4 P3 P2 P1 
pH [11 kobsd/[I1 kobsd/[I1 
(11M) (M-1 Sec -1) (rel) 
Ac-Ala-Ala-Pro-Ala-CMK 6.5 0.20 
6.5 0.40 
3.4 
3.3 1.0 
7.5 0.11 9.7 
Ac-Ala-Ala-Pro-Val-cMK 6.5 0.05 160* 49 
7.5 0.10 219 
Suc-Ala-Ala-Pro-Val-CMK** 6.5 0.025 320 97 
7.5 0.025 1400 
MeO-Suc-Ala-Ala-Pro-Val-CMK** 6.5 0.025 922 280 
Ac-Ala-Ala-Pro-Ile-CMK 
Ac-Ala-Ala-Pr o-Thr-CMK 
Z-Gly-Leu-Phe-CMK 
7.5 0.025 1560 
6.5 0.05 133*** 40 
6.5 10.0 0.15 
7.5 0.10 Oa 
HLE concentration 10 \.1M, O.lM phosphate, 0.06M NaCl 
pH 6.5, 5% (v/v) methanol, 300 C 
0.05 
HLE concentration 21 \.1M, 0.05M phosphate, 0.035M NaCl, pH 
7.5, 5% (v/v) methanol, 300 C 
* Average of three runs 
** O.lM pbosphate, 0.035M NaCl, elastase 0.94 llM, 300 C 
*** Average of tliD runs 
a No measurable activity after 4 daYI period. 
Prom tables 5.2 and 5.3 it •• concluded that threonine 
c01lpounds ware unreactive to WE' ds both ela.ta.... Por HLE, 
the valine and isoleucine chloro_thyl k.etonel were 
respectively 49 and 40 times more r.active at pH 6.5 than 
the alanine chloro_thyl ketones. However, at pH 7.5 the 
difference betwen valine and alanine •• leal mark.d. 
These results compare wall with the subltrates Ae-Ala-Ala-
Pro-X-p-nitroanillde hydrolysis in table 5.438• 
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TABLE 5.4 
HYDROLYSIS OF SUBSTRATES BY BOTH ELASTASES 
Substrates : Ac-Ala-Ala-~o-X-p-nitroanilide elastases, 
rates relative to Ala is 100. 
Enzyme X 
Ala Gly Val Leu 11e Phe 
PPE 100 1 5 25 0 0 
HLE 100 2-20 800 20 150 0 
Also in this case, the substrates with valine and isoleucine 
were hydrolysed 8 and 1.5 times faster respectively than 
Ala-p-nitroanil1de by HLE. Hence the overall conclusions 
Which emerge from these comparisons between the HLE and PPE 
subsite specificities are : firstly, HLE prefers valine to 
alanine at Pl. This indication has also been obset'ved in 
the digestion of the oxidised insulin B chain with HLE40 • 
It was directed towards valine compared to alanine with 
PPE43 • Hence the S1 subsi te prefer s lar gel' side chains than 
PPE. Secondly, subsi te S5 for HLE is observed to be 
structurally different', since it interacts more favourably 
with Suc or Meo-Suc than acetyl. From. table 5.2 the 
inhibition rate of PPE is not affected by this change. 
Powers et a137 found that the DIOst effective inhibitor for 
HLE was MeO-Suc- Ala-Ala-Pro-Val-CMK (table 5.3). 
36 Other subsites have also been compared by Tuhy et al with 
tri and tetra peptide chloro1l8thy1 k.etones inhibitors, table 
5.5. 
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TABLE 5.5 
INHIBITION OF HLE AND PPE WITH PEPTIDE CHLOROMETHYL KETONES 
Inhibitor [I] kobsd/[I] 
(M-1 Sec-1) 
P4 P3 P2 P1 (11M) HLE PPE
41
,44 
< 
Ac"';A1a-A1a-A1a-CMK 1.0 1.0 1.0 
Ac-A1a-Pro-Ala-CMK 1.0 4.0 1.6 
Ac-Pro-Ala-Ala-CMK 1.0 0 0 
Z-Gly-Leu-Ala-CMK 1.0 7.3 1.9 
Z-G1y-Leu-Phe-cMK 1.0 0 0 
Ac-A1a-A1a-A1a-A1a-cMK 0.2 3.5 18 
Ac-Ala-Ala-Pro-Ala-CMK 0.2 15.8 71 
Ac-A1a-Pro-A1a-Ala-CMK 0.2 8.1 0 
Ac-A1a-A1a-Phe-A1a-CMK 0.2 4.8 2.2 
Ac-Phe-G1y-A1a-Leu-cMK 0.2 2.2 
Tetrapeptides were found to be better inhibitors than the 
tripeptides with 5-fo1d lower inhibitor concentrations. 
From the inhibition studies, it is evident that an extended 
binding site in HLE exists. Position P2 is favoured by 
proline rather than alanine, from table 5.5, Ac-A1a-A1a-Pro-
A1a-cMK has 4 to 5 time 1ar gar kob8d/ [I] than Ac-Ala-A1a-
A1a-A1a-CMlt. A si1ll11ar indication is obtained in the case 
of tripeptide8. Leucine ia a180 accommodated in po8ition P2 40 aa waa a1ao obaerved in the hydro1Y8i8 of in8u1in B chain 
10 14 
-Ria-Leu-Va1-G1u-A1a-
16 J, 20 
-Tyr-Leu-Va1-CY8-G1y-
I 
S03K 
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The subsite S3 for HLE was found to differ from PPE i.e. the 
subsite was able to accommodate proline at this position if 
the substrate or inhibitor was a tetrapeptide but not a 
tripeptide. However, in the case of PPE, proline at this 
subsite caused no inhibition41 ,44. 
When the overall inhibitions are compared on the basis of 
41 44 the value of kobsd/[I] , , HLE is inhibited less rapidly 
with peptide chloromethyl ketones than is PPE. In going 
from tri- to tetrapeptides there is a considerable increase 
in the inhibition for PPE but not for HLE. Hence, this 
indicates differences in the detailed geometry of the 
extended binding sites and hence on the catalytic activity 
of the t~ elastases. 
Starkey and Barrett19 have also carried out inhibition 
studies using variou8 protein inhibitor 8 from plant and 
animal tissues, table 5.6. 
TABLE 5.6 
INHIBITION OF HLE AND PPE WITH VARIOUS PROTEIN INHIBITOR 
Enzyme activity is expressed as a percentage of activity 
in the absence of inhibitor. 
Inhibitor Final concentration Activity 
(lIM) HLE 
Soya-bean trypsin ~ 1 ma/1I1 3 
inhibitor (Kunitz) 0.1 111/111. 27 
Lima-bean trypsin 
inhibitor 0.1 ma/a1 63 
Bovine pancreatic 
trypsin inhibitor 
(Kunitz) 0.5 ma/a1 35 
Turkey ovomucoid 0.1 111/111. 8 
Chicken ovoinhibitor 0.1 111/111. 14 
(% ) 
PPE 
37 
67 
78 
92 
4 
0 
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From table 5.6, soya-bean trypsin inhibitor (Kunitz) and 
Lima-bean trypsin inhibitor are only moderate inhibitors of 
PPE but po~ful inhibitors of RLE as are a 2-macroglobulin 23 
and a 1-antitrypsin from human plasma RLE is also 
inhibited by turkey ovomucoid and chicken ovoinhibitor, 
which have also sOO1ll1 to inhibit PPE45 • 
Rence, it is very important to explain the specificity of 
RLE by structural studies. This allows one to distinguish 
the major differences and the simi lar i ties knom from 
solution studies and also to compare with PPE. 
5.3 CRYSTALLISATION OF HLE 
The crystallisation technique that has so far been employed, 
46 
vapor diffusion , is ideal for scanning a large number of 
possible conditions with a minimum of material (typically 
200 trials on lOms enzyme). The presence of cal'bohydrate 
_s expected almost certainly to give a diffel'ent form of 
crystal. This wu1d lead to an independent structure 
determination and interpretation of the electron density 
wu1d show the full sequence of RLE which is not yet 
available. 
5.4 EXPERIMENTAL 
Glasa-distilled _ter and "Ana1aR" grade reagent. ware used 
t~ougbout, except for polyethylene-glycol 6000 and 2-methy1 
-2,4-pentane dio1. Buffer solutions WIIl'e prepared according 
to the tables published in "Data of Biochemical 
Reaearch"ll,47. A radio_ter pH M 7010 with glass 
electrode _I used for all pH _alure_nts. All the 
inhibitora and substrates used ware a gift froll D M Shotton. 
The following experimental condition. have been tried. 
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A. PRECIPITATING AGENTS B. TEMPERATURE 
Ammonium sulphate 
Ammonium citrate 
Sodium chloride 
Magnesium sulphate 
Sodium sulphate 
Polyethylene glycol 6000 
2-methyl-2,4-pentane diol 
D. BUFFERS AND pH's 
O.OSM Sodium phosphate buffer 
0.05M Tris/HCl buffer 
O.lOM Sodium acetate buffer 
E. INHIBITORS AND SUBSTRATES 
L-Alanine 
(Ala)4 
Z-Ala3·OH 
H.~o-Leu-GlY-NH2 
Ac-Val-Val.OH 
H.Ala-~o-Ala.OH 
00 C 
40 C 
90 C 
pH 5.5, 
8.0, 
pH 6.5, 
9.0 
pH 5.0, 
C. DIVALENT ION 
Mg2+ 
Ca2+ 
Zn2+ 
None 
6.0, 6.5, 7.0, 7.5, 
8.5 and 9.0 
7.5, 8.0, 8.5 and 
6.0 and 6.7 
The concentration of inhibitor or substrate used _s 0.111M 
in all casea. 
The enzyme concentration _a kept constant at 8.57 lIl8/ml. 
All buffers and solutions were filtered through M1l11pore 
cellulose acetate membrane filter. (s1ze 13.. grade 
0.22 lJm). 
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5.5 RESULTS 
The precipitating agent that seemed most hopeful from the 
o 
above list ~s ammonium sulphate at 4 C. The divalent ions 
2+ Mg tended to produce crystals of salt in phosphate and 
2+ Tris buffers but ca appeared to enhance crystal growth. 
None of the inhi bi tor s or substrates used produced very 
hopeful results. 
The optimum conditions found where small sized crystals grew 
were in the pH range 8.0-9.0 with 0.05M sodium phosphate or 
0.05M Tris/HCl buffer and between 1.5-2.35M ammonium 
sulphate concentration. Crystal growth appeared to take 
about five days. Similar conditions were used whet'e the 
enzyme ~s substituted by the appropriate buffer in which 
the enzyme ~s dissolved. These blank determinations 
indicated no crystal growth. These experimental conditions 
have been repeated several times and also with t~ different 
batches of enzyme with silllilar result •• 
The experimental conditions were varied to try to increase 
the size of crystal to that suitable for data collection, 
i. e., varying the pH between 8.0 and 9.0 with both buffer s 
in step. of 0.2 and the ammonium sulphate concentration in 
steps of O.lM. However, this did not appear to enhance 
crystal growth. 
Sealed tube X-ray experiments were carried out on the small 
crystals but did not reveal a diffraction pattern. The 
synchroton at Daresbury .s also used but no diffraction 
pattern _s obtained. 
Finally, studies were carried out to remove 80me or all of 
the sugar content using various glycosidases at different pH 
values, in an attempt to enhance crystallisation. 
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5.6 PROCEDURE CARRIED OUT TO REMOVE THE SUGAR CONTENT 
All the glycosidases : a-Glucosidase (EC 3.2.1.20), 
S-Glucosidase (EC 3.2.1.21), a-Galactosidase (EC 3.2.1.22), 
S-Galactosidase (EC 3.2.1.23), a-Mannosidase (EC 3.2.1.24), 
S-Glucoronidase (EC 3.2.1.31), Almond emulsin and all the 
materials for gel electrophoresis were all supplied by Roche 
Products Ltd., We1wyn Garden City. 
HLE was purified from the crude product supplied by Dr 
27 Rober ts, which was obtained from purulent sputum. The 
dried material (30.5 mg) was dissolved in a small volume of 
O.05M Tris/HCl pH 7.5 buffer containing 0.2M NaCl and 
applied to a column (25 x 2 cm) of carboxymethyl cellulose 
(Whatman CM52) which had been equilibrated and wshed with 
o the same buffer at 4 C. After sample application the 
column was washed with 50 111 of buffer containing 0.2M Nacl 
followed by a linear salt gradient 0.2 to 1M NaC1 in 0 •. 05M 
Tris/HC1 pH 7.5 (2 x 250 ml). The eluate was monitored for 
extinction at 280 nm, collected in 4 m1 fractions at 40 C 
and screened for elastase activity using NBA as a 
48 
substrate • 
The four isoenzymes were pooled separately frOID the elution 
profile S001ll1 on the graph 5. O. Fraction 75-85, isoenzyme 
E4; Fraction 68-73, isoenzyme E3; Fraction 62-67, isoenzyme 
E2; and Fraction 45-51, isoenzyme 1 1• The fractions up to 
34 showed no elastase activity. 
The isoenzymes were dialysed separately against distilled 
water before freeze-drying. Percentage recovery for 
i soenzyae 14 , was ~ 43% • 
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GRAPH 5.0 
SEPARATION OF RLE ISOENZYMES BY CM52 ION-EXCHANGE CHROMATOGRAPHY 
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5.7 POLYACRYLAMIDE GEL ELECTROPHORESIS ON THE ISOENZYMES 
Slab gel electrophoresis was carried out in 7.5% 
cross-linked polyacrylamide gels at pH 4.3. 100g of protein 
per track was loaded and electrophor esis per formed at SmA 
per track for 130 minutes, migration ws towrds the 
cathode. Standard HLE prepared by Dr Roberts25 was also 
loaded. Gels were stained with 0.05% coomassie blue in lOX 
methanol/acetic acid for 30 minutes before de staining in lOX 
acetic acid/ methanol overnight. 
The isoenzyme E4 showed a single band identical to that of 
the standard HLE, pools containing E2 and E3 showed several 
bands, while there was no indication of protein band for 
isoenzyme El • 
5.8 PROCEDURE FOR TREATING ISOENZYME E4 WITH GLYCOSIDASES 
The glycosidases ware divided into tbree groups 
(1) a-Glucosidase, a-Galactosidase and a -Mannosidase at 
pH 4.5 in O.1M citric acid/0.2M sodium dihydrogen 
phosphate buffer. 
(2) a -Glucosidase, 6 -Galactosidase and 6 -Glucoronidase 
at pB 6.8 in O.075M potasaium phosphate buffer. 
(3) AlllOnd meal in 20 111M acetate buffer pH 5.0. This.a 
only pur iHed through atage one by the procedur e of 
Tasa et a149• 
Isoenzyme, !4 .a only treated with the glycosidaaea. The 
concentration of ilOenzyme !4 used .a 100 lJg/ml and the 
reaction carried out in duplicate. The ilOenzyme, !4 __ 
treated with the inhibitor R03-9782 (Roche inhibitor) 80 that 
it did not denature when incubated at 370 C for 24 hour a for 
group 1 and 2, and 4 hour a for group 3. 
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To 500 1..1 1 of isoenzyme, E4 , 5 1..11 of 1 mglml of glycosidase 
(except for almond meal 50 1Jl. of 1 mglml) were added and 
incubated. Control isoenzyme, E4 and control, glycosidase 
mixture were also incubated. After incubation they were 
dia1ysed at 40 C for 4 hour s against distilled wter to 
remove the inhibitor. Slab gel electrophoresis was then 
carried out in 7.5% cross-linked polyacrylamide at pH 4.3. 
The isoenzyme E4 , treated with three groups of glycosidases 
showed no change in the protein migration bands. Hence, it 
was decided to determine the sugar content left in the 
, 50 
isoenzyme E4 , by the method of Dubois et a1 using the 
standard curve of D-galactosidase. The procedure already 
described was carried out in duplicate and the protein 
content determined before and after dialysis. The only 
conclusive result from this, was the isoenzyme E4 , treated 
with almond meal showed some loss in sugar content. However, 
it was decided that the almond emultin 1I)u1d need to be 
33 purified through all the stages of Taga et a1 before 
treating isoenzyme E4• 
Since this 1I)rk was carried out during a short stay at the 
collaborating institute it was not possible to pursue this. 
It however is, hop~d that in the future this experimental 
conditions can be pursued further. 
The optimum conditions found previously at the 
crystallisation stage were not tried at crystallising the 
treated isoenzyme E4 , but could be tried once successful in 
removing the sugar content. This 1I)uld eventually open up a 
whole bost of studies relating to the treatment of disease, 
and comparison of binding studi.s with PPE. 
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CHAPTER SIX 
X-RAY CRYSTALLOGRAPHY 
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6.1 INTRODUCTION 
The most powerful technique available to 
structures of small and lar ge molecules 
study the 
is X-ray 
diffraction, since it provides a three-dimensional model of 
the structure. The normal procedure involved in the 
determination of a structure involves growing single 
crystals, measuring the structure factor amplitudes from the 
diffraction pattern, followed by evaluating their phases, 
obtaining an electron density map by Fourier tr ansformation 
and finally fitting an atomic model to the density 
distribution. Comparison of the calculated versus the 
observed amplitudes is used to indicate the validity of the 
model structure. 
X-rays are photons with an approximate range of wavelength 
of 0.1 to 100 A and are generated by decelerating rapidly 
moving electrons, converting their energy of motion into 
radiation. When a beam of X-r ays interacts wi th the 
electrons in the atom, which occupy a finite volume and are 
bound in well defined energy states, a fraction of incident 
X-rays is scattered. This leads to radiation propagating 
1 
away from the sample in all directions, Figure 6.0. The 
total wave scattered in a given direction depends on the 
phase differences between the various rays scattered by 
individual electrons. 
s. 
SOURCE 
s. 
Scatterlns shown by the path difference betueen radiation 
scattered by an electron. at r and that scattered by an 
electron at the origin. 
Figure 6.0 
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From figure 6.0, the path difference between the two rays is 
r.s-r.s. 
-~ 
It is convenient to define the scattering 
vector S as (s/A - s /A). 
o 
Therefore the path difference is equal to A ~.!. Hence, the 
phase difference • 
• 
21T x path difference 
r 
21Tr.S (6.0) 
Since the electrons are not localised, it is better to 
describe an electron density p(~) in a small unit of volume 
dv at a position I' relative to the origin, as propor tional 
to p (!.)dr. Therefore the total wave scatter ed in terms of 
amplitude and phase will be For 
continuous electron density at position r, the structure 
factor is given by 
(6.1) 
2 Hence, the expression for the atomic scattering factor 
which tak.es into account the individual contributions over 
the volume of the atom, is 
· J p (!..) exp(21T i~.: !)dv 
vol. of 
atom 
(6.2) 
The expression for the ato1ll1c scattering factor tak.es no 
account of the thermal vibrations of the atom. In 1914, 
3 Debye noticed that a deereaae in intensity by a factor 
exp[-B(sin2 9 )/ A 2} where B • 8 1T 2u2 was due to the thermal 
motion of atoms, U repreaents the mean displacement of 
atoma along the normal to the reflecting planes. Hence, the 
atomic scattering may take into account this term. 
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However, in general case the isotropic temperature factor B 
is usually replaced by an anisotropic temperature factor, 
since the atoms are not free to vibrate equally in all 
directions. The anisotropic vibration is represented by an 
ellipsoid of the vibration in reciprocal space with six 
parameters. That is, the reduction in intensity is given by 
(6.3) 
The expression for scattering by a molecule can be obtained 
for an assembly of atoms placed at defined positions in the 
unit cell. Individual contributions by the atoms are 
considered to arise at distances r l , r 2 , r3 etc. from the 
origin r. The shift in origin means that the distance ~ in 
equation (6.2) has to be substituted by !:.. + ~l for atom 1 
and so on. Therefore the scattering by atom 1 relative to 
the new origin is 
- J 
-
P (t,) exp [ (2 1T it, + ! 1 ). !1 dv 
vol. of 
atom 
where f1 is from equation (6.2). 
(6.4) 
Hence similar expressions can be obtained for all the other 
atoas in the unit cell and the total ~ve scattered will be 
the vector sum of the individual contribution of all the 
atoms, that i8 
G(!) - F 1 + F 2 + F 3 + •••••••• + F n 
N 
scattering of the unit 
.t1 l-
cell. 
fj exp(21f 1!:..f!) (6.5) 1.s the Hence 
159 
Scattering of X-rays by a crystal, can be obtained from a 
one-dimensional crystal, which is composed of a linear array 
of unit cells with a repeat distance~. The sum of the wave 
scattered by each unit cell will equal the total wave 
scattered. G(!) will be the ~ve scattered by the first unit 
cell relative to the origin, but the second unit relative to 
the same origin will be G{~) exp{2 1Ti~.!), since there is a 
shift of a. Therefore the total ~ve scattered by n cells 
will be 
F (S) -
T 
r 
n=l 
G{~,> exp21T1{n-1)!..! 
T - Total number of unit cells. 
(6.6) 
However, scattering will only be observed if the phase 
difference between the _ves scattered by successive unit 
cells Is equal to an integral multiple of 21T. 
i.e. 21T a.S 
- 21T h 
1.e. a.S 
- h h - an integer. 
Hence, for a crystal in three-dimensions, with unit cell 
dimensions defined by vector s !.. !!. and ~. the diffraction 
condi tions at e 
a. S - h; !!..! - k; c. S - 1 wher e h. k. 1 ar e 
all integer s. 
equations. 
These equationl are known as the Laue 
So the total _ve Icattered in direetion S will be 
F (S) - (6.7) 
Allowing the fraetional co-ordinatea for the jth atom to be 
x j • Yj and Zj 
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i. e. , 
Hence 
- hxj + kYj + 1zj from the Laue equation 
N 
Therefore F (hIt1) • j~l f j exp[21T i(hx j + kYj + lZj)] (6.8) 
This equation represents the structure factor, or the 
molecular transform sampled at the reciprocal lattice points 
hIt1. The diffractions pattern for the crystal can be 
calculated if the positions of all the atoms in the unit 
cell are know. 
Unfortunately to measure F(8) directly is impossible since F 
is a complex quantity representing the product of t~ terms 
: that is, 
F (hk1)· \ po (hk1) \ expi a (hk1) 
where F (hk1) is the ampUtude and a (hk1) is the phase. 
Alternatively, it can be .. itten as the sum of real and 
imaginary par ts, that is 
Where 
F (hlt1) • A + iB 
A· \F(hk1) I COB a (hk1) and 
B· \P(hk1) I sin a(hlt1) 
The Argand diagra1l, figure 6.1 show the relationship 
between these t~ representations of F (8). 
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IMAGINARY AXIS 
F· I 
Cl (hkll 
---~========~======:::::iI-----7 REAL AX IS 
Figure 6.1 
Expet'imentally, all information on the phase is lost and 
only the intensity of radiation scattered at an angle 29 can 
be observed. The intensity is exptessed by 
I(hkl) • F (hkl). F *(hkl) 
• F(hkl)2 
where * indicates the complex conjugate. 
The intensity is observable and must be real, however, the 
phase tet'm of a (hkl) of F(hkl) is not directly measurable 
and this is a major obstacle in X-ray diffraction studies. 
To solve a structure from its diffraction pattern one muat 
use the theory of Fourier transforms. To ahow this, the 
expression, equation (6.7) can be rewritten as a continuous 
summation ovet' the volume of the unit cell, that ia, 
F(!) • J p(!:) exp( 2 1T 1~. !) dv 
vol. of 
unit cell 
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By multiplying both sides of equation (6.7) by exp( -21T i~.!) 
and inte~ating over the volume of diffraction space, it may 
be shown that 
p (!:..) • J F (S) exp( -21T ir' • !)dv s 
vol. of 
diffraction space 
where dv 1s a small unit of volume in diffraction space. 
s 
For a crystal the integration is replaced by a summation 
since F (!) is not continuous and is non-zero only at the 
reciprocal lattice points. Hence, 
p(xyz) • (l/V) ! 'f 'f F(hkl) exp[-21T i 
h=-co k--co 1-"; 
(hx + ky + lz)] (6.9) 
v - volume of unit cell, V • a.bxc 
This equation represents the electron density and to 
calculate it,F'(hkl) must be known, that is, the amplitude 
\F(hkl) \ and the phase a(hkl) of the structure factor. 
This is emphasised by rewriting equation (6.9) as 
p (xyz) - (l/V) 'f \F(hkl)\ expia(hkl) (6.10) 
exp[ -2'11' l(hx + ky + lz)] 
The main proble1l, then, is to deterudne a (hkl). 
6.2 THE PRASE PROBLEM 
Several 1Iethods exist for deterudning the phases. 
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(1) Direct methods rely on mathematical relationships 
between the reflections to provide phase information. 
In this method usually there are no heavy atoms in 
the structure, and the solution by direct methods 
simply involves assigning a plus or minus sign to 
each observed structure amplitude. 
(2) The method for small molecules, which contain two or 
more heavy 
Patterson or 
atoms per unit 
2 4 F function. 
cell is to use the 
The Patterson summation 
1s a Fourier summation based on the experimentally 
observable F(hkl)2, which essentially gives a vector 
map5,6. The function used is 
P(UVW) • (l/V)! 'f ! 
haea k.w 1-
(hU + kV + lW)] (6.11) 
An F (hkl) 2 calculation shows peaks corresponding to 
all interatomic vectors. The atomic scattering factor 
is proportional to the number of z electrons and the 
resulting Patterson peaks from atoms i and j are 
proport~onal to ZiZj. Therefore, the Patterson maps 
shows N peaks in the vector map for N atoms in the 
unit cell. N are self vectors, which superimpose at 
the origin and the remaining N(N-l) vectors are 
distributed throughout the volume of the unit cell. 
Hence, the dominant features are vectors between pairs 
of heavy atoms. It is usually possible to obtain 
sufficient information about the location of the heavy 
atoms to proceed further with the structural analysis. 
Once the heavy atoas are located, the simplest 
approach to structure completion is to use the second 
Fourier function of importance, that i8, the 
difference synthesis or difference Fourier. In this 
case, tbe difference in tbe electron density between 
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the observed and calculated structures is expressed in 
the form : 
- (ltV)! ! ! 
h=-clO k=-clO l=-clO 
(hx + ky + lz)] 
where <l is the phase of F and 
c c 
6. Fexpi<l [-2 'IT i 
c 
(6.12) 
6. F - IF I - IF J 
o c 
The calculation of a difference Fourier, like that of 
Fourier synthesis, uses the phases of the calculated 
structure factors. The difference Fourier map shows 
the atoms not yet located. The two major facts about 
this Fourier are firstly, it reflects the correctness 
of the model used and the true structure implied by 
the I F I ' s. This is highly useful in refinement 
o 
(discussed later). Secondly if the phases are in 
error, the 6.F synthesis can provide information not 
easily obtained from the Fourier synthesis. It may 
also be possible from the final difference Fourier to 
locate the positions of the hydrogen atoms. 
Using the conventional Patterson and difference 
Fourier technique, two small molecules containing 
heavy atoms ruthenium (Ru) and platinium (Pt) have 
been solved (see Appendix I and II). Patterson map 
revealed the Ru-Ru vector for the first molecule and 
Pt-Pt vector for the other molecule. The remaining 
atoms in both molecules were obtained from difference 
Fourier synthesis. In fact, the Pt compound was 
solved in a lower symmetry space group than necessary 
as pointed out by Marsh7• The new coordinates are in 
Appendix II. 
The methods described earlier for small molecules are 
not successful with proteins. These macromolecules 
generally do not have heavy atoms in the molecule, 
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therefore to solve a crystal structure, heavy atoms 
have to be incorporated, that is, isomorphous 
8 
replacement • A perfectly isomorphous derivative 
should only have a change in the electron density 
between it and the native crystal at the position of 
the heavy atom. The heavy atom provides observable 
change in the difuaction pattern and the intensities 
of both the native and the derivative enables one to 
overcome the phase problem once the heavy atom is 
located. 
(3) A single isomorphous replacement will result in the 
sum of electron densities of the parent crystal and of 
the heavy atom substitution. Thus the structure 
factor F PH for the heavy atom isomor phous derivative 
is related to the structure factor F p of the native 
protein and the structure factor F H of the heavy atom, 
. that is, 
(6.13) 
and illustrated by a vector diagram, figure 6.2. 
IMAGINARY AXIS 
B 
---:T-------------~ REAL AXIS o 
Figure 6.2 
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Structure factors FpH and Fp are measured and the 
arrangement of the heavy atom in the crystal unit cell 
is known, the vector FH can then be calculated. From 
figure 6.2, applying the cosine law, the phase el p can 
be calculated : 
(6.14) 
This equation, however, results in two possible values 
for Cl p ' However, the ambiguity can be overcome by 
using the multiple isomorphous replacement (M. loR.) 
technique which involves using at least two heavy atom 
9-11 derivatives ,identical with the native protein, 
except for the presence of heavy atoms. 
(4) One additional technique which can be used for the 
calculation of phases for proteins in the presence of 
heavy atom is "anomalous scattering". 
the frequency of incident X-rays 
frequency to the absorption edge of 
It occurs when 
lies near the 
an atom. The 
atomic scattering factor previously treated as a real 
number, has in this case two additional factors : a 
real part ~jl (!) and an imaginary part iJl \!) such 
that 
(6.15) 
6.3 LOCATION OP HEAVY ATOMS BY DIPPERENCE PATTERSON 
When both an isoaorphous heavy atom derivative and a parent 
crystal are available with measured structure factor 
a1llP11tudes I PpU(hkl) I and I Pp(hkl)\ it is possible to 
evaluate an isomorphous difference Patterson map. Since 
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IFH(hk1)I is not experimentally measurable, it is estimated 
fairly well by equation (6.13) from which an isomorphous 
difference Patterson function Ii P can be calculated. 
!i P - (ltV)! ! ! 11 FpHI-IFpI2exp[-21T i(hx + ky + lz)] 
h=-oo k--- 1--00 
(6.16) 
Anomalous scattering difference can also be used to estimate 
FH using the expression 
I F p~ I - I F;H I - f1 F ano ~ I FH sln(a PH - a H) I (6.17) 
However, neither of these methods gives a particularly good 
estimate of FH, but combining the two expressions for FH 12 
will improve it 
!iFisO + !iFano~ FH cos2 (a pH - aH) + FH sin2 PpH -aH) 
Thus F ~ (!i Fi2 + Ii F 2 )1 H so ano (6.18) 
Once the structure factor amplitude is 
calculated, it is possible to obtain the phase a P of the 
native crystal. 
6.4 PHASE CALCULATION 
Once F H is known, then F p' F Hand F PH should form a 
closed triangle in which the magnitudes of three sides and 
direction of one of them are known (Figure 6.2). This 
implies perfect isomorphism and no experimental error. In 
practice, however ideal conditions do not exist and errors 
occur from inaccuracy in the measurement of intensity, lack 
of isomorphism and incorrect heavy atom positions. Blow et 
13 
al have considered the errors occurring in isomorphous 
replacement and provide a proper treatment of errors and 
best choice of weights in the calculation of electron 
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density map. They considered errors arose from tv) distinct 
sources : 
(1) an error, e, for the calculated heavy atom 
contribution, F U(calc), to the derivative structure 
factor. 
(2) inaccuracies in the determination of the amplitudes Fp 
and FpU' 
The "lack of closure" error is defined by 
(6.19) 
Blowet al13 showed that the probability of the phase angle 
being a for a single isomorphous replacement is 
(6.20) 
or, where a number of heavy atom derivatives is used 
simultaneously, the total probability of the phase angle is 
given by the product of the individual probabilities 
p(a) • ~ Pj(Cl) • exp[- ~ e j (Cl)2/2E/l (6.21) J J 
Blowet al13 have shown that the phase corresponding to the 
centroid of this distribution, results in the least mean 
square error in electron density over the unit cell. This 
can be shown by considering the errors in one reflection for 
the electron density. If the value of the coefficient used 
in the synthesis is F s and its true value is F t' then the 
mean square error over the unit cell from the reflection 1s 
where F • Fexpi a • t 
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Hence, the mean square error is 
<lip>' - (1/V)2 r~F . -(FeXp1<»~ P{ <> )d{ <» 
2'11" a~ 
I J p{a)da (6.22) 
a-o 
The numerator in equation (6.22) is equal to the moment of 
iner tia of ring mass P( a) and radius Fexpia. By the 
parallel axis theorem, when F is at the centre of the 
s 
ring, the inte~al has a minimum value, that is 
F s(best) - F J2'11" expia P(<l)d a/ J2'11" p(a)d<l 
a-o a-o 
.. mFexp(ia. t) Des (6.23) 
This equation repreaenta for the centre of ~avity of the 
probability distribution with polar co-ordinates 
13 (mF, <l best). Blow el at pointed out that, m acta as a 
wight, dependent not on the absolute probability of the 
phase determination but on its sharpness or unambiguity. 
They further showed that m, called the "Figure of merit" and 
~est could be obtained from the expression, 
taCos a - 1: p (a )cosa / 1: pea ) best j j j j j j 
main a best - 1: p (a )sin<l / 1: p(a ) j j j j j j 
The most c01lllOnly used 1I8aaure of the goodness of match 
betwen the observed and the calculated structure amplitudes 
is the disa~eement ratio, It. 
R _ ~1 \'bkl(Obl) \-\'bkl(calc) \ 
r \'hkl (Obs) \ 
hid 
It. - It.elidual index. 
(6.24) 
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Fhkl (obs) represents the square root of diffraction 
intensity after various corrections are applied for the 
experimental factors. Thus R gives a guide to how well the 
observed data I Fhkl(obs) I compares with the data calculated 
from the structure, I Fhkl(calc) I. 
R also gives indication about the molecules being centric, R 
~uld equal to 0.83 and to 0.59 ~uld mean the molecule is 
14 15 
without centre of symmetry J • For small molecules it is 
possi ble to refine to the R value of < 0.05 but for pr oteins 
the R value are usually high in the ear ly stages because 
solvent and thermal motion are not taken into consideration 
in the structure determination. A good protein structure 
determination at high resolution should result in an 
R ~ 0.15. 
6.5 INTERPRETATION OF THE ELECTRON DENSITY MAP 
Once the best phases and the figure of merit, m have been 
calculated the electron density map can be computed. The 
expression used is 
p(~) - 1: mFpexp(i a best)exp[-21T ih.!J (6.26) 
The map i8 calculated to a certain resolution uling the 
ampl1tudes and phases. The resolution (that 1s, the number 
of measureable reflections) is a function of the actual 
crystal and also on the isomorphous derivatives. To obtain 
a high resolution structure one usually requires excellent 
phases to at least 2.5 A spac1ngs. 
The interpretation of the map is usually made with the aid 
of plotting the electron density (on a scale 2A Icm) on 
per spex sheets. These sheets at e stacked together and 
viewed on a light box. The interpretation of the amino-acid 
residues in the protein will depend on the knowledge of the 
sequence obtained from chemical studies. 
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More, recently computer graphics are used to view the 
electron density map. This technique being best in Which an 
existing interpretation of the molecule is available. 
6.6 DIFFERENCE FOURIER SYNTHESIS IN STUDYING 
LIGAND-MACROMOLECULE INTERACTION 
Once the stt'ucture of the pt'otein is known, then studies 
r elating to the binding of small molecules, (substt ates or 
inhibitors), can be accomplished by means of a dUfet'ence 
15 Fourier synthesis. Sttyer et al were fir at to apply this 
technique in pt'otein crystallography by binding azide ion to 
myoglobin. Since then, it has been applied to a wide number 
of proteins and has provided much information about the 
~oteins active sites. Difference Fourier maps also provide 
detailed infot'mation regarding any changes that may occur in 
the conformation of the native protein sttucture and atomic 
shifts of less than 1 Acan be detected. 
The diffraction intensities are measured for the liganded 
protein, then the diffet'ence Fourier is calculated by using 
these intensities with the phases calculated for the native 
protein. This t'esults, in showing the electt'on density of 
the bound ligand and also any difference in the native 
enzyme caused by the binding of the small molecule. The 
disadvantage is that it is only useful wbere there is a 
small change. 
The technique works well for locating a bound Ugand since 
the presence of the ligand changes the phase of most 
sttucture factors relatively little and, by analogy to the 
equation for a heavy atom, 
(6.26) 
172 
where F PL represents the parent-ligand complex and the 
structure factor for the ligand is F L (Figure 6.3). From 
the figure 6.3, Fp is known, and IFpL I is known. Equation 
(6.26) will only work 1£ FL < Fp and F L < FpL ' hence the 
possible value of FpL will lie in a small range of phase 
angles. Thus to a first approximation, a P' will be good 
estimate of apL ' Since the native phases which are 
determined from the heavy atom isomorphous replacement 
method are associated with a figure of merit, m, it is 
conventional to weight the difference Fourier map also by m. 
Thus the difference Fourier ~p is usually defined by 
- (l/V) 
h _-GO k--oo 1--00 
expia(hkl)exp [-2 'IT i (hx + ky + 1z)] 
Figure 6.3 
6.7 REFINEMENT 
( 1 ) SMALL MOLECULES 
The refinement technique most often used to give the 
beat fit between a set of observed and a set of 
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calculated data on a trial set of parameter is a 
17 least-square procedure • This procedur e refines the 
atomic co-ordinates, the atomic vibration parameters 
and scale factor. The observed data are the structure 
factors obtained from the intensity data whose phases 
have been determined by direct or indirect methods. 
In least-squares procedure the quantity, that is, 
minimised is given by : 
D • W (f - f }2 r o,r c,r (6.27) 
wher e Wr r epr esents the weight assigned to the 
observation, f , the value of the function and also 
o,r 
to the corresponding calculated value, f • To gain 
c ,r 
a satisfactory fit, the 
variables, so that they 
parameters, P, are regarded as 
can be adjusted to minimize D. 
The function minimised in the equation (6.27), takes 
into account a weighting factor 18 for each observation 
which gives a measure of the reliability in the 
observation. 
(2 ) PROTEINS 
The least-square refinement of a protein is usually 
only effectively applied to high resolution data. 
There are several sources of error: in any 
crystallographic analysis. (1) The phases determined 
from M.I.R. and anomalous scattering contain both 
random and non-random errors (inaccuracies in 
measurement and lack of isomorphism between the native 
derivative crystals). (2) The phases for d < 2 A. may 
not have 'been calculated by M. I. R. even though the 
observable native data may extend to higher 
resolution. (3) The model obtained may not represent 
the best fit to the calculated electron density. 
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Least-squares refinement provides the opportunity to 
refine the phases, to extend them to higher resolution 
and to obtain a model which is the best fit to the 
observed data. 
For a protein anywhere between three and nine 
parameters, Pj , are needed for each atom. This means, 
that a large number is required for the entire 
asymmetric unit. 
As before, the function minimised is 
D - ! ! ! Whkl [ \ Fo(hkl) \ -\KFc(hkl)\ ]2 (6.28) h _-ex> k --()() l--cn 
Where Whkl is a weighting factor giving the 
reliability between the observed and calculated 
points, K is a scaling parameter. 
One of the most useful approaches in the initial 
cycles of refinement, is to treat both the protein 
phases, and structure factor amplitudes, ap(calc) and 
Fp as observations. This makes it possible to adjust 
the model to the density and then, the protein phases 
can be recalculated from the atomic position and the 
fitting process repeated. 
However, recently, two approaches to reciprocal space 
refinement methods have been considered. 
(1) To reduce the number of parameters by treating 
groups of atoma as rigid bodies, where each 
group is described by only six (three 
translational and three rotational) positional 
(2) 
19 parameter • 
Increase the number of observations by 
introducing subsidiary distance restraints to 
. 20 
maintain proper sterochem1stry • 
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(1) CONSTRAINED LEAST-SQUARES 
For each group of atoms, three translational and 
three rotational parametet's are used to describe 
the geometry. Fot' a set of co-ot'dinates X given 
in A, the fractional co-ordinates x are obtained 
ft'om 
• 
Where tg is the tt'anslational vecto!' in 
fractional co-ordinates of the origin of the 
group relative to the unit cell ot'igin. lu I is 
the matrix to transform cartesian co-ot'dinates 
to ft'actional ct'ystallographic co-ordinates21 • 
I R I is the rotation matt'ix22• g 
The derivatives of F with t'espect to the group 
c 
parameters are obtained ft'om the individual atom 
derivatives by application of the chain rule21 • 
The normal matrix 1s constructed and the 
equations solved in the usual way. 
Th1 s procedur e r educes the number of par ameter s 
dr ama tically , since only six positional 
parametet's for each rigid group. lIence the 
method is applicable to low resolution. 
(2) RESTRAINED LEAST-SQUARES 
The function to be mini1liaed ts a sum of 
structure factot' and restraint ter,.s. 
D· t whkl(\r (hkl)I-lr (hkl)2 \ )+ hkl c 0 
r W (d -d )2 
r r o,t' c,t'· 
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The first term is the normal structure factor 
component of leas t-squares and the second term 
is a sum over the subsidiary distance. 
It is the restraints of the weighted square of 
the difference between an "ideal" distance, d o,r 
between pairs of atoms and the calculated 
distance, d • 
c,r 
The distance restraint may include terms for 
bonded atoms, next nearest neighbour atoms to 
define bond angles, Ca ••••• 0 dis tances to 
restrain the w torsion angle, planar groups of 
atoms and repulsive restraints for non-bonded 
contact distances. 
6.8 OTHER METHODS USED IN REFINEMENT OF PROTEIN MOLECULES 
Other techniques are available which could be used for 
refinement, these are classified into two broad categories : 
real space least-squares methods, difference Fouriers 
procedures and the reCiprocal 
methods23 ,24 already described. 
space least-squares 
(1) Real space least-squares refinement was developed by 
Diamond23 ,25. This procedure uses a constrained 
geometry based on conformational angles. In this 
case, the electron density is considered to be an 
objective expression of experimentally quantity 
mnimised, that is, (P - P ). P i8 the observed 
o m 0 
electron density and P is the calculated electron 
m 
denaity from the model. 
(2) Difference Fourier methoda are mainly used for 
locating side-chains which are not positioned properly 
and are also useful in locating solvents atoms in the 
structure. 
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CHAPTER SEVEN 
INTENSITY-DATA COLLECTION AND DATA REDUCTION 
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7.1 INTENSITY-DATA COLLECTION 
The diffracted intensities can be measured using either 
photographic or diffractometer (counter) methods. The 
photographic method involves measuring the degree of the 
blackening of spots on the diffraction photographs Which is 
taken as propor tional to the intend ty of beam. However , 
the diffractometer method has advantages. It provides a 
more precise intensity measurements and the data output is 
in a form ready to be processed by a computer, which 
relieves the tedium involved with photography. Moreover, 
wi. th protein molecules crystallising with lar ge unit cells, 
the number of reflection to be measured at any given 
resolution is corresponding large and therefore the 
diffractometer is usually ideal for it. 
The data are collected using a computet' controlled 
1 four-circle diffractometer operating with "Normal-beam 
equatorial" geometry. The crystal orientation is determined 
by three Eulerian angles which need to be calculated for 
each reflection. The detector is constrained to move in the 
equatorial horizontal plane Which contains the incident beam 
and is set to the 29 value appropriate for each reflection. 
A small on-line computer calculates the crystal and detector 
setting and also controls the digital diffractometer shaft 
setting. 
The intensities for the tWD small molecules were measured on 
a Nonius CAD4 diffractometer with monochromatised Molybdenum 
(Mo-K
a
) radiation (see details in the Appendix I and II). 
Data collection for the PPE crystals soaked in 
substrate/inhibitor _8 a180 carried out on an Erap-NoniuB 
CAD4 diffractometer but with filtered copper (Cu-K
a
) 
radiation (details in Chapter Eight). 
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7.2 DATA REDUCTION 
The raw data which are collected on the diffractometer are 
not in the form used in the determination of the crystal 
structure. Several corrections have to be applied which 
are, correction for Lorentz-polarisation, absorption and 
radiation damage effects. After correction, if different 
sets of data are collected they need to be scaled together 
and for protein molecules the scaling of heavy atoll 
derivative or substrate bound data need to be scaled to the 
native data. After all the corrections and scaling have 
been done, the data set obtained can be used for the lIethods 
discussed in Chapter Six for solving the crystal structure. 
7.2.1 LORENTZ-POLARIZATION CORRECTION2- 4 
The Lorentz factor, L, arises because the tille required by a 
reciprocal lattice point to pass through the reflection 
sphere is not constant but varies with its position in 
reciprocal space and the direction in which it approaches 
the sphere. 
The L, depends on the geometry which is used to measure the 
X-ray intensity. The expression for a four circle 
symmetrical A setting diffractometer where the "X.-eirc1e is 
arranged to bisect the angle between the incident and 
diffracted beams. Hence, the L is given by 1/sin295• 
The polarization factor, p, i. a function of 29 and arises 
because of the nature of the X-t'ay beam. Since the usual 
X-t'ay beaa is unpo1arized, which means that the azimuth of 
the electric vector assuaes all directions with time. The 
effective amplitude of the radiation after it has reflected 
by the crystal at the angle 29' conlilts only of the 
components of these azimuths after reflection. This in turn 
will affect the reflection. for the crystal under study and 
the factor, p, 1IUst be accounted for the correction in the 
structure amplitudes equation (7.1)2. 
where 
7.2.2 ABSORPTION 
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I Fhk1 I - j I hk1 /Lp 
p 
-
1 + cos 229 
2 
The corrections for absorption are the most difficult to 
determine especially when a three-dimensional data set is 
collected by the diffractometer 6• In this case the crystal 
presents many different facets to the X-ray beam. In 
applying the correction for small molecules, computer 
method/,8 are available which calculates from a knowledge 
of crystal shape, the absorption for the actual path length 
travelled within the crystal by the beam reflecting from 
each infinitesimal por Hon of the cr ysta1. However, for 
protein molecules this is not suitable since various factors 
need to be considered which are difficult to estimate, these 
are, crystal shape, the surrounding mother liquor and the 
glass capillary tube. Also, due to 1ar ge number s of 
reflections measured, the time t'equir ed fot' calculation of 
the path length for each reflection becomes peohibitive. 
Hence, the most used method in peotein crystallography is 
that described by North et a19 where an empirical absorption 
curve is obtained from the variation in the intensity of 
strong Bragg reflection as the crystal is rocked about the 
normal to the corresponding planes. 
7.2.3 RADIATION DAMAGES 
Radiation damage corrections have to be applied since it is 
observed that the intensity decreases as the crystal is 
exposed. This correction is simple to apply and is 
constructed from a set of reference reflections measured at 
intervals throughout the data collection. Radiation damage 
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usually affects high angle reflections more than the lower 
ones. Hence for high I' eso1ution data it is essential to 
measure intensity controls throughout data collection for 
hoo, OkO and 001 rows of reflections at various angles and 
various direction. 
7.2.4 SCATTERING FACTORS10 
In the case of small molecules it is essential for the data 
reduction program to know the necessary X-ray scattering 
power of each kind of atom in the cell, since the output 
serves as input to the structure factor program. Thi s 
program calculates the structure factor s on the basis of 
some assumed arrangement of atoms and compares these 
calculated values with those actually observed. 
The scattering curves have been calculated for all elements 
using theoretical electron distributions of varying degr ees 
of elegance. The results are available in tabular form in 
the International Tables and also in the literature11 ,12. 
It is economical to have tabulated scattering factor data 
for the atom types in the crystal included in the input to 
the data reduction program. This is because the structure 
factors are usually calculated several times during the 
course of a structure analysis. Hence the output associates 
with each reflection an interpolated scattering factor which 
corresponds to the value of (sine/A) 
7.3 SCALING DIFFERENT SETS OF DATA 
Intensity data collection for saall molecules usually 
requires only one crystal and therefore there is no scaling 
~oble.. However, for ~otein molecules, an intensity data 
collection at high resolution will certainly involve several 
crystals, and 80 'it is necessary to scale these different 
seta of data together on the baaia of the common reflections 
between the sets. A method i8 required which accounts for 
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the fact that some 'sets may contain reflections which may 
overlap with other sets but not with every set. Hamilton et 
13 
a1 have developed a method which has proved useful and 
reliable. 
7.4 ABSOLUTE SCALING 
In 1949, Wilson14 derived a plot which gave an approximate 
value of the absolute scale of data and also including an 
estimate of the effects of the thermal motions of the atoms. 
It is essential to take into consideration the effect of 
temperature on the X-ray intensitieslS • The normal 
scattering-factor curves are calculated on the assumption 
that the atoms are stationary, but in fact they are 
vim-ating about their rest points in the crystal. The 
de~ee of vibcation is dependent on factors, such as 
temperature, the mass of the atoll and the firmness with 
which it is held in place by covalent bonds or other forces. 
It has been sbolim both theoretically and practically that 
thermal vibration may be represented by an average isotropic 
temperature factor B equation (7.2). 
2· /,2 Exp[-2B(sin 9) A 1 (7.2) 
It is convenient to have an estimate of the average value of 
B for the whole structure before beginning the actual 
analysis and a value is provided by the Wilson plot. 
where 
I 
reI In n 
2 2 
- lnC - 2B(sin '9)~ 
r f2. 
i-l 01 
n 
I 1 and r f2. 
re • 1 01 1-
are the average values of the observed intensities and the 
sum of the squares of the scattering factors of the atom. 1n 
the molecule. C 1s a scale factor. A plot of 
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n 2 2 
In(I 1/ r f2 J versus (sin 9)/).. 
re . 1 01 1= 
should give a straight line with slope of -2B and intercept 
of lnC. 
Hence to convert I F I to I F I ' C is related to the rel abs 
scale constant, K, by equation (7.3). 
where 
- KIF 11 re (7.3) 
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CHAPTER EIGHT 
CRYSTALLOGRAPHIC STUDIES OF SUBSTRATE BINDING 
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8.1 INTRODUCTION 
Several studies were undertaken to complex PPE with various 
substrates (Ac-Pro-Ala-Pro-Ala.OB, Ac-Pro-Ala-Pro-Alaninal 
and TFA-Pro-Ala-Pro-Alaninal prepared in Chapter Three) and 
1 the inhibitor (TFA-Ala3-CMK, a gift from Bieth et a1 ). 
Concurrently studies were carried out between the 
anhydroe1astase (prepared in Chapter TlIIO) and the 
hexapeptide inhibitor B.Pro-Ala-Pro-Ala-Lys-Phe.OB. 
However, data were only able to be collected on tlllO crystal 
complexes to 2.5 A resolution: Ac-Pro-Ala-Pro-Ala.OH and 
TFA-Ala3-cMK. In the case of the others, crystals soaked in 
the substrates and inhibitors are mounted and ready for data 
collection. 
8.2 EXPERIMENTAL 
Crystals of native PPE and of the anhydroelastase 
preparation were grom from dilute sodium sulphate solutions 
as described by Shotton et a12• They were then transfert'ed 
to 1.2M sodium sulphate-O.01M sodium acetate pB 5.0, in 
which they wet'e stable indefinitely at 1'0011 tempet'ature. 
The conditions used for preparing each of the derivatives 
was as followa : 
(1) Ac-Pro-Ala-Pro-Ala.OH 
The native PPE cryatals Wl'e transferred into 2M 
potassi WI phosphate t pH 8.5 for 24 hour a befor e being 
soaked in lomM substrate (in the sa .. buffer) at room 
temperature. 
(2) Ac-Pro-Ala-Pro-Alaninal and TPA-Pro-Ala-Pro-Alaninal 
The inhibitor/PPB complex WIfe crystallised using the 
technique of co-crystallisation, by incubating for 
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ha1f-an-hour 0.25 m1 of 10 mg/m! PPE solution (made up 
in 0.01M sodium acetate buffer, pH 5.0), with 12.5 A 
of 10mM inhibitor in the same buffer. Followed by 
adding 5 A of 1M aqueous solution of sodium sulphate, 
o pH 5.0. Crystals grew in 3 days at 4 C. 
Inhibitor.PPE complex crystals were then transferred 
to a 1M sodium sulphate solution at pH 5.0 containing 
500'\.1 M of the inhibitor at room temperature. 
(3) H.Pro-Ala-Pro-Ala-Lys-Phe.OH 
Similar conditions and concentrations to that of 
Ac-Pro-Ala-Pro-Ala.OH were used to crystallise 
H.Pro-A1a-Pro-Ala-Lys-Phe.OH.Comp1ex. In this case, 
anhydroe1astase crystals were used which were obtained 
in similar conditions to those of native PPE. 
(4)· TFA-Ala3-cMK 
The native PPE crystals were soaked for 3 days in 20 
mM inhibitor in l.2K sodium sulphate-O.OlM sodium 
acetate pH 5.0 buffer. 
The optimum conditions described above were selected for 
each of the peptides in the soaking experiments. The 
maximum peptide concentrations were used which did not crack 
the crystals. 
Selected crystals of the native PPE (0.4 x 0.2 x 0.3 ma3), 
Ac-Pro-Ala-Pro-Ala.OH (0.4 x 0.2 x 0.3ma3) and TFA-Pro-
Ala-Pro-A1aninal (0.5 x 0.2 x 0.3 .. 3) were mounted in their 
mother liquors, in thin-walled capillary tubes for analysis 
by X-ray diffraction methods. Precession photographs of the 
native PPE confirmed the space group (P21212t) and the cell dimensions to be those of Shotton at al (table 8.1). 
Similar X-ray photographs of the crystals of Ac-Pro-Ala-Pro-
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Ala.OR and TFA-Pro-Ala-Pro-Ala-Alaninal derivatives showed 
that they were both isomorphous. A comparison of the cell 
dimensions are shown in table 8.1. 
TABLE 8.1 
CELL PARAMETERS 
Coapound Method a (A> b (A> c (A) Referenc-e No. 
Native PPE P 51.50 58.00 75.50 (2) and (3) 
P 50.80 58.15 75.20 (4) 
D 51.48(43) 57.99(20) 75.19(16) (5) 
P 50.76 57.80 75.19 
Ac-Pro-Ala-Pro-Ala.OH/ ..... \.0 
PPI Coaplex P 50.66 57.34 75.59 this 1IlO1:' k N 
TFA-Pro-Ala-Pro-Alaninal/ 
PPE Coaplex P 50.72 57.25 75.83 t hi S 1IlO1:' k 
TFA-Ala3-CMK/PPE Coaplex P 51.12(1) 58.00(1) 75.08(1) this 1IlO1:' k 
TFA-Lys-Ala-NU-C6H4-p-cF3/ PPE Coaplex D 52.53(42) 57.47(10) 75.26(5) (5) 
N. B. 1) The values in parentheses indicate the root JIlean square error. 
2) P - Precession lleasUt'e.ents. 
D - Diffractolleter aeasurellents. 
3) The diaensions JleasUt'ed by diffractol8eter v1.11 be a mean values of several measurements. 
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8.3 DATA COLLECTION AND PROCESSING 
Data for the TFA-Ala3-CMK crystal complex was collected on 
an Enraf-Nonius CAD4 diffractometer (computer controlled) to 
2.5 A resolution by Dr. L. Sawyer. The data collection was 
o performed at 15 C with nickel filtered Cu-Ka. radiation and 
were measured on one crystal. A total of 8162 unique 
reflections (28 .;;. 360 ) were recorded by the 29-w scan 
technique. 
A computer controlled Enraf-Nonius CAD4 diffractometer was 
used for the data collection of Ac-Pro-Ala-Pro-Ala. OR to 
2.5 A resolution. The data collection was per formed at 180 
filtered Cu-K 
a. 
C with nickel 
tw crystal. 
were recor ded 
A total of 7249 
radiation and were measured on 
unique reflections (29 <; 360 ) 
by the w scan. 
The data set for TPA-Ala3-cMK and Ac-Pro-Ala-Pro-Ala.OH were 
corrected for Lorentz polarization and absorption 
correction. Data collection parameter 8 are shown in Table 
8.2. 
TABLE 8.2 
DATA COLLECTION PARAMETERS 
TFA-Ala3-CMK Ac-Pro-Ala-Pro-Ala.OR 
Resolution Limits 
No. of recorded 
reflections (including 
controls). 
No. of radiation 
damaged control 
reflections 
No. of absorption 
correction curves 
2.5 A 2.5 A 
11529 9424 
6 3 
146 1 
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8.4 RESULTS AND DISCUSSION 
(i) ..;;.TF;...;A_-..;..A_l..;...a3~ 
The phase set for the native PPE structure4 was used 
with the reflections of TFA-Ala3-cMK in order to 
calculate the difference Fourier map [FDER-FNAT]. The 
Evans and Sutherland graphics system (at the 
University of Leeds) was used for positioning the 
inhibitor molecule, in the active site region. 
The program used, FROOO6 , allowed the atolllic 
parameters to be adjusted to fit best both to the 
X-ray data and for a given set of geometrical 
dimensions expected in the amino-acid residues. The 
inhibitor molecule will be described in the text in 
t1llO orientations: one with the N-trifluoroacetyl group 
in s{ and the other wi th the CMK group in Sl. 
The atomic labels for the inhibitor molecule are in 
figure 8.1 and the shorter inbibitor-PPE interactions 
are in table 8.3. Table 8.4 shows the 
hydrogen-bonding between the hydrogen atom attached to 
the nitrogen atom of the inhibitor and PPE molecules. 
Atollic parameter s for the inhibitor molecule and 
selected neighbouring PPE residues are shown in table 
8.5. The inhibitor molecule co-ordinates are in 
diamond format. 
Figure 8.1 
• 
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TABLE 8.3 
SHORTER INTERACTIONS BETWEEN THE INHIBITOR AND PPE MOLECULES 
Atom (A) Atom (B) 7 Distance A-B Subsite 
A 
CT-~TFA OG -Ser 195 3.03 
O-Ser 214 2.94 
F1_TFA OG -Ser 195 2.12 
O-Ser 214 3.17 
F3-TFA O-Ser 214 2.44 
C-Ser 214 2.71 
N-Phe 215 S' 1 2.75 
CA-Phe 215 2.44 
C-Phe 215 3.08 
C OG .-Ser 195 3.13 
O-Sar 214 2.88 
0 OG. -Ser 195 3.04 
CEI-HiS 57 3.18 
N1 CA-Phe 215 3.13 
CB-Phe 215 3.22 
O-Ser 214 2.48 
CBl C02-HiS 57 Sl 3.30 
c1 CB-Phe 215 3.29 
01 CA-Phe 215 3.06 
CB-Phe 215 2.53 
CA2 O-Val 216 } 2.93 CB2 O-Val 216 82 2.79 
N3 CD2-Phe 215 } 3.22 O-Val 216 83 3.14 
c5 CE2-Phe 215 } 3.27 CG1-Val 99 3.11 Cl CGI-Val 99 S4 2.02 
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TABLE 8.4 
HYDROGEN-BONDING BETWEEN THE HYDROGEN ATOM ATTACHED 
TO THE NITROGEN ATOM OF THE INHIBITOR AND PPE MOLECULES 
Atom (H) Atom (B) Distance (H) ••••• (B) 
A 
N1-a N-Val 216 3.91 
N-Phe 215 2.82 
O-Ser 214 1.86 
NE2-His 57 3.64 
CG-Phe 215 3.83 
N3-a O-Val 216 2.34 
CG-Phe 215 3.51 
CZ3-Trp 172 3.97 
TABLE 8.5 
ATOMIC CO-oRDINATES (A) FOR (i) THE TFA-Alaa-CMK and 
(ii) RESIDUES OF THE PPE MOLECULES WHICH SuiitOUND THE 
INHIBITOR MOLECULE 
(i) THE INHIBITOR MOLECULE, TFA-Ala -CMK 3 
X Y Z 
CT-C'3 -10.698 23.625 38.726 
'1-C'3 -11.353 24.152 37.942 
'2-CF3 -11.162 23.686 39.751 
F3-C'3 -9.695 24.189 38.759 
C-CF3 -10.444 22.187 38.269 
0-C'3 -9.799 21.961 37.247 
N1-Ala1 -10.964 21.220 39.013 
CAl-Ala 1 -10.950 19.820 38.504 
1 
-10.177 18.934 39.582 CB -Ala1 
c1-Ala1 -12.387 19.520 38.572 
01-Ala1 -12.757 20.586 38.915 
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x y Z 
2 
-13.630 18.882 38.327 N -Ala2 2 
-14.923 19.444 38.677 CA -Ala2 2 
-15.653 19.882 37.406 CB -Ala2 
C2-Ala2 -15.720 18.414 39.482 
02-Ala2 -15.662 17.220 39.196 
N3-Ala3 -16.445 18.916 40.470 
CA3-Ala3 -17.120 18.091 41. 458 
CB3-Ala3 -18.373 17.471 40.837 
C3-Ala3 -16.147 17.035 41. 984 
03-Ala3 -16.129 15.906 41. 497 
C4-CMK 65.505 -100.000 5.843 
H-CMK 90.048 -100.000 36.717 
H-CMK 66.729 -100.000 100.00 
Cl-CMK -15.391 17.433 42.935 
(ii) RESIDUES OF PPE MOLECULE 
N-His 57 -3.817 18.052 41.621 
CA-His 57 -4.612 17.733 40.431 
C-His 57 -3.922 18.195 39.152 
O-His 57 -3.791 17.397 38.213 
CB-His 57 -6.121 17.688 40.203 
CG-Hia 57 -6.666 19.092 39.910 
ND1-Ria 57 -6.625 19.629 38.652 
CD2-Hia 57 -7.259 19.973 40.733 
CEI-Ria 57 -7.914 20.873 38.712 
NE2-R!. 57 -7.584 21.084 40.005 
N-Val 99 -11.543 13.717 43.722 
CA-Val 99 
-11.178 15.101 44.049 
C-Val 99 -12.121 15.687 45.098 
O-Val 99 
-11.664 16.435 45.973 
CB-Val 99 
-11.153 15.984 42.797 
198 
x y Z 
CG1-Val 99 -12.568 16.295 42.315 
CG2-Val 99 -10.351 17.272 42.975 
N-Thr 175 -20.362 16.958 48.611 
CA-Thr 175 -19.186 16.976 47.726 
C-Thr 175 -18.035 17.767 48.338 
O-Thr 175 -16.885 17.308 48.330 
CB-Thr 175 -19.561 17.575 46.372 
OG1-Thr 175 -20.599 16.791 47.795 
CG2-Thr 175 -18.317 17.634 45.407 
N-Gln 192 -11.130 26.644 34.322 
CA-Gln 192 -10.012 25.856 33.784 
C-Gln 192 -8.750 26.675 33.523 
O-Gln 192 -8.804 27.692 32.822 
CB-Gln 192 -10.447 24.934 32.645 
CG-Gln 192 -11.273 23.734 33.112 
CD-Gln 192 -12.340 24.170 34.110 
OE1-Gln 192 -12.943 25.236 33.929 
NE2-Gln 192 -12.817 23.183 34.854 
N-Ser 195 -6.651 26.604 38.533 
CA-Ser 195 -6.289 25.523 39.474 
C-Ser 195 -4.490 25.680 40.163 
O-Ser 195 -3.922 25.926 39.513 
CB-Ser 195 -6.335 24.137 38.837 
OG-Ser 195 -7.669 23.561 38.722 
N-Ser 214 -9.288 24.330 43.566 
CA-Ser 214 -9.451 22.904 43.287 
C-Ser 214 -10.379 22.606 42.112 
O-Ser 214 -9.925 22.064 41.097 
CB-Ser 214 
-9.926 22.170 44.535 
OG-Ser 214 -9.912 20.776 44.267 
N-Phe 215 
-11.672 22.837 42.314 
CA-Phe 215 
-12.677 22.533 41.278 
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x y Z 
C-Phe 215 -13.874 23.481 41.194 
O-Phe 215 -13.972 24.445 41. 966 
CB-Phe 215 -13.158 21.077 41. 361 
CG-Phe 215 -13.870 20.728 42.682 
CD1-Phe 215 -13.140 20.258 43.761 
CD2-Phe 215 -15.250 20.818 42.775 
CE1-Phe 215 -13.781 19.931 44.961 
CE2-Phe 215 -15.900 20.493 43.971 
CZ-Phe 215 -15.164 20.054 45.070 
N-Val 216 -14.553 23.353 40.059 
CA Val 216 -15.833 24.009 39.746 
C-Val 216 -16.885 22.989 39.316 
O-Val 216 -16.586 21.792 39.217 
CB-Val 216 -15.668 25.055 38.642 
CG1-Val 216 -14.934 26.305 39.121 
CG2-Val 216 -15.067 24.480 37.361 
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The discussion will be mainly directed towards the 
binding of the inhibitor molecule. The inhibitor is 
found to bind at sites adjacent to the ~imary 
specificity pocket. The N-terminus shows 1 t to be 
bound at S1'subsite close to the active centre 
serine-195 and three amino-acid residues ar e 
associated in a parallel pleated-fashion with the 
~otein chain at subsites 51' 52 and 53 from residues 
214 to 216. The CMK group was found close to the 
subsite 54 (Figure 8.2-8.4). This arrangement is 
51 
similar to that found by Hughes et al regarding the 
inhibitor TFA-Lys-Ala-NH-C6H4-p-CF3• 
1 8-10 Various groups • have ~eviously ~edicted the 
19 1 
mode of binding of TFA-peptides using F and H 
N.M.R. spectroscopy and also by kinetic measurements. 
1 Dimicol! et al predicted the position of TFA group in 
TFA-peptide-CMK to be close to the serine-195 in the 
, 
51 . subsites. They also showed that the reaction of 
the CMK with histidine-57 was hindered, which is also 
evident from X~ay crystallographic study. 
Hence, it seems that the TFA-peptides bind in the 
opposite direction to that of the acetylated 
11 peptides. Further PPE shows the direction of 
binding, as defined frolll alll1no to carboxyl termini of 
the ligand to be reversed compared with other serine 
12-14 
cOlllplexes • However, recently protease inhibitor 
Meyer et al15 have complexed Ac-Ala-Pr o-Ala-p-
nitroanilide with PPB at 1.65 A resolution and found 
the inhibitor to coaplex in a si1ll11ar unner to that 
of Hughes et a15 and TFA-Ala3-CMK. 
An alternative 1IlOde of binding for the TPA-Ala3-CMK 
.- fitted compared to that of Hughes et a15• The 
whole of the peptide was positioned in the similar 
unner except the TPA group wa. directed a., from the 
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active site serine-195. There was no interaction 
between the tWl groups, (Figure 8.5-8.7). 
(11) Ac-Pro-Ala-Pro-Ala.OH 
A difference Fourier map [FDER-FNAT1 and a Fourier map 
4 
were calculated using the phases of the native PPE • 
Both maps were viewed on the Evans and Sutherland 
graphics system. Neither revealed continuous density 
around the serine-195, that is, neither of the Sl or 
, ' S1 subsites was occupied and it seems that perhaps the 
substrate did not bind by soaking the native crystals. 
To obtain adequate binding the technique of 
co-crystallisation should be tried. 
(iii) CONCLUSION 
It is evident from the study carried out, the 
TFA-peptides binds in a unique way compared to the 
acetyl-peptides. Fur ther evidence to clarify the 
affinity of the TFA ~oup is to compare the complexed 
structure of the TFA-Pro-Ala-Pro-Alaninal with PPE. 
This wuld also show the formation of tranaition atate 
analogue as mentioned in Chapter One. 
Since recently Meyer et al15 have found the subltrate 
Ac-Ala-Pro-Ala-p-nitroanilide binding in a similar 
manner to the TFA-peptides, fur ther conful1on a. to 
the binding sites is raiaed. 
Howver t more recently the inhibitor, Ac-Pro-Ala-Pro-
Alaninal was found to bind in a si1l1.l81' I18nner as to 
the other serine proteaaes. That i. at subaite. 81-S4 
along the protein chain 214-216, figure 8.8-8.9 
(unpublished resulta of Dr Sa""er). This theref()t'e 
fur ther a the issue about the whole binding at te. in 
PPE and hence various studie. need to be carried out 
before reaching a definite conclulion. 
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It is essential to pur sue fir st1y, with the substrate 
Ac-Pro-A1a-Pro-A1a.OH and the inhibitor TFA-Pro-A1a-
Pro-A1anina1 to distinguish the S 8ubsites. Secondly, 
with the complex between the anhydroe1astase and 
H. Pro-A1a-Pro-A1a-Lys-Phe.OH to also establish the S 
and S'subsites. The S' subsites can also be found 
from complexes between the protease and protein 
inhibitor and then by analogy, possibly through model 
building studies. 
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PPE RESIDUES (ORANGE) + TFA-ALA3 -CMK INHIBITOR 
(GREEN) BOUND AT SERINE-195 
FIGURE 8.2 
FIGURE 8.3 
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THE DENSITY AROUND THE TFA-ALA3-CMK INHIBITOR 
FIGURE 8.4 
PPE MOLECULE (ORANGE) + TFA-ALA3-CMK INHIBITOR 
(GREEN) BOUND AWAY FROM SERINE-195 
FIGURE 8.5 
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FIGURE 8.6 
THE DENSITY AROUND THE TFA-ALA3-CMK INHIBITOR 
BOUND AWAY FROM SERINE-195 
FIGURE 8.7 
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PPE RESIDUES (ORANGE) + AC-PRO-ALA-PRO-ALANINAL 
INHIBITOR (GREEN) BOUND AT SERINE-195 
FIGURE 8.8 
FIGURE 8.9 
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CHAPTER NINE 
CONCLUSIONS 
209 
9.1 INTRODUCTION 
PPE might be expected to exhibit similar substrate 
binding sites to those of the other serine proteases. 
However, low resolution studies (3.5 A ) by Shotton et 
all have shown that the binding sites for substrate are 
apparently different to those of chymotrypsin and 
2 3 
trypsin ' • 
Therefore, the objective was to map out conclusively the 
substrate binding sites both to the N-terminal and 
C-terminal sides of the scissile bond. This could be 
investigated by; firstly binding synthetically produced 
substrate and inhibitor analogues with native PPE, 
secondly co-crystallisation of native PPE crystals with 
naturally occurring inhibitors and lastly, the modi-
fication of the enzyme's active site, thus allowing the 
binding of a complete peptide without it being 
hydrolysed. 
Further justification for these studies was the confusion 
4 
which had arisen inv.olving the binding of a tri-
fluoroacetyl dipeptide inhibitor to PPE. (Details in 
section 1.9). Hence, the binding of two tetrapeptide 
inhi bi tors* TFA-Pro-Ala-Pro-Alaninal and Ac-Pro-Ala-Pro-
Alanina1 were investigated. The rationale behind these 
peptide aldehydes was firstly to distinguish the 
different modes of binding of acetyl and TFA groups. 
Since, it had been suggested that the TFA group binds to 
4 5 PPE in a unique binding mode '. Secondly, they bind to 
PPE more tightly than the substrates (refer to table 
1.7). This is probably due to the formation of a 
6 transition state analogue, a hemiacetal, which 1s 
analogous to the tetrahedral intermediate (figure 1.7). 
A further two peptide inhibitors; Ac-Pro-Ala-Pro-Ala.OH* 
7 
and TFA-Ala3-CMK (prepared by Bieth et a1 ) were examined 
for anomalous binding at 2.5 A resolution. Investigation 
of Ac-Pro-Ala-Pro-Ala.OH was carried out since previous 
210 
8 
work by Sawyer (unpublished reported by Johnson et a1) 
1 had failed to reproduce the results of Shotton et a1 • 
The modification of the active site serine-195 entails 
inhibition by a su1phonyl fluoride inhibitor, followed by 
an elimination reaction to convert the -CH20H into =CH2• 
This totally inactivates the PPE. Low resolution studies 
9 (3.5 A ) on the modified enzyme , anhydroelastase have 
shown some changes in the active site. The refined 
structure of anhydroe1astase together with that of the 
enzyme modified by diffusion of a substrate, e.g., H.Pro-
Ala-Pro-Ala-Lys-Phe~OH* into the crystals should there-
fore reveal the binding sites on both sides of the 
scissile bond. 
A further modification attempted was to convert 
serine-195 to cysteine with thiolacetate, either by 
substitution of sulphonyl derivative of PPE or by 
Michael-type addition to the double bond in anhydro-
elastase. This is of interest, since thiol proteases are 
analogous to the serine proteases and the conversion may 
provide completely different insight into the reactivity 
of PPE. Figure 9.0 summarises the overall scheme of the 
investigation. 
* Refer to section 1.8 for the preference of these 
peptides and to section 3.8 for their synthesis. 
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CHzSH 
I 
,(HI *" Thiol-Enzyme L ~ E . 7 ~-
CH-SCOCH3 
I 
CCH~ 
E 
Substitution 
CH3COSH 
Addition 
CH3COSH 
CH20-X I 
CH 2 II 
_In_h_ib_ite_d_~) r CH] 
by X ~E _O_H-~> [~~ * 
Inhibitor's 
1(1),(2), (3) and (4) 
CH20H --·Inhibitor I 
[~~* 
X= Tosyl fluoride 
= PMSF 
= Oansyl halide 
= NPA 
Inhibited Anhyd roelastase 
Enzyme 
Substrate 
Y = H· Pro-Ala-Pro-Ala- Lys-Phe- OH 
(1)= Ac - Pro -Ala- Pro-Ala·OH 
(2) = TFA-Pro - Ala-Pro- Alaninal 
(3) = Ac -Pro-Ala-Pro- Alaninal 
(4) =TFA-Ala3- CMK 
* Crystal structures to be investigated 
FIGURE 9-0 
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9.2 PREPARATION AND MODIFICATION OF PPE 
PPE was purified from trypsin 1-300 by the method of 
10 Shotton (details of the preparation in section 2.3.1). 
The preparation of anhydroelastase, is a two stage 
process as shown in figure 9.0. The first stage can be 
performed using non-radioactive label inhibitor, because 
the per cent inhibition will give an indication of the 
inhibition measured using a substrate, NBA. However, the 
second stage is crucial since the base elimination of the 
inhibitor is difficult to detect. Moreover, since the 
anhydroelastase formed is effectively inactive, there is 
no certainty that the inhibitor has been removed. 
9 11-14 Earlier studies on serine pancreatic protease ' have 
already shown, the enzyme can be fully inactivated with 
14 
radioactive labelled i.e., C labelled tosyl fluoride or 
PMSF and also used in the preparation of anhydroenzyme, 
so the elimination of inhibitor can be followed. 
Therefore, it might seem most feasibile to use these 
inhibitors, but for reasons of expense, availability and 
local restrictions it was considered desirable to attempt 
modification by non-radioactive reported groups as 
9 optimum conditions had already been found by Murphy • 
Thus, the possibility of detecting the formation of 
anhydroelastase by substituting the latter inhibitors 
with fluorescent chromophores was investigated. The 
following were tried: Dansyl fluoride or chloride and 
NPA, since they had been found to inhibit cx-chymotryp-
15-17 
sin • These could easily be detected on binding to 
the enzyme by fluorescent emission spectra at 505 ~ for 
dansyl elastase and 422 1I1l1 for anthraniloly elastase. 
On base elimination to the formation of anhydroelastase 
no fluorescent emission spectra should be obtained. 
Details of the preparation of the inhibited elastase , 
anhydroelastase and thiol-elastase are given in section 
2.3. 
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9.3 DISCUSSION 
PPE was fully inhibited (~ 98%) by tosyl fluoride and 
PMSF within a time of 5 hours compared to 24 hours for 
the latter. However, with the fluorescent inhibitor's 
Dansyl halide and NPA no inhibition was achieved at the 
active site serine-195, whereas the serine-195, in the 
15-17 
case of a-chymotrypsin was inhibited • 
Although, no dansylation was achieved at the active site 
15 
at pH 8.4 , the dansyl elastase showed a fluorescence 
spectra on excitation at 340 m~. A fluorescence maximum 
was observed at 505 m ~ (figure 9.1). Thus, indicating 
that dansylation had probably taken place somewhere else 
on the molecule. A possible explanation is that under 
mild alkaline conditions the amino-acids most prone to 
dansylation were the £: - amino groups of lysine. PPE has 
exactly three lysine residues in the external positions 
available for dansylation. These are lysine-87, lysine-
177 and lysine-224 which are 23.4 A , 16.5 A and 18.0 A 
respectively from serine-195. From these, the lysine 
residues most prone to dansylation would be the second 
one. The N-terminal NH2 is not available since it is 
buried forming a ion pair with asparate-194. 
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A FLUORESCENCE SPECTRUM OF DANSYL ELASTASE AT pH 8.4 
ON EXCITATION AT 340 m 1.1 • 
" u C 
o 
0-3 
-e 0-2 ] 
c( 
0-1 
50S 387 
Wovelenght 
Figure 9.1 
Further, attempts were carried out to dansylate PPE by 
varying the conditions from those of Horton et aIlS and 
Gold16 • That is, performing the inhibition between pH 
5.5-7.5, but no change in the activity and no fluor-
escence spectrum were obtained. 
Hence, the only successful means that remained for 
preparing anhydroelastase were from tosy! elastase or 
PMSE. However, doubt remained in the formation of the 
double bond, since both the inhibited PPE and 
anhydroelastase were inactive. Hence, other methods for 
the detection of the double bond needed to be 
investigated; using Dansyl halide and thiolacetate. 
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Attempts to dansylate anhydroelastase, indicated no 
fluorescence maximum, demonstrating that the serine-195 
was converted to dehydroalanine, and hence the OH was not 
available to dansylation. Also, there was no indication 
of dansylation taking place anywhere else in the molecule 
(as happens in the native elastase). This suggested that 
the amino-acids prone to dansylation were affected under 
the strong alkaline conditions in the preparation of 
anhydroelastase. 
Secondly, addition to the double bond to convert 
serine-195 into cysteine by thiolation and substitution 
of inhibited PPE proved experimentally difficult. This 
9 
was also observed by Murphy with tosyl elastase. 
Varying the conditions form his, that is, pH 5.3 to pH 
6.5 and 7.S and performing the reaction at 00 C and room 
o temperature rather than at 2 C did not result in any 
change in the reaction. 
TABLE 9.1 
SUMMARY OF THE INHIBITION OF PPE BY VARIOUS INHIBITORS 
Inhibited PPE 
Native PPE 
Tosyl elastase 
PMSE 
Anthraniloyl elastase 
Dansyl elastase 
Thiol-elastase 
from 
Tosyl elastase 
or 
PMSE 
Anhydroelastase 
pH 
7.2 
7.2 
7.2 
6.8 
5.5,6.0,6.5 
7.2 and 7.5 
8.4 
6.5 
and 
7.5 
6.5 and 7.5 
Time Temgerature 
(hours) ( C) 
24 4 
24 4 
4 4 
24 6 
48 4 
48 4 
6 o and 20 
6 o and 20 
6 o and 20 
* No alkaline treatment, since no inhibition was observed 
Inhibition A£tivity After Fluorescence 
(%) OH treatment (%) (mll) 
~97 
~98 !!!2 
~98 !:!2 
~ 2 
* 
~40 
* 
~ 
t-' 
~20 
* 
505 0'\ 
~ 2 
~ 2 
~ 2 
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Thus, uncertainty still remained as to whether the 
formation of anhydroelastase had been achieved. There-
fore, a 2.4 A resolution data set was collected, but 
after processing and comparing the electron density 
around the active site region showed no change. (Refer 
to the mono and stereo figure 2.0-2.1 showing a small 
region around the serine-195 with the electron density 
around these residues). The serine 0y is still clearly 
visi ble, indicating the tosyl and the PMS groups were 
removed but the expected elimination had not occurred. 
However, the anhydroelastase prepared was inactive and 
further more it crystallised indicating no gross 
conformational changes or denaturation. Hence it was 
decided to investigate further by soaking the crystals in 
the hexapeptide substrate, H.Pro-Ala-Pro-Ala-Lys-Phe.OH. 
Collecting the data to 2.5 A. resolution followed by 
processing should reveal the mode of binding. If residue 
195 were dehydroalanine, the whole peptide should be 
found intact straddling the active site. But if the 
enzyme was active only the Ac-Pro-Ala-Pro-Ala.OH would be 
observed. 
For further details on the discussion refer to section 
2.4 
9.4 EXPERIMENTAL CONDITIONS FOR BINDING OF THE SUBSTRATE/ 
INHIBITOR TO PPE 
Details of the experimental conditions and cell 
parameters are specified in section 8.2 and table 8.1. 
However, of all the complexes prepared only two data sets 
to 2.5 A. resolution could be collected (Ac-Pro-Ala-Pro-
Ala-OH and TFA-Ala3-cMK). In the case of the others, 
crystal complexes are mounted and ready for data 
collection in the future. 
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9.5 DATA COLLECTION AND PROCESSING 
Intensity data for both derivatives (Ac-Pro-Ala-Pro-Ala.OH 
and TFA-Ala3-CMK) were collected on a computer controlled 
Enraf-Nonius CAD4 diffractometer. All of the data for 
TFA-Ala3-CMK were measured on a single crystal; a total 
of 8162 unique reflections (29 ~'360 ) were recorded by 
the 29-w scan technique to 2.5 A resolution by Dr L 
Sawyer. Two crystals were required for Ac-Pro-Ala-Pro-
Ala.OH; with a total of 7249 unique reflections 
(29 ~ 360 ), recorded by the w scan to 2.5 A resolution. 
Both data collections were performed just below room 
temperature (150 and 180 C) with nickel filtered Cu-Ka. 
radiation. 
The data sets were TFA-Ala3-CMK and Ac-Pro-Ala-Pro-A1a.OH 
were corrected for Lorentz polarization, absorption and 
time-falloff (Refer to table 8.2 for Data Collection 
Parameters). After applying all the corrections, the 
data for the two crystals of Ac-Pro-Ala-Pro-Ala.OH were 
merged together by scaling the common reflections. The 
R = I: (l(i) - <: I> )/ r l(i) for this was 0.032, 
merge 
(with l(i) being the intensity value of an individual 
measurements, <I> being the corresponding mean value of 
the i measurements; the summation is over all reflections 
with more than one measurement). 
The phase set for the native PPE structure18 was used 
together with the reflections of TFA-Ala3-CMK and 
Ac-Pro-A1a-Pro-A1a.OH in order to calculate difference 
Fourier maps, with coefficients lFDER\ -\FNATI, ~AT and 
also a Fourier map for the latter derivative. The 
difference Fourier map for the TFA-A1a3-CMK revealed only 
contiguous density around the active site region of the 
PPE molecule. However, neither map for the Ac-Pro-Ala-
Pro-A1a.OH revealed any continuous density around the 
serine-l95 even when the-contour level was reduced to the 
level of the noise. 
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The Evans and Sutherland graphics system (at the 
University of Leeds) was used for positioning the 
TFA-Ala3-CMK molecule in the active site region. The 19 program, FRODO was used to adjust the atomic 
parameters to be fitted best both to the X-ray data and 
for a given set of geometrical dimensions expected in the 
amino-acid residues. The TFA-A1a 3-CMK molecule will be 
described in two orientations: One with the 
N-trif1uoroacety1 group as the, N-termina1 amino-acid and 
the other with the CHK group as the C-terminus. 
Refer to figure 8.1 for labelling of the inhibitor 
molecule and to tables 8.3-8.5 for shorter inhibitor-PPE 
interactions, hydrogen-bonding and atomic parameters for 
the inhibitor molecule and selected neighbouring PPE 
residues. 
9.6 CRYSTALLOGRAPHIC RESULTS FOR THE INHIBITOR TFA-ALAl-CMK 
The inhibitor, TFA-Ala3-CKK is found to bind at sites 
adjacent to the primary specificity pocket but in the 
opposite direction to that of the other serine protease 
20-22 inhibitor complex • Figures 8.4 and 8.7 show a 
continuous chain of electron density running from the 
region close to histidine-57 and serine-195 and along the 
main chain of PPE from residues serine-214 up to the 
vicinity of serine-217. Figure 8.7 shows an alternative 
mode of binding of the TFA group with the rest of the 
peptide positioned in the similar manner to figure 8.4. 
In figure 9.2, 
contact is 3.3A 
the NE2-histidine-57 ••••••• 0G-serine-195 
18 in native elastase but the histidine 
ring is not in the correct orientation to form a good 
hydrogen bond. This point is still controversial as 
discussed by Tsukada et a123 • 
However in contrast, the binding of TFA-Ala3-CMK with PPE 
results in a slight shift of the histidine ring and hence 
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in a good hydrogen bond of 2.6 A 
observed by Hughes et a14 but not 
This was also 
in the complex of 
Ac-Pro-Ala-Pro-Alaninal (Figure 9.3 (c) and (d)). 
However, a weaker hydrogen bond between OD2-asparate-102 
•••••• ND1-histidine-57 of 3.0 A results but previous 
crystallographic studies on the other serine proteases 
have shown to be similar to the native elastase (2.6A) 
18,25-25 This was also observed in TFA-Lys-Ala-NH-C6H4-
p-CF3 and Ac-Pro-Ala-Pro-Alaninal complexes. 
The inhibitor molecule and all its surrounding residues 
of PPE molecule are shown in stereo figure 9.3 (a) and 
(b) and figure 9.3 (c) shows the similar binding of 
TFA-Lys-Ala-NH-C6H4-p-CF3, inhibitor that was observed by 4 Hughes et al. Figure 9.4 shows a schematic representa-
tion of the interactions formed between the inhibitor's 
and PPE at Sand S' subsites. 
Figure 9.2 shows the active centre region of native PPE 
(pH 5.0). Hydrogen bonds are shown as dotted and all 
distances are inA. Labels are associated with the C 
2- a. 
atoms. In the figure the S04 ion represents the sulphur 
atom with the oxygens ~ 2.0 A away. 
The active centre region showing hydrogen bond contacts 
(shown as dotted and all distances are in A ) between the 
inhibitor molecule and PPE residues in Figure 9.3; (a) 
TFA-Ala3-CMK (b) TFA-Ala3-CMK (alternative mode of 
binding) (c) TFA-Lys-Ala-NH-C6H4-p-CF3 (d) Ac-Pro-Ala-
Pro-Alaninal. Labels are associated with the C - atoms. 
ex. 
Stereoviews of the inhibitor molecules and the 
surrounding residues are exactly equivalent to the above 
figures to which reference should be made for labelling. 
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STEREOVIEW OF NATIVE ELASTASE (pH 5.0) 
Figure 9.2 
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(a) 
STEREOVIEW OF TFA- ALAJ-CMK 
223 
(b) 
STEREOVIEW OF TFA-ALAa-CHK (ALTERNATIVE MODE) 
224' 
(c) 
225 
(d) 
STEREOVIEW OF Ac-PRO-ALA-PRO-ALANINAL 
Figure 9.3 
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Schematic representation of the interaction between various peptide inhibitors and PPE. 
Hydrogen bonds are shown as dotted. and all the inhibitors. except (1) take on an 
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peptide inhibitors 4 (2) and 5. 
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The N-terminus shows it to be bound at S subsite close 
1 
to the active centre with OG-serine-195 equidistant from 
each C-, 0- and CT-TFA and with the F2_TFA and F3-TFA 
4 
about 3.7 A away. This contrasts with Hughes et al 
where the C-, CT- and the two fluorine's of the TFA group 
were equidistant at 3.3 A from OG-serine-195. The three 
alanine residues are associated in a parallel-pleated 
fashion with the protein chain at subsites S1' S2 and S3 
from the main chain residues 214 to 216. This 
arrangement is stabilised 
N-A1a1-H ••••• 0-serine-214 
There is also a twist of 
found in 26 {3 -sheets • 
by strong hydrogen bonding of 
and N-Ala3-H ••••• 0-valine-216. 
o 
about 90 consistent with that 
observed by Hughes et 
This arrangement is that also 
4 
al and very recently on two 
peptide inhibitors Ac-Pro-Ala-Pro.OH and Ac-Pro-A1a-Pro-
Tyr.NH2 complexed with PPE were found to bind in the 
similar manner27- 28 , that is, parallel to 214-216. 
5 29-31 Various groups ' have previously predicted the mode 
19F 1 of binding of TFA-peptides using and H N.M.R. 
spectroscopy and also by kinetic measurements. Dimicoli 
7 
et a1 predicted the position of TFA group in TFA-
peptide-CMK to be close to the serine-195 in the Si 
subsites. They also showed that the reaction of the CMK 
with histidine-57 was hindered, which is also evident 
from X-ray crystallography study (the CMK group is not 
shown in figure 9.3 (a) and (b) since the resolution was 
not good and the CMK end is more mobile, being towards 
the solvent). Hence it seems that the TFA-peptides bind 
in the opposite direction to that of the acetylated 
peptides. Further, PPE shows the direction of binding, 
as defined from the carboxyl termini of the ligand to be 
reversed compared with other serine proteases inhibitor 
complexes. This is clearly seen when comparing the TFA 
and the aldehyde inhibitors. 
This result contrasts sharply with those reported for 
N-acetylated short peptide substratel and inhibitor32 
molecules where the amino-acids residues are associated 
228 
at subsites S1' S2 etc and the N-acetyl group at subsite 
S4' far removed from the active site (figure 9.3 (d». 
9.7 OVERALL CONCLUSION 
It is obvious from the studies carried out on the 
modification of PPE, that the use of the fluorescent 
chromophores gave some indication of the mode of binding, 
since these inhibitors were found to inhibit a. -chymo-
trypsin efficiently. It suggested that the binding site 
of PPE (P1) is different and can only accommodate a small 
group such as methyl because of the occlusion by 
valine-216 and threonine-226, whilst in a.-chymotrypsin 
these amino-acids are replaced by glycines-216 and 226. 
It has also shown that radioactive labelled tosyl 
fluoride or PMSF need to be used in the preparation of 
anhydroe1astase to be able to monitor its formation in a 
fully satisfactory manner. 
The X-ray analyses have confirmed the TFA group in the 
inhibitor, TFA-Ala3-CMK, binds in a unique mode and in 4 the same orientation as Hughes et a1. However, recent 
cyrstal10graphic studies on two peptide inhibitors; 
27 28 Ac-Ala-Pro-Ala.OH and Ac-Pro-Ala-Pro-Tyr. NH2 wi th PPE 
have contradicted the previous results of acetyl peptides 
and shown these peptides to bind in similar directions to 
the TFA-peptides. 
However, the results on the inhibitor, Ac-Pro-Ala-Pro-
Alaninal, (figure 9.3 (d» indicates the inhibitor 
binding in a similar manner to the other serine 
proteases. That is, at subsites 81-84 along the protein 
chain 214-216 with acetyl group at subsite 84 and the 
inhibitor forming an anti-parallel sheet with the enzyme. 
These small peptide inhibitors are apt to be artifacts 
but in vivo, one excepts a unique binding between the PPE 
and its natural substrate, elastin33 • Elastin is large 
in structure and is elastic fibrous protein of connective 
tissue. 
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Thus, the overall picture remains somewhat confused as 
regards substrate binding to PPE. It seems more obvious 
now that a great deal of research is required on binding 
of substrates/inhibitors to PPE and by collating all the 
results before one can come to some definite conclusion. 
This can be pursued, firstly with the substrate 
Ac-Pro-Ala-Pro-Ala.OH, by ensuring adequate binding, by 
using the technique of co-crystallisation. Further, data 
on the inhibitor complex of TFA-Pro-Ala-Pro-Alaninal 
needs to be collected to clarify the affinity of the TFA 
group and would also show the formation of transition 
state analogue as mentioned in chapter one. Secondly, to 
establish the Sand S' subsites the complex between 
anhydroelastase and the substrate H.Pro-Ala-Pro-Ala-Lys-
Phe·OH needs to be investigated. Further, it might help 
solve the problem of binding by complexing Ac-Pro-Ala-
Pro-Ala-Lys-Phe.OH and TFA-Pro-Ala-Pro-Ala-Lys-Phe.OH 
peptides with anhydroelastase. 
34-36 been Various protein inhibitors ,have already shown to 
" inhibit PPE, thus enabling one another means of 
investigating the possible S' subsites. These could be 
found from the complexes between the protease and protein 
inhibitor and then by analogy, possibly through model 
building studies. 
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